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Dedication 
 
In the epilogue of Altneuland, Theodor Herzl famously wrote: 
 
“Dreams are not so different from deeds as some may think. All the deeds of men are dreams at 
first, and become dreams in the end.” 
 
Medical advances undergo a similar progression, from invisible to visible and back.  Before they 
are accomplished, advances in the physician’s art are illegible: no one differentiates from the rest 
the suffering and death which could be alleviated with methods which do not yet exist.  
Unavoidable ills have none of the moral force of avoidable ones. 
 
Then, for a brief period, beginning shortly before it is deployed in mainstream practice, and 
slowly concluding over the generation after it becomes widespread, an advance is visible.  
People see the improvements and celebrate them. 
 
Then, subsequently, for the rest of history, if we are lucky, such an advance is more invisible 
than it was before it was invented.  No one tallies the children who do not get polio, the firm 
ground that used to be a malarial swamp, or the quiet fact of sanitation.  Few remark on the 
novelty of the un-novel. 
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This thesis contemplates medical advances which do not yet exist, which are invisible.  It 
contemplates the means by which medical science may make the genetic component of variation 
in disease risk, drug response, adverse events, and other medical phenotypes visible to the 
clinician so that informed decisions on the basis of this information may improve patient 
outcomes.  It is offered in the fervent hope that it can contribute, in a small way, to improving 
and hastening the subsequent work of making these informed decisions possible. 
 
Accordingly, it is dedicated to the patients, currently largely anonymous, who suffer invisibly in 
ways which can be ameliorated by genetic testing and by actions undertaken on the basis of 
knowledge gleaned from genetic testing.  May their alleviated suffering soon be equally 
invisible. 
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Preface 
 
This work describes my modest contribution to a scientific project which has been underway, in 
one form or another, for thousands of years: the analysis and parsing of genetic inheritance and 
the use of genetic inferences to aid humanity’s unceasing labors. 
 
Specifically, it describes a suite of bioinformatics tools I have constructed, in an attempt to 
translate recent advances in the use of the epigenome and spatial genome to identify and parse 
important phenotypic variants, to an area of medical science, pharmacogenomics, which has 
largely failed to benefit from them. 
 
The bulk of this work is based on published and soon-to-be-published papers which were 
collaborative in nature and have other authors.  I have endeavored in this narrative to tell the 
story of my work, but that narrative involves collaborative work which is not fully separable.  
Where there is any doubt, I urge you to maximize your appraisal of my colleagues. 
 
I begin by describing, in the first chapter, the preeminent role these advances have taken in 
biomedical science and in genetics in other contexts, and the disjunction between this picture and 
the picture in pharmacogenomics.  This chapter is partially based on the 2015 review [Higgins et 
al 2015]. 
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I then describe, in the second chapter, three variant analyses I and others undertook to explore 
pharmacogenomic phenotypes with this powerful new explanatory framework, in 
neuropsychiatric small molecule medications, lithium, and valproic acid, and the success of these 
analyses in discovering mechanistic and predictive variants.  This chapter is largely based on the 
primary papers reporting these experiments [Higgins et al 2015, Higgins et al 2015, Higgins et 
al 2017]. 
 
I then describe, in the third chapter, the Pharmacoepigenomics Informatics Pipeline, a tool I built 
with the object of making such analyses easier to perform, more reproducible, and amenable to 
advanced methods which were not tractable in the semi-manual analytic mode in which such 
analyses had previously been run.  I further describe the success of the PIP in reproducing the 
glutamatergic lithium pathway previously discovered, and in uncovering a previously unknown 
genetic basis for warfarin response.  This chapter is largely based on the PIP paper [Allyn-Feuer 
et al 2018]. 
 
I then describe, in the fourth chapter, the H-GREEN Hi-C compiler, a tool I built to function as 
one portion of a target gene module for a future version of the PIP, to address the finding of 
distal target genes, an important gap which existing methods could not fill.  I further describe its 
success at detecting distal chromatin contacts existing methods could not find in a head-to-head 
comparison, and in building spatial contact networks of phenotypically important chromatin 
domains.  This chapter is currently being adapted for publication. 
 
  viii   
 
I conclude by describing, in the fifth and final chapter, my vision for a future evolved PIP 
featureset, for the use of such pipelines to develop genetic tests, and for the extension of such 
methods in parallel across thousands of phenotypes to develop a pharmacophenomic atlas.  This 
chapter is currently being adapted for publication, and a small part was based on the 2018 
machine learning review [Kalinin et al 2018]. 
 
This work is not complete; no scientific work is ever truly complete.  There are logical 
developments to be undertaken, separate elements to combine, more experiments to perform, and 
ultimately, widespread clinical deployments to be undertaken.  It is my fond wish that this work 
take place, under whatever aegis, so that future students may have more to learn, and so that 
some of those who are sick may be well. 
 
Ari Lawrence Allyn-Feuer 
Ann Arbor, Michigan, United States of America 
July 2018  
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Abstract 
 
Over the last decade, biomedical science has been transformed by the epigenome and spatial 
genome, but the discipline of pharmacogenomics, the study of the genetic underpinnings of 
pharmacological phenotypes like drug response and adverse events, has not.  Scientists have begun 
to use omics atlases of increasing depth, and inferences relating to the bidirectional causal 
relationship between the spatial epigenome and gene expression, as a foundational underpinning 
for genetics research.  The epigenome and spatial genome are increasingly used to discover 
causative regulatory variants in the significance regions of genome-wide association studies, for 
the discovery of the biological mechanisms underlying these phenotypes and the design of genetic 
tests to predict them.  Such variants often have more predictive power than coding variants, but in 
the area of pharmacogenomics, such advances have been radically underapplied.  The majority of 
pharmacogenomics tests are designed manually on the basis of mechanistic work with coding 
variants in candidate genes, and where genome wide approaches are used, they are typically not 
interpreted with the epigenome. 
  
This work describes a series of analyses of pharmacogenomics association studies with the tools 
and datasets of the epigenome and spatial genome, undertaken with the intent of discovering 
causative regulatory variants to enable new genetic tests.  It describes the potent regulatory variants 
discovered thereby to have a putative causative and predictive role in a number of medically 
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important phenotypes, including analgesia and the treatment of depression, bipolar disorder, and 
traumatic brain injury with opiates, anxiolytics, antidepressants, lithium, and valproate, and in 
particular the tendency for such variants to cluster into spatially interacting, conceptually unified 
pathways which offer mechanistic insight into these phenotypes. 
 
It describes the Pharmacoepigenomics Informatics Pipeline (PIP), an integrative multiple omics 
variant discovery pipeline designed to make this kind of analysis easier and cheaper to perform, 
more reproducible, and amenable to the addition of advanced features.  It described the successes 
of the PIP in rediscovering manually discovered gene networks for lithium response, as well as 
discovering a previously unknown genetic basis for warfarin response in anticoagulation therapy. 
 
It describes the H-GREEN Hi-C compiler, which was designed to analyze spatial genome data and 
discover the distant target genes of such regulatory variants, and its success in discovering spatial 
contacts not detectable by preceding methods and using them to build spatial contact networks that 
unite disparate TADs with phenotypic relationships. 
 
It describes a potential featureset of a future pipeline, using the latest epigenome research and the 
lessons of the previous pipeline.  It describes my thinking about how to use the output of a multiple 
omics variant pipeline to design genetic tests that also incorporate clinical data.  And it concludes 
by describing a long term vision for a comprehensive pharmacophenomic atlas, to be constructed 
by applying a variant pipeline and machine learning test design system, such as is described, to 
thousands of phenotypes in parallel. 
 
  xvi   
 
Scientists struggled to assay genotypes for the better part of a century, and in the last twenty years, 
succeeded.  The struggle to predict phenotypes on the basis of the genotypes we assay remains 
ongoing.  The use of multiple omics variant pipelines and machine learning models with omics 
atlases, genetic association, and medical records data will be an increasingly significant part of 
that struggle for the foreseeable future.   
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Chapter 1: Pharmacoepigenomics 
 
Pharmacogenomics Lags Other Genetics Disciplines in Benefiting from the Epigenome 
 
Pharmacogenomics began with pharmacokinetics, and pharmacokinetics began with association.  
From the antique period, commenters as early as Pythagoras noted that susceptibility to some types 
of food poisoning ran in families [Pirmohamed 2001].  More formal reports of such heritability 
of response to pharmaceutical drugs dates from the 1950s [Evans et al 1961], and formal study of 
such relationships from the 1960s [Vesell et al 1968].  In the 1960s it was discovered that 
cytochrome P450 (CYP) enzymes in the liver metabolize many pharmaceutical drugs and natural 
substances [Danielson et al 2002, Zanger et al 2013, Zanger et al 2014].  With the cloning of 
CYP genes and the emergence of crystal structures [Poulos et al 1987], it was discovered that 
coding SNPs altering the sequences of these enzymes altered the metabolic rates of these enzyme 
activities, and that differences in metabolic rates altered the peak concentrations and time courses 
of these drugs and their active metabolites in the body [Skoda et al 1988].  With these 
developments, the stage was set for the eventual development of tests to stratify patients by drug 
response by assaying these SNPs. 
 
During the 1990s, the realization dawned that this pattern, of the approximately 60 CYP enzymes 
metabolizing drugs with varying speeds based on genetics, underlay not only the metabolism of 
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most pharmaceutical drugs [Zanger et al 2013, Zanger et al 2014], but also the metabolism of 
many food substances, and that competition for enzyme activity underlay many drug-drug 
[Guengerich 1997, Ogu et al 2000] and drug-food interactions for substances as diverse as 
grapefruit [Bailey et al 2004], starfruit [Zhang et al 2007], and watercress [Leclercq et al 1998].  
Even the genetic basis of Pythagoras’ fava bean sensitivity was parsed, with “Favism” syndrome 
attributed to deficiency in Glucose-6-phosphate dehydrogenase [Laosombat et al 2006], which, 
although not a CYP, is a metabolizing enzyme.   
 
The search for variants that predict a phenotype is also intimately connected, in pharmacogenomics 
as in other disciplines, with the search for mechanisms underlying that phenotype, which may be 
both explanatory and also amenable to medical intervention.  For example, the discovery that 
warfarin acts by inhibiting vitamin K epoxide reductase (VKORC1) enabled both the development 
of warfarin pharmacogenomics tests [Pirmohamed et al 2013, Kimmel 2013], and the 
development of novel VKORC1 antagonist drugs [Griminger 1987].  The discovery of 
pharmacogenomic loci and mechanisms in other systems may also contribute to the development 
of diagnostic and therapeutic methods. 
 
Due to this historical legacy, pharmacogenomics variant discovery has prioritized the search for 
protein coding variants with genetic association and biochemical methods [Black et al 2007].  
With the sequencing of the human genome, the initial hope for immediate discovery of highly 
penetrant coding variants for many phenotypes [Collins et al 2001, Ganguly et al 2001] did not 
bear out, both in pharmacogenomics and in many other fields [Weinshilboum et al 2004].  And 
with the advent of GWAS (genome wide association studies), pharmacogenomic phenotypes 
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began to be investigated with this powerful new tool [Giacomini et al 2017].  While most available 
pharmacogenomics tests were and are based on highly penetrant coding variants, GWAS studies 
have revealed that the bulk of genetic variation in drug response, like many other phenotypes, 
comes from noncoding regulatory variants which are cooperative and combinatoric [Boyle et al 
2012]. 
 
In the first decade of this century, the accumulation of knowledge about such variants and genes 
began to take on systematic scope [Mrazek 2010] and to result in the construction and 
deployment of genetic tests to predict drug response and adverse event phenotypes in a number 
of clinical domains [Mrazek 2010, Hall-Flavin 2013, Trinks et al 2014, Moaddeb et al 2013].   
 
Pharmacogenomic tests developed with coding variants discovered by mechanistic work have a 
spotty record.  They have demonstrated clinical validity and utility in systems as diverse as 
neuropsychiatry [Health Quality Ontario 2017] and oncology [Xin et al 2017], and in these 
domains, have been used widely in the clinic.  However, in other domains, great effort has been 
expended on the development of tests for highly heritable phenotypes without yielding clinically 
useful tests [Pirmohamed et al 2013, Kimmel 2013].  Even in domains wherein 
pharmacogenomic tests have been deployed and added value, they often account for only a 
fraction of the heritability of the phenotypes they predict [Health Quality Ontario 2017]. 
 
If pharmacogenomics testing and concomitant advances in diagnosis and treatment are to realize 
their potential, the discipline must make wider use of high throughput methods, regulatory 
variants, and the epigenome.  This chapter will chronicle the ways in which these methods have 
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transformed much of biomedical science, how they have as yet failed to transform 
pharmacogenomics, and the stirrings of movement in pharmacogenomics toward the 
“Pharmacoepigenomics” vision.  It will set the stage for my contributions to this transformation, 
which are described in subsequent chapters. 
 
The GWAS Interpretation Challenge 
 
Genome wide association studies (GWAS) [Visscher et al 2017] have become a cornerstone 
technique of biomedical locus discovery over the last twelve years, and all signs point to the 
continuing escalation of this trend.  The parallel measurement of millions of SNPs throughout the 
genome on a microarray at tractable cost [LaFramboise 2009] has allowed the traditional methods 
of genotypic association studies to be carried out in parallel across the entire genome.  The 
resulting explosion in locus discovery for many systems has yielded fundamental discoveries in 
every area of biology and medicine [Visscher et al 2017].  As a result of this, the GWAS catalog 
[MacArthur et al 2017] has swelled to contain over five thousand GWAS from the published 
literature, while industrial concerns have amassed large numbers of proprietary GWAS. 
 
This trend shows no sign of stopping and every sign of accelerating.  Over the last five years, the 
genetic association methods of GWAS have been applied to two additional forms of high 
throughput biomedical data analysis, which add additional dimensions of parallelization across 
many phenotypes.  In the case of molecular quantitative trait locus (mQTL) screening [Delaneau 
et al 2017], GWAS is performed in parallel for a collection of molecular QTLs spanning the entire 
genome.  This may include, for example, gene expression QTL analysis [Gilad et al 2008, Peters 
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et al 2016], but also including an ever-expanding array of molecular phenotypes like DNA 
methylation [Banovich et al 2014, Hannon et al 2016], DNase accessibility [Degner et al 2012], 
histone acetylation [McVicker et al 2013], etc.  And in the case of Phenome-wide association 
study (PheWAS) [Denny et al 2010], GWAS methods are parallelized across a large number of 
medical phenotypes (disease diagnoses, drug responses, physiological measurements, etc) 
extracted at scale from an electronic medical record [Hebbring et al 2015].  The amount of GWAS 
data available, the array of phenotypes tested, the amount of undiscovered insight latent in these 
experiments, and the interest in interpreting them will continue to grow. 
 
At the same time, however, the results of GWAS have not lived up to some of the original 
excitement.  At the inception of the technique after the sequencing of the human genome, it was 
believed by many that the GWAS technique would lead to the recovery of the bulk of the genetic 
heritability of studied phenotypes [Collins et al 2001, Ganguly et al 2001].  As the GWAS 
techniques matured, however, it became clear that for most complex phenotypes, discovered loci 
accounted for only a fraction, often a minority, of the heritability of the phenotype [Slatkin et al 
2009, Manolio et al 2009, Gusev et al 2013].  And in some cases, well powered GWAS recovered 
few or no significant loci for a heritable trait [MacArthur et al 2017].  This “missing heritability” 
problem has been the topic of perennial debate, with opinion settling around a number of 
hypotheses: 
 
1) That the missing heritability is accounted for largely by independent causal variants with 
very small effect sizes below the detection threshold of even powerful GWAS, known as 
the “gold dust” [Shi et al 2011] or “omnigenic” hypothesis [Boyle et al 2017]. 
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2) That the missing heritability is accounted for largely by rare variants not covered in 
individual GWAS, known as the rare variant hypothesis [Schork 2009, Gibson 2011]. 
 
3) That the missing heritability is accounted for largely by cooperative epistatic interaction 
between multiple loci, rather than linear summation of the statistical heritability of 
individual loci, known as the epistatic hypothesis [Zuk et al 2011, Sivakumaran et al 
2011]. 
 
4) That the missing heritability is accounted for largely by direct epigenetic inheritance not 
mediated by DNA sequence, known as the epigenetic inheritance hypothesis [Slatkin 
2009, Franklin et al 2010]. 
 
5) That the missing heritability is largely illusory, the result of shared environmental factors 
between family members creating concordant phenotypic outcomes which inflate 
heritability estimates, known as the environmental hypothesis [Gage et al 2016]. 
 
Despite the enduring popularity of the environmental hypothesis in the lay press [Rossiter 1996, 
Feldman et al 2018], detailed investigation of family members of different levels of relatedness, 
raised separately or together, from the same and different pregnancies, have decisively refuted this 
hypothesis for a number of well-studied phenotypes [Plomin et al 2015, Plomin et al 2018].  Less 
clarity has emerged on the topic of the omnogenic, rare-variant, epistatic, and epigenetic 
hypotheses.  It is likely that each of these factors contributes to the heritability problem to some 
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extent and that such extents vary for different types of phenotypes, but this landscape remains 
murky. 
 
Interpreting GWAS results is a very difficult problem.  It involves a number of major challenges, 
principally discerning the reality of associations, attributing causal character to them, finding the 
causal variants within linkage regions, and discerning their function.   
 
In GWAS design, investigators typically attempt to find a socially and genetically homogeneous 
population with a good match between cases and controls, in order to minimize the potential for 
lifestyle and environmental factors with a causative role in the phenotype to cause erroneous 
association hits through their association with ethnicity-linked or other genetic variants [Amos et 
al 2007].   
 
The Nexus Between Genetics and Epigenomics Integrates Environmental Stimuli   
 
To some extent these distinctions may be artificial; recent results document a significant 
enrichment of regulatory SNPs identified by GWAS in chromatin domains carrying epigenomic 
marks consistent with enhancer functions, affecting transcription factor (TF) binding  sites (TFBS) 
[Farh et al 2015].  As a result, specific causal variants affect TF binding and recruitment of 
epigenomic mechanisms, which leads to alteration of enhancer and promoter function.  This event 
can be detected with chromatin immunoprecipitation methods, as documented for VKORC1 
(vitamin K epoxide reductase complex subunit 1) [Wang et al 2008].   These effects are often 
tissue-specific and influenced by external stimuli, such as drug exposure, generating a dynamic 
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nexus between genetics, epigenetics, and environmental factors such as stress, abuse, famine, and 
others [Provencal et al 2014, Stankiewicz et al 2013, Yao et al 2014].   
 
Because of chromatin looping between enhancers and promoters, a genetic variant at one enhancer 
can influence epigenomic changes over long distances.  As each enhancer and promoter can reach 
multiple target regions, evidenced by chromatin conformation assays, a single variant can spread 
epigenomic marks across multiple chromatin regions and distinct gene loci.  This paradigm is 
incompatible with a simplistic gene variant-effect relationship, but rather highlights the highly 
non-linear and adaptive dynamic nature of genomic-epigenomic processing. 
 
Statistical Problems in GWAS Interpretation 
 
Performing millions of association tests in parallel creates serious multiple comparison problems, 
rendering statistical significance far from a binary.  Because of the linkage between adjacent loci, 
not all of the methods for multiple comparison control are appropriate for GWAS [Benjamini et 
al 1995, Blanchard et al 2009].  The resultant widespread use of Bonferroni comparison control 
(in the form of a single threshold of 1e-8 for “genome wide significance”) [Johnson et al 2010, 
Fadista et al 2016] has exacerbated the statistical problems.  In many cases, causative variants 
discovered in subsequent GWAS on a particular phenotype were trending toward significance in 
prior less-powered GWAS, but were not distinguishable from noise with those samples and the 
methods then in use [Visscher et al 2017]. 
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However, this situation also resists the thoughtless use of more sophisticated tools like the 
Benjamini and Hochberg FDR [Benjamini et al 1995], which evade the stringency of the 
Bonferroni method but have the cost of assuming statistical independence between comparisons.  
With adjacent loci exhibiting linkage, the naïve use of FDR methods may allow a cluster of linked 
SNPs around a lead SNP to falsely “demote” real and significant hits.  Accordingly, thinking in 
this area is trending toward the use of fine mapping and coimputation approaches which are 
informed by linkage structure and do not blithely assume either a single genome wide threshold or 
statistical independence [Fadista et al 2016, Wang et al 2016]. 
 
Once investigators are confident of the reality of a GWAS hit, there is still no certainty which 
variant or variants are causatively linked to the study phenotype and responsible for the 
association.  Significance regions typically span a number of linked variants all attaining genome 
wide significance of association with the study phenotype.  And because over 90% of causative 
GWAS SNPs are noncoding regulatory SNPs [Boyle et al 2012], it is often unclear what the 
mechanism of causation is: which genes are being regulated by the causative SNP, in what tissues, 
under what conditions. 
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The Epigenome 
 
During the same period of time, array- and sequencing-based assays for a large number of 
epigenome features, and experiments and atlases conducted with such assays, have revealed that 
the multifaceted, tissue-specific epigenome has a relationship with gene expression, cell fate, 
organismal function and dysfunction, and disease, which is both intricate and powerful.   
 
In contrast to the genome, which is relatively well defined, the epigenome comprises a large and 
growing number of modalities measurable with various assays, most of which take the form of 
“tracks” comprising numeric levels of observed signal at various positions in the genome, and 
often a genome-wide vector of signal.  These include gene expression (RNA microarrays and 
RNA-seq, and proteomics) [Lonsdale et al 2013], DNA methylation (assayable with MeDIP-seq 
[Staunstrup et al 2016], RRBS [Yong et al 2016], WGBS [Olova et al 2018], and other methods), 
hydroxymethylation (hydroxylmethylation WGBS) [Huang et al 2010, Wen at al 2016], 
chromatin accessibility (DNase-seq [Song et al 2010], ATAC-seq [Buenrostro et al 2015]), 
histone post-translational modifications principally including acetylation and mono-, di-, and 
trimethylation of lysine residues at H3K27, H3K9, H3K36, and H3K4 [Roadmap Epigenomics 
Consortium 2015], but also including a large and growing number of subsidiary histone marks 
(ChIP-seq, ChIP-Exo), transcription factor binding for hundreds of transcription factors (ChIP-
seq), and others.  In addition to this are epigenome assays relating to the spatial and functional 
genome which express themselves as contacts and relationships in squared and other higher-
dimensional genome spaces, including molecular QTL (mQTL) screening, enhancer mapping, and 
spatial genome measurements including 3C [Dekker et al 2002], 4C [Simonis et al 2006], 5C 
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[Dostie et al 2006], Hi-C [Lieberman-Aiden et al 2009], ChIA-PET [Li et al 2014], Genome 
Architecture Mapping [Beagrie et al 2017], Hi-ChIP [Mumbach et al 2016], and SPRITE 
[Quinodoz et al 2018]. 
 
Epigenome elements differ from cell type to cell type and across the cell cycle in multicellular 
organisms [Roadmap Epigenomics Consortium 2015], and from person to person [Flanagan et 
al 2006, Schneider et al 2010], and according to physiological, environmental, and medical 
conditions [Schneider et al 2010].  Thus, the space of possible assays dwarfs any real dataset.  
Nevertheless, there have been increasingly systematic attempts to produce comprehensive 
spanning sets of epigenome data with standardized methods, yielding a set of epigenome “atlases” 
under the rubrics of ENCODE [ENCODE Project Consortium 2012], the Epigenome Roadmap 
[Roadmap Epigenomics Consortium 2015], the International Human Epigenome Consortium 
[Stunnenberg et al 2016], and the upcoming Human Cell Atlas [Regev et al 2017], as well as 
more focused efforts from many quarters.  IHEC data now includes a set of core epigenome marks 
for over a hundred tissues throughout the human body.  As a result of this, despite the inherent 
sparsity of any real dataset, the epigenome is increasingly regarded like the reference genome: as 
a resource to be consulted for systems and loci of interest, rather than an unknown quantity to be 
queried experimentally in specific contexts. 
 
The epigenome atlases have identified a set of “core” epigenome elements which determine a set 
of chromatin states corresponding to the various categories of regulatory states (for genes) and 
regulatory elements (for noncoding regions of the genome).  The most influential method for 
calling chromatin states is ChromHMM [Ernst et al 2012], which uses a hidden Markov model 
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on “core” epigenome tracks to call fifteen chromatin states including seven types of 
promoters/enhancers and eight types of activity/repression states.  Chromatin states which emerge 
in particular genomic locations in particular tissues have become a widely used and powerful guide 
to the functions of the host loci and the tissues in which they operate. 
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[A]  
  
[B] 
  
Figure 1-1. The Spatial Epigenome from the Nucleus to Atoms  
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Schematic of a generic interphase nucleus showing different compartments involved in 
determining transcriptional regulation.  [A] Higher order components of 4D nucleome 
organization, including the nucleus as a whole, the nucleolus, and chromosome territories 
containing TADs, LADs, NADs, and loop domains in Transcription Factories.  [B] Lower order 
components of 4D nucleome organization, including chromatin fibers of several types, 
nucleosomes and histones with associated subtypes and covalent chemical modifications, and 
naked DNA.  In the nucleosome core particle, H3 and H4 are shown in purple while H2A and H2B 
are shown in green.  See text for further details.  
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In addition to this, the validation of enhancer and promoter elements with reporter assays based on 
the transcription of their target genes under the influence of element excision with CRISPR 
genome editing [Lopes et al 2016, Gasperini et al 2017, Klein et al 2018], what is referred to as 
“CRISPR validation” of an element, has been increasingly used.  Under the influence of these 
methods, researchers are increasingly able to assess the function, activity, and targets of regulatory 
elements in a tissue-specific manner by consulting these resources, even in the absence of any 
purpose-specific experiments. 
 
In addition to this, a powerful set of tools have emerged that use machine learning and explicit 
algorithms to make predictions about the effects of sequence changes and other perturbations on 
epigenome outcomes.  These have included both explicit algorithms and machine learning methods 
for predicting TF binding, machine learning methods for predicting variant effects on epigenome 
tracks and chromatin states, and machine learning models for predicting enhancer targets. 
 
Position weight matrices (PWMs) [Stormo et al 1982] have been used to define transcription 
factor motifs since the 1980s.  Despite their algorithmic crudity, their performance at defining 
binding sites has been surprisingly strong relative to competing methods, and they have the 
advantage of being very simple to define and use, and very interpretable.  With the sequencing of 
the genome and genome wide ChIP-seq experiments for many transcription factors, it became 
possible to define motifs for large collections of TFs [Liefooghie et al 2006] and assay them 
genome wide.  With the reference and alternate alleles of SNPs, it is thus possible to gauge the 
comparative adherence of the flanking sequences to the TF under the influence of the various 
alleles of the SNP.  This is performed at scale by algorithms like TFM-Scan [Liefooghie et al 
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2006] and MotifDB [Shannon et al 2018].  In addition to this, recent work by Nishizaki [Nishizaki 
et al 2017] and others has focused on predicting the occupancy of TF binding sites by reference to 
both variants and the chromatin states exhibited by the host loci in tissue-specific data. 
 
In addition to this a large number of machine learning algorithms have been published and widely 
used that predict the influence of variants on epigenome tracks, especially chromatin accessibility, 
and on chromatin state.  Support vector machines based on gapped k-mers and trained on positive 
and negative sequences from a specific epigenome track emerged as a potent predictor of variant 
effects on chromatin accessibility beginning with gkm-SVM [Gandhi et al 2016], deltaSVM [Lee 
et al 2015], and lsGKM [Lee 2016].  But in addition to this, deep neural networks including 
DeepSEA [Zhou et al 2015] and Basset [Kelley et al 2016] have been trained on collections of 
epigenome tracks in a large number of tissues to predict variant effects on epigenome tracks and 
chromatin states in specific tissues, and have exhibited performance increases over SVM-based 
methods, including the ability to attain increased speed of training by transfer learning from a 
trained multi-tissue model to a single-tissue model. 
 
Finally, integrative computational methods for predicting enhancer target genes on the basis of 
tissue-specific integrative epigenomics and Hi-C data have proved extremely effective at 
predicting proximal enhancer targets [Spurrell et al 2016, Hardison et al 2014].  Such methods 
have prominently included TargetFinder [Whalen et al 2016], which took an integrative approach, 
as well as methods of Lieberman-Aiden et al [Durand et al 2016], which are based purely on Hi-
C and sequence data. 
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The Spatial Genome 
 
The period since the sequencing of the genome has also seen two epochal discoveries advancing 
in parallel: firstly that the spatial organization of the genome inside the 3D space of the nucleus 
varies from cell type to cell type [Rao et al 2014], cell to cell [Nagano et al 2013, Stevens et al 
2017, Ramani et al 2017], condition to condition [Chen et al 2017], and over time [Seaman et 
al 2018], and has a powerful and intricate connection with gene expression, cell fate, and 
organismal function and dysfunction including disease, and secondly that such organization can 
be measured in parallel across the multidimensional vector spaces over genomic position which 
represent combinatorial genomic interactions [Quinodoz et al 2018]. 
 
Prior to the emergence of genome sequencing based biochemical assays, the existence of a role for 
genomic spatial organization was already known from imaging studies and the biochemical 
methods of chromosome conformation capture (3C) [Cremer et al 2000, Dekker et al 2002], to 
some extent.  It was known that chromosomes in the interphase nucleus segregated into 
chromosome territories (CTs) resolvable with fluorescent in-situ hybridization (FISH) probes 
[Cremer et al 2000], that the loci involved in common translocations in cancer were often spatially 
close to each other in normal interphase nuclei of the tissues from which the cancers arose [Lee et 
al 1993], and that transcriptional activity demarcated by RNA polymerase II (Pol2) took on a 
punctate form inside the nucleus [Hughes et al 1995, Eskiw et al 2008].  
 
But such awareness took on a new height with the advent of new measurement methods.  In 
imaging, labeling, imaging, and interpretation all took on new power.  Not only did FISH probes 
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of the cell nucleus take on a new precision with the availability of genome-wide collections of 
bacterial artificial chromosome (BAC) libraries for the easy generation of FISH probes for 
arbitrary loci [Baumgartner et al 2006], but oligomer FISH (Oligo-FISH) methods [Schmitt et 
al 2010] became easier and cheaper to perform with the availability of the reference genome, 
bioinformatics tools for probe design, and the rapidly plunging cost of de novo DNA synthesis.  
The wider availability of 3D confocal microscopes and more powerful imaging methods like 3D 
SIM [Shao et al 2011], PALM [Betzig et al 2006] and STORM [Rust et al 2006] super resolution 
microscopy, labeling methods for multiple probes at the same time, spectral deconvolution 
[Zimmerman et al 2003] and white light lasers [Chiu et al 2012] to make channels easier to 
separate, and other methods made it possible to discern label positions better than ever before.  
CRISPR imaging [Chen et al 2013, Chen et al 2014] made it possible to image nuclear labels in 
live cells.  And the proliferation of 2D and 3D image parsing packages, including the work of 
Rajapakse et al [Rajapakse et al 2011, Seaman et al 2015] and Misteli et al [Shachar et al 2015, 
Jowhar et al 2018], as well as Kalinin et al [Kalinin et al 2017], made it easier to extract high 
content semantic information from nuclear architecture imaging. 
 
This imaging work confirmed the earlier explorations of the pre-genome era and added new 
discoveries.  It was discovered that the punctate elements of Pol2 activity were in fact collections 
of co-regulated genes from different chromosomes being transcribed and regulated together 
[Papantonis et al 2013], that they assemble stochastically on timescales of minutes for 
transcriptional bursting [Ghamari et al 2015], that they are located on the periphery between 
chromosome territories and preferentially located in the center of the nucleus [Cremer et al 2015], 
and that their assembly predates transcription [Krijger et al 2017].  It was discovered that 
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repressive lamin-associated domain (LAD) elements in the genome are transcriptionally repressed 
[van Steensel et al 2017] and that escape from transcriptional silencing depends on spatial escape 
from the lamin [Robson et al 2017].  It was discovered that proximal promoters and controlling 
enhancers unite spatially for transcription [Rao et al 2014], including super enhancers controlling 
collections of co-regulated genes [Thibodeau et al 2017, Gong et al 2018, Huang et al 2018].  
And experiments in serial FISH of a collection of FISH probes along the length of a chromosome 
showed that the spatial compaction of collections of loci within a collection of loci recapitulates 
their contact frequencies as measured by 3C-based methods [Wang et al 2016]. 
 
And the developments in sequencing-based methods for gauging chromatin spatial information 
were even more profound.  The sequential development of parallel 3C-based methods including 
4C (one genomic location against the genome) and 5C (a collection of probes against each other) 
reached a disjunction with the development of Hi-C: high throughput chromatin conformation 
capture.  It involves cross-linking fixed cells and digesting the genome with a restriction enzyme 
(or, for Micro-C, mainly used in small genomes, an unselective endonuclease like MNase), 
followed by religation, sonication, and paired end sequencing.  The result is a paired end 
sequencing library wherein the genomic locations of the paired reads do not correspond to 
elements close to each other in sequence space, but in physical space.  Such reads can be compiled 
into a chromatin contact map, potentially of the entire squared genome. 
 
This method, which allowed parallel 3C-style measurement of the entire genome against the entire 
genome, producing maps of chromatin contacts in square genome space, electrified the field of 
chromatin structure and became the standard in genome structure research.  Progressive protocol 
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optimization has allowed the methods to produce higher quality data with lower effort, and to 
address a wider collection of cell lines and tissues.  Experiments in a large number of cell lines 
and conditions have highlighted the commonalities in genome organization and the ways that 
organization differs over time.  Hi-C data is increasingly being used for fundamental genomics 
tasks like assembling reference genomes [Korbel et al 2013], phasing haplotypes [Ben-Elazar et 
al 2016, Selvaraj et al 2013], and detecting chromosome translocations [Chakraborty et al 
2017]. 
 
But even more than this, Hi-C data has been produced a revolution in our understanding of spatial 
genome organization, the largest component of which has been the discovery of topologically 
associating domains (TADs) [Dixon et al 2012] in the human genome and other genomes.  These 
self-associating regions have been identified as potent spatial and functional elements in the human 
genome.  The division of approximately 80% of the human genome into approximately 2500 TADs 
is remarkably robust, being largely conserved between cell types in the human body [Rao et al 
2014], between different humans [Ruiz-Velasco et al 2017], and under disease states [Rao et al 
2014].  In fact, syntenic regions of related genomes (e.g. mouse) often share the same TAD 
structure as the related regions of the human genome [Krefting  et al 2017, Nora et al 2013].  
TADs also function as replication domains [Pope et al 2014].  Moreover, TADs mediate long 
range spatial interactions [Rao et al 2014]: the contact frequency in any given portion of the 
squared genome will more closely correlate with a more sequence-distant portion which is in the 
same TAD pair than a sequence-proximal portion spanning TAD boundaries. 
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While the portion of a genome which composes a TAD is relatively invariant, TADs differ from 
one cell type and biological condition to another in their degree of transcriptional activity.  This 
differentiation between the “A” and “B” compartments is connected with the sign of the dominant 
eigenvector of a genome-wide Hi-C matrix [Dekker et al 2013], the degree of spatial openness as 
observed by both Hi-C, imaging, and biochemical experiments [Roadmap Epigenomics 
Consortium 2015], the degree of gene expression [Roadmap Epigenomics Consortium 2015], 
the presence of active histone marks [Roadmap Epigenomics Consortium 2015], the presence 
of activating transcription factors [Roadmap Epigenomics Consortium 2015], replication timing 
[Pope et al 2014], and the extent of long range and interchromosomal contacts [Rao et al 2014].  
Genes located in the same TAD tend to be co-regulated, and they are regulated partially by their 
TAD context. 
 
Moreover, the sequence context governing these regulatory interactions is beginning to illuminate 
under sustained investigation.  High resolution Hi-C experiments have discovered a hierarchy of 
super- and sub-TADs running all the way down to the level of “loop domains” [Rao et al 2014] 
which spatially unite the proximal enhancers of genes with their intra-TAD proximal enhancers.  
These contacts, and those above them in the hierarchy, are largely governed by the presence of 
convergent pairs of CTCF sites [Nichols et al 2015, de Wit et al 2015] which form a CTCF-
cohesin anchor binding loci together by means of a loop extrusion mechanism which has been 
verified by biochemical and imaging methods [Fudenberg et al 2016, Sanborn et al 2016].  
Perturbations of these sequence elements by CRISPR in vitro, or by disease-related mutations in 
vivo, as for example in enhancer hijacking in cancer, have the predictable effects on Hi-C maps, 
the epigenome, and gene expression [Wutz et al 2016, Sanborn et al 2016].   
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The march of Hi-C in genomics shows every sign of continuing to escalate, with the number and 
variety of Hi-C experiments escalating year by year.  Recent work shows that genome assembly 
benefits from Hi-C data [Korbel et al 2013], so that in the future, Hi-C library preparation may be 
used for routine genome sequencing, making Hi-C data available in larger numbers of samples 
than any other epigenome modality (aside from gene expression).  In addition, the upcoming 
Human Cell Atlas [Regev et al 2017] is widely expected to feature in-depth Hi-C data on every 
major cell type in the human body.  Single cell Hi-C is shining a light on the variation of cellular 
organization between cell types and over the cell cycle.  Promoter capture Hi-C [Mifsud et al 
2015] is being explored as a medical diagnostic [Mishra et al 2017, Baxter et al 2018].   
 
And new methods of gauging chromatin organization with sequencing continue to proliferate, 
offering new discernment of various features.  Micro-C [Hsieh et al 2015], using endonucleases 
instead of restriction enzymes, has carried the resolution of Hi-C all the way down to the 
nucleosome level in small genomes (e.g. yeast and drosophila).  SPRITE [Quinodoz et al 2017], 
which uses serial dilution and combinatorial labeling to uniquely suspended label chromatin 
complexes before single ended sequencing, is producing deeper Hi-C style maps with less 
sequencing, and also allowing the exploration of multiple-locus contacts in higher order 
combinatorial genome spaces.  Genome Architecture Mapping [Beagrie et al 2017], which uses 
single cell sequencing of cryosectioned nuclei followed by statistical modeling of the co-
occurrence of pairs of sequence regions, cannot produce high resolution intra-TAD information, 
but generates Hi-C style contact maps with less sequencing, and also can be used to produce 
calibrated physical distances. 
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This proliferation of data is increasingly being used to form three dimensional models of 
chromosome territories and even the entire nucleus.  Early work in this area met with difficulty 
due to low resolution data, the complexity of the task and the overconstrained nature of the data, 
and the challenges caused by structural heterogeneity [Nagano et al 2013].  This may be clearly 
seen by the preeminence and then rejection of the “superaxis” model of chromosome territory 
structure, in which the sequence of a chromosome is approximately recapitulated by the spatial 
ordering of TADs along a “superaxis,” with the string of tads threading back and forth between 
the A and B compartments of the territory, possibly by means of a coil.  Multiple spatial modeling 
investigations based on different modeling methods and different Hi-C datasets independently 
discovered the superaxis [Hu et al 2013, Nagano et al 2013], but it was subsequently demolished 
by the publication of serial FISH data on threading TAD positions in chromosome territories in 
single cells [Wang et al 2016].  The latest modeling methods use single cell data to refine models 
based on higher-resolution ensemble Hi-C [Lando et al 2018], and do not produce superaxis 
behavior in the models.  They show better accord with 3D FISH data than prior models. 
 
Spatiotemporal Gene Regulation: From Atoms to Cells and Seconds to Decades 
 
Multiple scales of spatial resolution demonstrate that the three dimensional (3D) organization of 
the nucleus, and its chromatin components, provides the basis for the regulation of gene expression 
on a genome-wide level and on a per gene basis.  These 4D nucleome components exist on spatial 
scales ranging from higher order nuclear structures including chromosome territories, the nuclear 
lamina, nuclear pore complexes, nucleoli [Cremer et al 2001, Wendt et al 2014] to transcription 
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factories (TFac) that unite topologically-associating domains (TADs) [Dixon et al 2012, 
Lieberman-Aiden et al 2009, Rao et al 2014] from multiple portions of one or more 
chromosomes for coordinated transcription, to the coordinated loop domains [Rao et al 2014] that 
hold active genes open in TFac TADs, through chromatin fibers down to naked DNA.  In the 
temporal dimension, phenomena such as the circadian rhythmicity of gene expression [Zhang et 
al 2014] and the timing of interactions between specific CLOCK (clock circadian regulator) gene 
loci [Chena et al 2015] operate on scales ranging from the rapid transcriptional stimulus response, 
to ultradian rhythm, to the circadian rhythm, to the life cycle of organisms.   
 
The genome in the nucleus is divided into chromosome territories, discrete spatial domains 
physically containing the DNA of each chromosome [Chena et al 2001, Cremer et al 2010].  In 
a diploid human cell, there are a total of 46 chromosome territories; the autosomes occupy distinct 
territories and are differentially regulated.  There is increasing recognition that allele-biased 
transcription, both stochastically and in a coordinated imprinted manner, is quite common in 
mammalian cells as determined using single cell RNA-seq and 3D FISH (Fluorescence In Situ 
Hybridization) at the cellular level [Deng et al 2014, Palacios et al 2009].  The chromosome 
territories fold  into Topologically Associating Domains (TADs) [Dixon et al 2012, Rao et al 
2014], compact, self-associating regions whose sequence extent is canonical between tissues of 
the body and between individuals, and whose boundaries are marked by coordinated CTCF and 
cohesin binding.  These TADs condense in a fractal globule polymer model, whose configuration 
is regulated in response to the transcriptional program of the nucleus.  TADs with transcribed genes 
migrate preferentially to the exterior of chromosome territories in the nuclear interior, where they 
mingle in TFacs for coordinated regulation.  In contrast, lamin-associated domains (LADs) located 
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near the inner surface of the nuclear membrane, repress approximately 90% of gene expression as 
a consequence of their location in heterochromatin. A layer of heterochromatin also surrounds 
nucleoli, so localization of a gene in this nuclear compartment using datasets from, e.g. the human 
brain atlas of the Allen Brain Science Institute [Sunkin et al 2013] is suggestive of repression 
within nucleolar-organizing or associated domains (NADs).  An overview of the higher level 4D 
nucleome components and their association with classes of organizing domains (TADs, LADs, 
and NADs) is shown in Figure 1-1A. 
 
Within TADs, the genome is organized into chromatin loop domains.  Chromatin loops form the 
basis of transcriptional regulation of many genes, as confirmed by the results of a recent study, 
which demonstrated that the fundamental functional topology of transcriptional regulation at a 
genome-wide level in humans occurs within spatial interaction networks [Rao et al 2014]. These 
are composed of enhancer-promoter loops that regulate transcription within and between 
chromosomes in cis and trans [Rao et al 2014].  Loop domains playing host to active transcription 
have a signature spatial interaction distinct from repressed loops, detectable with spatial mapping 
techniques [Rao et al 2014].  Inter-chromosomal loops have been visualized using super-
resolution microscopy [Cremer et al 2001], and these trans interactions may not only be 
functionally active, but the underlying loci’s status as active TADs or repressive transcriptional 
hubs may be propagated through cell division and transgenerational inheritance.  These features 
may be seen in Figure 1-1A and B. 
 
At the fundamental level, 146 base pairs of naked DNA wrap in one and three quarters turns around 
a hetero-octamer of Histone proteins composed of 1 tetramer of Histones H32H42, and 2 histone 
H2A-H2B dimers, to form the nucleosome core particle, a disc 11nm in diameter and 5.5nm in 
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height.  Nucleosome core particles are connected by variable lengths of linker DNA.  A fifth 
histone subtype, Histone H1, known as the “linker Histone” regulates fiber condensation in 
heterochromatin.  The subtype of histone proteins which make up the octamer, post translational 
modifications to these proteins, their position and frequency along the sequence of the genome 
(called nucleosome repeat length), and their organization into several types of euchromatin and 
heterochromatin chromatin fibers, are all epigenomically significant and regulated both by base 
sequence and programmatic context [Bannister et al 2011, Luger et al 2012].  Areas of active 
transcription are associated with nucleosome variants and post translational modifications  
indicative of lower binding strength, coordinated nucleosome positions around transcription start 
sites and generally lower density, more DNase sensitive sites, and less condensed, less regular 
fibers lacking in H1 binding [Woodcock et al 2010].  Repressed regions carry Histone variants 
and post translational modifications conducive to tighter binding, and regular nucleosome spacing, 
with condensation by H1 binding into regular, compact crossed-linker fibers with a diameter of 
about 30nm [Williams et al 1986, Athey et al 1990].  This area of lower level chromatin regulation 
is a rich matter for research with a number of techniques.  Such features are shown in Figure 1-1 
B.    
 
Pharmacoepigenomics 
 
Integrative Epigenome Models of Variant Function Applied to Association Hits 
 
The combined power of multiple epigenome modalities to interpret variant function began being 
exploited to address the interpretation challenges of GWAS around the time of the publication of 
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the Phase 2 ENCODE maps [ENCODE Project Consortium 2012], and was in wide development 
by the time the Epigenome Roadmap [Roadmap Epigenomics Consortium 2014] data landed.  
The most visible sign of this was in the variant annotation and interpretation methods being 
published, prominently including the early contributions of RegulomeDB [Boyle et al 2012] and 
HaploReg [Ward et al 2012].   
 
These pipelines work by annotating SNPs multimodally with information from multiple types of 
omics information.  In the case of RegulomeDB, this included DNase sensitive regions, validated 
promoter and enhancer regions, transcription factor binding sites, and predicted regulatory 
elements.  HaploReg expanded on this suit by adding tools to gauge the relevance of SNPs in the 
area of a lead SNP with linkage, and looking at PWM perturbation by SNPs, deeper epigenome 
data from the Roadmap, and eQTL data.  Both have been widely used. 
 
All such models rely on an overall paradigm of genomic regulation sometimes described as the 
“pharmacoepigenome,” [Higgins et al 2015] in which, by virtue of the facts that 1) associations 
arise from causative regulatory variants influencing the underlying genomic machinery of a 
phenotype, 2) regulatory variants and their targets can be identified and parsed by looking for the 
hallmarks of regulation in epigenome datasets, and 3) the machinery underlying genetic variation 
in a phenotype is often joint with the machinery underlying the phenotype itself and related 
phenotypes, it is concluded that powerful insights into the mechanisms of a wide variety of 
phenotype, not necessarily constrained to pharmacogenomics, can be obtained by looking for 
tissue-specific regulatory variants and their targets in the regions surrounding association hits for 
a collection of related phenotypes. 
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Such models have been used to interpret GWAS, looking in significance regions for regulatory 
variants, by a large number of different methods mostly comprising individual ad-hoc analyses.  
They differ significantly but largely adhere (fully or partially) to a number of common themes: 
 
1) Analyzing multiple GWAS on the same (or related) phenotypes together in the same 
analysis. 
 
2) Analyzing many variants, not just lead SNPs.  For primary GWAS this is often done with 
the significance region or with a p-value fold change cutoff from the lead SNP.  In 
secondary analysis, it is often done by linkage.  Some analyses have used sequence distance 
cutoffs, but this is not biologically informed and is inadvisable. 
 
3) Looking for regulatory variants with tissue-specific data that is relevant to the phenotype 
under investigation. 
 
4) Attempting to identify the target genes of candidate regulatory variants discovered in the 
analysis. 
 
5) Filtering, ranking, and organizing the result genes together with pathways and ontologies, 
looking either for genes of preexisting known relationships to the phenotype, or genes that 
cohere with each other, e.g. by shared pathway or ontology membership, or coregulation 
by a known transcription factor. 
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Such analyses have become more common, with epigenome-based causal variant methods 
appearing in even primary GWAS analyses. 
 
Early Pharmacoepigenomics Efforts in Neuropsychiatry 
 
The intent of GWAS is to detect statistical correlation between genotypes, often SNPs, and a 
phenotype of interest using a large number of samples.  As opposed to candidate gene association 
studies often used in neuropharmacology and in CNS pharmacogenomics, the objective is to 
enable unbiased prediction of phenotype based on allelic data.  Early GWAS of psychiatric 
pharmacogenomic phenotypes yielded two startling results: (1) Most associations did not reach 
the stringent statistical threshold required to rule out false positive associations, which was based 
on Bonferroni correction for multiple comparisons [Gao et al 2010], and (2) The majority of 
pharmacogenomic SNP associations detected are located within non-coding regions of the 
genome, including introns and intergenic domains, as is true in GWAS for other traits [Farh et al 
2015]. It is now understood that these noncoding variants impact functional regulatory elements 
such as enhancers, and that differential regulation of enhancer-promoter interactions within 
chromatin interaction networks is largely responsible for variation in pharmacogenomic response, 
contributing much more than non-synonymous variation in the exome [Kellis et al 2014].  
 
The early agnostic approach to GWAS analysis required stringent adjustments for multiple 
hypotheses testing; however, with more information available on each variant, a new approach has 
emerged, taking advantage of prior knowledge. Since the first GWAS was conducted in 2006, 
there has been an increasingrecognition that the parameters needed to be changed, with consensus 
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around several modifications of the original precept: (1) Focus has been placed on the use of 
noncoding variants found in GWAS as components of related biological pathways [Califano et al 
2012]; and (2) Joint GWAS analyses of related disease phenotypes are now commonly accepted 
as over-lapping sets of variants are becoming the norm, not the exception [Califano et al 2012]. 
 
The clinical utility of any biomarker must be based on studies in humans.  However, in variant 
discovery, explanatory and predictive annotation of human GWAS using a bioinformatics 
framework has the potential to provide insight into previously unrecognized pathways.  There is 
precedence in the use of such approaches including: (1) Imputation and chromatin state annotation 
of GWAS SNPs in the context of the regulome [Califano et al 2012, Schaub et al 2012, Tasan 
et al 2014, Boyle et al 2012]; (2) Interpretation of GWAS SNPs using known cellular 
transcriptional networks with inclusion of new sequencing data [Kellis et al 2014, Network and 
Pathway Analysis Subgroup 2015]; (3) Joint analysis of multiple, seemingly unrelated disease 
GWAS to discover novel shared pathways [McGeachie et al 2014, Kuhn 1962]; and (4) “Prix 
fixe” scoring using multiple GWAS to uncover shared regulatory genes involved in biological 
pathways [Tasan et al 2014].   
 
Joint analysis of GWAS in psychiatric disorders using open source pathway analysis software has 
implicated shared, common pathways among multiple disorders such as bipolar I disorder, major 
depressive disorder and schizophrenia [Network and Pathway Analysis Subgroup 2015].  
Pathways from public databases were compiled, then significant SNPs from psychiatric GWAS 
were gathered as components of pathways. These pathways were then assessed statistically using 
different strategies, ranked and averaged. Empirical p-values were calculated by comparing 
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average ranks in disease data to average ranks in simulated data. Finally, a combined p-value for 
bipolar disorder 1, major depressive disorder and schizophrenia study showed that a significant 
shared effect was the methylation of histones H3K4 (histone H3 lysine), which are defining histone 
marks that differentiate H3K4me1, a histone mark that defines enhancers, from H3K4me3, a 
histone mark that defines promoters [Ernst et al 2010]. 
 
The Paucity of Pharmacoepigenomics in Clinical Practice 
 
By contrast, the discipline of pharmacogenomics has historically made little use of any of the 
advanced variant discovery and interpretation methods discussed above.  To date, the most widely 
used biomarkers for clinical pharmacogenomic testing are a set of pharmacokinetic (PK) gene 
variants located in CYP genes, encoding the main drug metabolizing enzymes, while only a small 
family of pharmacodynamic (PD) genes have been utilized, and regulatory variants, even less 
[Higgins et al 2015].  While such tests often achieve clinical utility and cost-of-care reduction 
[Higgins et al 2015], they often account for a minority of the inter-individual genotypic variation 
in important drug-related phenotypes [Higgins et al 2015].  By and large, however, these tests are 
designed manually using variants in a small pool of candidate genes. 
 
Although pharmacogenomic phenotypes have been investigated with GWAS since its inception 
[Giacomini et al 2017], most available pharmacogenomics tests continue to be based on highly 
penetrant coding variants revealed by gene-specific work, with GWAS findings, PD genes, and 
regulatory variants persistently underutilized.  Deployment of GWAS in pharmacogenomics 
variant discovery has lagged deployment in other disciplines, epigenomic interpretation of GWAS 
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results has been underutilized, and the translation of GWAS results into clinical tests has been 
slower still in most areas. 
 
Indeed, much pharmacogenomics variant discovery still proceeds along traditional lines involving 
the search for coding variants to be designated as star (*) alleles, with a particular emphasis on PK 
genes for absorption, distribution, metabolism, and excretion (ADME).  Such genes have formed 
the focus for test development for response, dosing, and adverse drug events (ADEs) and adverse 
drug reactions (ADRs). 
 
For example, consider neuropsychiatry.  As of 2015, the Table of Pharmacogenomic Biomarkers 
used in drug labeling from the U.S. Food and Drug Administration (FDA) listed 145 precautions 
for 24 psychiatric medications, 9 neurology medications, and 2 anesthetics.  None of these 
precautions reference PD genes expressed predominantly in the CNS; all are CYP metabolizer 
subtypes of genes expressed in liver, drug-drug interactions, or gene effects in peripheral tissues 
(Table 1).   The predominance of CYP gene variants in early research and testing for risk of ADEs 
led to a commonly-used, CYP-based phenotypic stratification of patients into metabolizer classes 
such as poor, intermediate, extensive, and ultra-rapid, for genes such as CYP2D6 (cytochrome 
P450 family 2 subfamily D polypeptide 6).  
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Drug Therapeutic Area 
HUGO 
Symbol 
Referenced 
Subgroup Labeling Sections 
Amitriptyline Psychiatry CYP2D6 CYP2D6 poor metabolizers Precautions 
Aripiprazole Psychiatry CYP2D6 CYP2D6 poor metabolizers 
Clinical Pharmacology, Dosage and 
Administration 
Atomoxetine Psychiatry CYP2D6 CYP2D6 poor metabolizers 
Dosage and Administration, Warnings and 
Precautions, Drug Interactions, Clinical 
Pharmacology 
Carbamazepine (1) Neurology HLA-B HLA-B*1502 allele carriers Boxed Warning, Warnings and Precautions 
Carbamazepine (2) Neurology HLA-A HLA-A*3101 allele carriers Boxed Warning, Warnings and Precautions 
Citalopram (1) Psychiatry CYP2C19 CYP2C19 poor metabolizers Drug Interactions, Warnings 
Citalopram (2) Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Clobazam Neurology CYP2C19 CYP2C19 poor metabolizers 
Clinical Pharmacology, Dosage and 
Administration, Use in Specific Populations 
Clomipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Clozapine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions, Clinical Pharmacology 
Codeine Anesthesiology/ Analgesia CYP2D6 
CYP2D6  
ultra-rapid 
metabolizers 
Boxed Warnings, Warnings and Precautions, Use 
in Specific Populations, Clinical Pharmacology , 
Patient Counseling Information 
Desipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Dextromethorphan 
and Quinidine Neurology CYP2D6 
CYP2D6 poor 
metabolizers 
Clinical Pharmacology, Warnings and 
Precautions, Drug Interactions 
Diazepam Psychiatry CYP2C19 CYP2C19 poor metabolizers Drug Interactions, Clinical Pharmacology 
Doxepin Psychiatry CYP2D6 CYP2D6 poor metabolizers Precautions 
Fluoxetine Psychiatry CYP2D6 CYP2D6 poor metabolizers Warnings, Precautions, Clinical Pharmacology 
Fluvoxamine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Galantamine Neurology CYP2D6 CYP2D6 poor metabolizers Special Populations 
Iloperidone Psychiatry CYP2D6 CYP2D6 poor metabolizers 
Clinical Pharmacology, Dosage and 
Administration, Drug Interactions, Specific 
Populations, Warnings and Precautions 
Imipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Modafinil Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Nefazodone Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Nortriptyline Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Paroxetine Psychiatry CYP2D6 CYP2D6 poor metabolizers Clinical Pharmacology, Drug Interactions 
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Perphenazine Psychiatry CYP2D6 CYP2D6 poor metabolizers Clinical Pharmacology, Drug Interactions 
Phenytoin Neurology HLA-B HLA-B*1502 allele carriers Warnings 
Pimozide Psychiatry CYP2D6 CYP2D6 poor metabolizers 
Warnings, Precautions, Contraindications, 
Dosage and Administration 
Protriptyline Psychiatry CYP2D6 CYP2D6 poor metabolizers Precautions 
Nefazodone Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Risperidone Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions, Clinical Pharmacology 
Tetrabenazine Neurology CYP2D6 CYP2D6 poor metabolizers 
Dosage and Administration, Warnings, Clinical 
Pharmacology 
Thioridazine Psychiatry CYP2D6 CYP2D6 poor metabolizers Precautions, Warnings, Contraindications 
Tramadol Analgesic CYP2D6 CYP2D6 poor metabolizers Clinical Pharmacology 
Trimipramine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
Valproic Acid (1) Neurology POLG POLG mutation positive 
Boxed Warning, Contraindications, Warnings 
and Precautions 
Valproic Acid (2) Neurology 
NAGS, 
CPS1, 
ASS1, 
OTC, 
ASL, 
ABL2 
Urea cycle 
enzyme 
deficient 
Contraindications, Warnings and Precautions, 
Adverse Reactions, Medication Guide 
Venlafaxine Psychiatry CYP2D6 CYP2D6 poor metabolizers Drug Interactions 
 
Figure 1-2. Table of Neuropsychiatric Medications 
Drug labels for medications used in psychiatry, neurology and anesthesiology from the Table of 
Pharmacogenomic Biomarkers, U.S. Food and Drug Administration.  [United States FDA 2015] 
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Almost all current psychiatric drugs are members of pharmacologic classes discovered and first 
applied in the 1950s, including medications such as chlorpromazine, imipramine, iproniazid, and 
lithium [Hyman 2014].  There exist off-target effects of these psychotropic drugs whose pathways 
remain uncharacterized to this day, and such drugs are associated with at least half of all ADEs 
stemming from prescribed medications.  Data extrapolated from IMS Health, Inc. as described in 
[Hyman 2014], show that 15 of the top 30 prescribed medications in 2013 exhibiting 
pharmacogenomic risk are drugs used in psychiatry and pain management, including sertraline, 
citalopram, escitalopram, diazepam, tramadol, fluoxetine, codeine, venlafaxine, methylphenidate, 
paroxetine, amitriptyline, oxycodone, risperidone, aripiprazole, and mirtazapine.  Figure 1-3 lists 
major medications used in psychiatry in the U.S., and the incidence of serious adverse drug events 
as evidenced by resulting emergency room visits and hospitalizations from 2009 to 2011 
[Hampton et al 2014].  Although more detailed information is lacking, it seems unlikely that most 
of these ~90,000 visits to emergency departments on an annual basis are due solely or primarily to 
CYP gene variations or the other precautionary indications shown in Figure 1-2.   
 
It may be that some of this ADE burden, and our difficulty ameliorating it, results from lack of 
knowledge of mechanisms of lengthy, difficult-to-study emergent adverse events such as 
extrapyramidal syndromes, weight gain, and actinic keratosis.  In addition, because 
benzodiazepines and opiates have significant consequences in substance abuse and addiction, they 
are widely considered an “undesirable and difficult” domain for study outside of addiction 
research.  
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Such cases are complex and probably involve a number of indications including dose, 
polypharmaceutical interactions among both psychiatric and non-psychiatric medications, and 
differential response due to ethnicity, age, gender, and variation in the genome.  Data on 
inheritance of drug response phenotypes strongly suggest that other biological mechanisms, such 
as epigenomic and transcriptional regulation, are likely to play a significant role and could be 
applied to informing and improving combinatorial PK metabolizer-class models.  Recent work 
[Zanger et al 2013, Zanger et al 2014] has indicated that noncoding regulatory SNPs could play 
a role in the regulation of PK CYP genes.  In addition, the relative paucity of PD mechanisms in 
describing drug efficacy suggests a significant future opportunity for the development of increased 
understanding of new PD pathways for neuropsychiatric drugs.   
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 ED Visits, Adverse Drug 
Events 
 
Medication 
Category and Class 
Estimated 
Annual No. 
of Visits 
% 
Hospitalization 
Rate 
Examples of Approved Medications in the U.S. 
Sedatives and anxiolytics 
Short-acting 
benzodiazepine 14387 
24.4 
Alprazolam, Clobazam, Clonazepam, Estazolam, Lorazepam, 
Midazolam, Oxazepam, Temazepam, Triazolam 
Non-benzodiazepine 10360 22.1 
Buspirone, Butabarbital, Chloral Hydrate, Eszopiclone, 
Meprobamate, Phenobarbital, Ramelteon, Secobarbital, 
Zaleplon, Zolpidem 
Long-acting 
benzodiazepine 2633 
21.8 
Chlordiazepoxide, Amitriptyline/Chlordiazepoxide, 
Clorazepate, Diazepam, Flurazepam, Quazepam 
Miscellaneous 3327 25.5  
Antidepressants 
SSRIs 12019 11.2 
Citalopram, Escitalopram. Fluoxetine, Fluoxetine/Olanzapine, 
Fluvoxamine, Paroxetine, Sertraline 
SNRIs 3887 * Desvenlafaxine, Duloxetine, Milnacipran, Venlafaxine 
Triazolopyridines 3443 18.5 Trazodone 
Aminoketones 2573 * Bupropion 
Tricyclics 1835 * 
Amitriptyline, Amitriptyline/Chlordiazepoxide, 
Amitriptyline/Perphenazine, Amoxapine, Clomipramine, 
Doxepin, Imipramine,Nortriptyline, Protriptyline,Trimipramine 
Tetracyclics  655 * Maprotiline, Mirtazapine 
MAOIs * * Isocarboxazid, Phenelzine Sulfate, Selegiline, Tranylcypromine 
Miscellaneous 838 * Nefazodone 
Antipsychotics 
Atypical 15272 16.9 
Aripiprazole, Clozapine, Fluoxetine/Olanzapine, Olanzapine, 
Paliperidone, Quetiapine, Risperidone, Ziprasidone 
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Typical 5804 10.6 
Chlorpromazine, Fluphenazine, Haloperidol, 
Haloperidol/Fluphenazine, Loxapine, Perphenazine 
Amitriptyline/Perphenazine, Thioridazine, Thiothixene, 
Trifluoperazine 
Miscellaneous * * Pimozide 
Lithium salts 3620 53.6  
Stimulants 
Amphetamines 2331 * 
Amphetamine, Amphetamine / Dextroamphetamine, 
Dexmethylphenidate, Lisdexamfetamine Dimesylate, 
Methamphetamine, Methylphenidate 
Miscellaneous * * Armodafinil, Atomoxetine, Modafinil 
 
Two drugs from 
different psychiatric 
medication 
categories 
5033 24.2  
 
Total 88017 
 
Figure 1-3. Table of Neuropsychiatric Medication Classes 
Estimation of the incidence of adverse drug events involving psychiatric medications based on 
annual visits to emergency departments in the U.S. from 2009-2011. *Indicates unknown or 
statistically unreliable data. Modified from [Hampton et al 2014]. 
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For another example, consider the anticoagulant warfarin.  Warfarin has a complicated 
pharmacokinetics and pharmacodynamics, with its influences on the action of a number of clotting 
factors each exhibiting a different half-life [FDA 2017].  It is widely acknowledged that warfarin 
dosing requirements and other phenotypes exhibit a strong patient-specific genetic element.  
Factor-of-ten differences in typical dosing requirements based on alleles in CYP2C9, the primary 
metabolic enzyme of warfarin, are present on the package insert label [FDA 2017], and data on 
association between warfarin requirements and other genetic loci have proliferated.  There have 
been multiple attempts to provide clinicians with genotype-guided dosing algorithms based 
typically on genotypes of VKORC1 and CYP2C9 [Flockhart et al 2008].  Despite the strength of 
variation in these two key genes, there is a “missing heritability” problem: identified loci in these 
genes account for only 30% to 50% of the predictive power implied by heritability estimates 
[Flockhart et al 2008].  Current generation tests use only variants in these two genes, and almost 
all use the same three SNPs: rs1799853, rs1057910, and rs9923231 (a promoter SNP for VKORC1) 
 
The design of these tests has not benefited from the epigenome or GWAS.  These variants were 
discovered and validated prior to GWAS.  Variants discovered in GWAS of warfarin-related 
phenotypes have not been incorporated into warfarin pharmacogenomics tests, and prior to the 
experiments described here, regulatory variant discovery with the epigenome had not been applied 
to the epigenome. 
 
Partially because of this, these tests have achieved only limited success despite intensive 
development and validation effort.  Despite hopes that two large trials (EU-PACT [Pirmohamed 
et al 2013] and COAG [Kimmel et al 2013]) would report good results, their appearance in the 
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same issue of the NEJM did not bear out such hopes.  COAG reported no difference in time within 
the therapeutic range (TTR), and EU-PACT reported a difference, but only compared to fixed 
starting doses with subsequent adjustment, not to initial dosing methods based on clinical 
indications that represent the real-world alternative to genetic dosing.  Neither trial was powered 
to report a difference in bleeding and embolism events.  Subsequently, a published meta-analysis 
of nine randomized controlled trials (RCTs) of warfarin pharmacogenomics dosing algorithms vs 
manual dose determination showed that current-generation tests using VKORC1 and CYP2C9 offer 
no improvement in TTR, percentage of patients with high INR, or bleeding and coagulation events 
[Stergiopoulos et al 2014]. 
 
Since the conclusion of these trials, expert comment has indicated a consensus that such algorithms 
do not add clinical value relative to dosing on the basis of clinical indications, despite their 
predictive power [Kimmel et al 2015, Johnson et al 2016].  Although the recent GIFT RCT of 
genomic warfarin dosing found that genome-guided dosing provided a significant benefit in the 
composite endpoint of major bleeding, INR of 4 or greater, venous thromboembolism, or death 
[Gage et al 2017], this generalizability of the study’s results is limited.  GIFT had narrow inclusion 
criteria: patients aged 65 years or older initiating warfarin for elective hip or knee arthroplasty. 
Those patients are at higher risk, and thus the generalizability of these results to larger patient 
populations and indications is debatable.  
 
Despite their predictive power, such tests have failed to deploy in mainstream clinical practice.  
Accordingly, it is clear that the failure of the warfarin pharmacogenomics community to benefit 
from the GWAS studies it had conducted and interpret them with the epigenome was not benign. 
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There is a critical need for the pharmacogenomics community to begin using GWAS and advanced 
epigenomic methods in the design of pharmacogenomics tests and decision support products.   
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Chapter 2: Manual Experiments in Epigenome Variant Discovery 
 
Pharmacoepigenomics in Application 
 
Motivated by the incomplete predictive power of current psychotropic pharmacogenomics tests, 
and the dominance of coding variants in both existing tests and ongoing work, and the potential 
for noncoding variants to contribute to resolving this problem, the Athey lab in 2014 initiated a 
series of variant discovery experiments in neuropsychiatric drug-disease systems, initially falling 
under the aegis of its partnership with Assurex Health.  By uniting association data with consortium 
omics and preexisting expert knowledge, we hoped to discover new noncoding variants for these 
phenotypes and their target genes, to enable development of second and subsequent generation 
neuroyschiatric pharmacogenomics tests. 
 
This chapter will cover three semi-manual experiments undertaken under the auspices of this 
initiative.  They are:  
1. An exploration of a number of GWAS results in neuropsychiatric pharmacogenomics 
which had not yielded coding variants [Higgins et al 2015] 
2. A comprehensive survey of association studies in lithium pharmacogenomics[Higgins et 
al 2015] 
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3. A mechanistic study of the action of valproic acid [Higgins et al 2017]. 
 
All three experiments were undertaken under the lead authorship of Gerry Higgins, and involved 
a number of people, principally including myself and Brian Athey. 
 
In the process of developing the methods for these exploratory experiments, carrying them out, 
and analyzing the results, a number of principles emerged, codified under the orienting framework 
I later began to call the Five Box Model of regulatory variant discovery.  These principles and 
ideas formed the basis for the Pharmacoepigenomics Informatics Pipeline, which was designed to 
carry out such experiments in a more automated, more reproducible manner and with advanced 
features which would not be plausible in a semi-manual environment. 
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Epigenomic Mapping of Noncoding Psychotropic Variants 
 
Motivation 
 
Joint GWAS analyses of related disease phenotypes are now commonly accepted, as the evidence 
has mounted that overlapping sets of variants for related phenotypes are the norm, not the 
exception [McGeachie et al 2014]. In addition, joint analysis of GWAS in psychiatric disorders 
using pathway analysis software has implicated shared, common pathways among multiple 
disorders such as bipolar disorder, major depressive disorder, and schizophrenia [Sullivan et al 
2012]. Pathway analysis from multiple GWAS studies has been applied to recognize regulatory 
networks shared among common complex diseases including coronary artery disease (CAD), 
rheumatoid arthritis (RA), Type 1 Diabetes (T1D), Type 2 Diabetes (T2D) and bipolar 
disorder [Cross-Disorder Group 2013]. 
  
Fine mapping of associated loci in GWAS yield causal variants that may differ from a reported 
lead SNP and are typically located in noncoding regions of the genome. For example, epigenetic 
mapping of enhancers using the histone marks H3 lysine27 acetylation (H3K27ac) and H3 lysine 
4 monomethylation (H3K4me1) in concert with mRNA-seq of neighboring genes was able to 
identify causal SNPs in enhancers in autoimmune disease, in which only 14% of associated 
protein-coding SNPs appear to be causal, while 60% of known causal SNPs map to 
enhancers [Farh et al 2015].  The relative scarcity of missense coding SNPs in GWAS of disease 
risk and other human traits can now be simply explained: regulatory DNA harbors causal SNPs in 
addition to protein coding domains [Kellis et al 2014]. 
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An ongoing challenge in pharmacogenomics is that many medications used in psychiatry and pain 
are clinically suboptimal and exhibit high frequencies of serious adverse events. In pain 
management, opioids are highly addictive but very effective, so it would be better to develop 
analgesics without risk of abuse. However, the model compounds for almost all neuropsychiatric 
drugs were discovered in the 1950s or earlier, and included opiates, as well as chlorpromazine, 
imipramine, iproniazid, and lithium. Since many medications used to treat patients with 
neuropsychiatric disorders were discovered over 50 years ago and/or serve as antecedents to later 
refinements of these seminal mid-century formularies, it is clear that greater emphasis should be 
placed on pharmacodynamic targets in the human CNS [Hyman 2014]. 
  
In this study, we developed a multi-level mapping method to identify novel noncoding SNPs in 
neuropsychiatry that exhibit epigenomic characteristics of genomic regulatory factors, and applied 
this method to screen SNPs derived from 26 pharmacogenomics association studies sourced from 
the NHGRI GWAS catalogue [Welter et al 2014] and 3 published candidate gene association 
studies. We used multiple known attributes of noncoding SNPs corresponding to genomic 
regulatory elements such as enhancers, promoters, and transcribed domains using extant public 
resources. These included public databases of chromatin interaction mapping for prediction of cis- 
and trans-regulation, including Hi-C and ChIA-PET data [Dixon et al 2012, Li et al 2013, Li et 
al 2014], to predict putative spatial interactions at the allelic level. These interactions were also 
investigated for legitimacy based on “guilt-by-association” methods [Lee et al 2011], leveraging 
multiple GWAS using pathway analysis [Califano et al 2012, McGeachie et al 2014], and GWAS 
imputation and annotation methods published by the epigenome roadmap consortium [Farh et al 
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2015, Yao et al 2015, Roadmap Epigenomics Consortium 2015, Zhou et al 2015, Leung et al 
2015, Ernst et al 2015]. At every phase of the experimental design, we used multiple independent 
analytic methods to ensure the validity of our in silico results using the current knowledge base. 
 
Methods 
 
An overview of methodology is shown in Figure 2-1. We used parallel approaches for SNP 
imputation, determination of functionally-significant variants for a given pharmacogenomic 
association, annotation of SNPs and assignment to a genome regulatory element such as enhancer, 
promoter and transcribed element, prediction of putative functional interactions in cis- and trans- 
using chromatin interaction mapping data and novel pathway reconstruction using multiple 
methods, including assignment to the most plausible pathway in terms of known functional, 
pharmacologic and/or morphologic data. Most results were independently gathered by 2 
investigators who were often not aware of the results obtained by the other. Since this study was 
performed in silico, several different, but sometimes related, methods were used to determine 
whether the results were the same. The objective of this study was to provide evidence for 
subsequent experimental studies for scientific validation in cell lines, animal models and other 
biological systems.  
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Figure 2-1. Diagram of ‘Variants’ Analysis Methods 
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Examination of GWAS and Candidate Gene Association Studies 
  
We examined neuropsychiatric pharmacogenomics GWAS contained in the NHGRI GWAS 
catalogue [Welter et al 2014] in psychiatry, neurology, analgesia and addiction, herein referred to 
collectively as “neuropsychiatric.” These included 26 GWAS and 3 candidate gene association 
studies.  The candidate gene studies were chosen for analysis because they were large case-control 
studies performed in circumscribed human populations that had identified significant variants 
associated with lithium response, citalopram response, and heroin addiction, to demonstrate proof-
of-concept. The gene association studies used for the analysis are shown in Figure 2-2. 31 variants 
from the 26 GWAS and 3 candidate gene association studies were initially selected that reached 
the criterion of a pharmacoepigenomic SNP from a total of 2024 variants in linkage disequilibrium 
(LD) > 0.8 (r2) with the reported lead SNP within the population being measured. 94% (1903) of 
the 2024 SNPs were noncoding and 6% (121) were coding.  
 
SNP Imputation and Selection 
  
In certain cases, standard methods were used for dense genotyping and imputation from 
association loci that had not been performed in the original study, including removing spurious 
associations and checking population stratification [Farh et al 2015, Wellcome Trust Case 
Control Consortium 2007].  In GWAS, if lead SNPs met the stringent statistical criterion of p < 
5 x 10-08, then the SNP(s) were checked for epigenomic classification using both our workflow 
and the reference human epigenome reference [Roadmap Epigenomice Consortium 2015]. In 
all but 1 case, the 31 SNPs analyzed using our workflow and using the human reference epigenome 
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produced the same results for the putative active regulatory elements that we identified. For SNPs 
that were associated with mutations in an enhancer that controlled a subnetwork responsible for 
drug efficacy and adverse events, then these variants were prioritized for further analysis. All gene 
definitions used in this study were acquired from the HUGO database [Gray et al 2012]. Genes 
were mapped to UCSC hg19 coordinates [Karolchik et al 2014]. Variation data from dbSNP 
[Sherry et al 2001] were also mapped to UCSC hg19 coordinates, and linkage-disequilibrium 
(LD) data for SNP pairs within population-specific haplotypes was downloaded from HaploReg 
[Ward et al 2012]. After compiling a master spreadsheet containing pharmacoepigenomic SNPs 
as output our workflow, we compared the results with those using the roadmap epigenome browser 
[Zhou et al 2015]. Although this study was only focused on what may be functionally active 
genome regulatory elements such as enhancers, promoters and transcribed domains, the epigenome 
roadmap classification system includes 15 chromatin states. Nonetheless, for every variant that we 
characterized as a promoter, enhancer, transcribed domain or quiescent, 30 out of 31 closely 
correspond to the chromatin state annotated from the epigenome roadmap. These data are 
presented in the results section. 
 
In cases wherein dense genotyping and epigenetic fine mapping had not been performed in the 
original GWAS analysis, we used a simple derivation of the method used in [Farh et al 2015] but 
with several modifications. We did not restrict GWAS selection to only those studies that 
contained SNPs which met the rigid statistical criterion of p < 5 x 10-08. The rationale was that, as 
has been shown by others, SNPs that appear to be less significant may in fact contribute function 
or be casual, based on pathway analysis showing that the SNP may impact a genome regulatory 
elements such as an enhancer [Onengut-Gumuscu et al 2015, Farh et al 2015, Maurano et al 
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2012]. Distal H3K27ac peaks were assigned to their potential target genes if they were located 
within introns or within 500kb regions upstream of a transcription start site of a gene in which 
likely a target of an enhancer. It is presumed that within an associated locus, a linear trend should 
be observed such that where a causal variant has been demonstrated using functional studies, with 
the assumption that neutral SNPs demonstrate association signal in proportion to their LD to the 
causal variant. However, in GWAS, multiple causal SNPs that effect regulatory pathways may 
occur within a haplotype block with an LD (r2) > 0.8 in the same population [Farh et al 2015]. 
Conversely, a given locus may harbor causal SNPs associated with more than one phenotype, in 
what is referred to as pleiotropy. Thus, we did not discard what may have been considered neutral 
SNPs in the context of a pharmacogenomics association, but instead applied both statistical and 
knowledge-based methods to prioritize SNPs and identify them as functional, but not causal in lieu 
of biological validation. If a reported lead SNP in an association study associated with a 
psychotropic drug response but was not correlated with a genome regulatory element expressed in 
human brain, and was not associated with pharmacokinetic response, we examined all SNPs with 
a LD >0.8 in the haplotype of that population to determine if there were any in tight LD that 
exhibited correlation with human brain. This contributed to reprioritization of the variants in the 
LD block based on neuroanatomical localization.  
 
  
  51   
 
Associations Study Population PMID 
Habitual coffee 
consumption 
and caffeine 
addiction 
Genome-wide association analysis of coffee drinking 
suggests association with CYP1A1/CYP1A2 and 
NRCAM  
Caucasians 21876539
Sequence variants  at CYP1A1 – CYP1A2 and AHR 
associate  with coffee consumption  
European 
and 
American 
21357676
Genome-wide meta-analysis identifies regions on 7p21 
(AHR) and 15q24 (CYP1A2) as determinants of habitual 
caffeine consumption  
European  21490707
Number of 
cigarettes 
smoked per 
day and 
nicotine 
dependence 
Haplotypes with copy number and single nucleotide 
polymorphisms in CYP2A6 locus are associated with 
smoking quantity in a Japanese population  
Japanese 
 23049750
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 
affect smoking behavior  European  20418888
Genome-wide meta-analyses identify multiple loci 
associated with smoking behavior  European  20418890
CHRNB3 is more strongly associated with Fagerström 
test for cigarette dependence-based nicotine dependence 
than cigarettes per day: phenotype definition changes 
genome-wide association studies results  
Mixed  22524403
Opioid 
dependence 
Genome-wide association study of opioid dependence: 
multiple associations mapped to calcium and potassium 
pathways  
African-
American 24143882
NCK2 is significantly associated with opiate addiction in 
African-origin men 
African-
American 
males 
23533358
Heroin 
addiction 
Association of OPRD1 polymorphisms with heroin 
dependence in a large case-control series  
Mixed 
American 
22500942
* 
Cocaine 
dependence 
Genome-wide association study of cocaine dependence 
and related traits  
Mixed 
American 23958962
Alcohol 
consumption 
and 
dependence 
Genome-wide association studies identify genetic loci 
related to alcohol consumption in Korean men Korean  21270382
Genome-wide association study identifies two loci 
strongly affecting transferrin glycosylation  
European 
ancestry 21665994
Lithium 
response in 
bipolar 
disorder 
Influence of an interaction between lithium salts and a 
functional polymorphism in SLC1A2 on the history of 
illness in bipolar disorder  
European  23023733* 
A genomewide association study of response to lithium 
for prevention of recurrence in bipolar disorder  
European 
ancestry 19448189
Adverse drug 
events and 
antipsychotic 
drugs 
Genome-wide association study of antipsychotic-
induced QTc interval prolongation  European  20921969
Genomewide pharmacogenomic study of metabolic side 
effects to antipsychotic drugs American 20195266
Genomewide association study of movement-related Mixed 19875103
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adverse antipsychotic effects  American 
Carbamazepin
e-induced 
cutaneous 
adverse drug 
reactions 
Genome-wide association study identifies HLA-A*3101 
allele as a genetic risk factor for carbamazepine-induced 
cutaneous adverse drug reactions in Japanese population  
Japanese 21149285
HLA-A*3101 and carbamazepine-induced 
hypersensitivity reactions in Europeans  European  21428769
Individual 
variability in 
post-surgical 
anesthesia 
Genome-wide association study of acute post-surgical 
pain in humans  European  19207018
Genome-wide association study identifies a potent locus 
associated with human opioid sensitivity  
Japanese 
females 23183491
Antidepressant 
response and 
remission in 
depression 
Citalopram and escitalopram plasma drug and metabolite 
concentrations: genome-wide associations  European  24528284
Genome-wide pharmacogenetics of antidepressant 
response in the GENDEP project  European  20360315
A genome-wide association study of a sustained pattern 
of antidepressant response  European  23726668
FKBP5 genetic variation: association with selective 
serotonin reuptake inhibitor treatment outcomes in major 
depressive disorder  
European  23324805* 
A genomewide association study of citalopram response 
in major depressive disorder  Mixed 19846067
Lamotrigine- 
induced 
hypersensitivit
y  
Genome-wide mapping for clinically relevant predictors 
of lamotrigine- and phenytoin-induced hypersensitivity 
reactions  
European  22379998
 
Figure 2-2. GWAS Studies Used in ‘Variants’ Analysis 
Selected GWAS and candidate gene pharmacogenomic association studies in psychiatry, 
neurology, addiction medicine and pain medicine used for identification of pharmacoepigenomic 
variants using the method in this study. PMID: PubMed Identification accession number. 
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Annotation of Pharmacoepigenomic SNPs and Assignment to Regulatory Elements 
 
As part of our workflow, we assigned SNPs to regulatory elements combining data from 
chromatin conformation capture, correlation with CTCF and cohesion (RAD21, SMC3) 
transcription factors associated with chromatin loop boundaries, chromatin state annotation, 
DNase I hypersensitivity, hypomethylation, anatomical localization, and biochronicity. The 
method focused on variants, including SNPs associated with drug response and adverse drug 
events, which are used to identify genomic regulatory elements that are expressed in human brain 
or the liver in the case of a CYP gene, or regulate gene transcription, and are located in noncoding 
regions of the human genome. The workflow is comprised of several components, including 
determination of whether an epigenome variant may be functional, followed by its expression in 
brain (pharmacodynamic, PK) or liver (pharmacokinetic, PD).  
 
Input variants are screened by ethnic population, followed by mapping of functional SNPs to 
determine the causal nature of a given SNP using methods based on the assumptions that, in the 
majority of GWAS, it is necessary to discriminate SNPs that represent the most likely functional 
variants from those with strong but significantly less association to the drug response trait, so that 
the majority of SNPs at a given locus can be excluded from further analysis.   As a consequence 
of tight LD that exists within a haplotype or haplotypes associated with a trait, the ‘lead’ SNP(s) 
as reported may or may or may not attain the threshold of significance used in GWAS and may 
not necessarily the best candidate to serve as the functional or ‘causal’ SNP. 
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The steps of the bioinformatics pipeline workflow in were developed independently of the 
epigenome roadmap consortium. The method is optimized for association studies in 
pharmacogenomics in psychiatry, addiction medicine, pain medicine, and neurology, herein 
referred to collectively as “psychotropic” variants. The method focuses on variants, including 
SNPs associated with drug response and adverse drug events, which are used to identify genomic 
regulatory elements expressed in human brain or the liver in the case of a cytochrome P450 (CYP) 
gene, or to regulate gene transcription in pharmacodynamic pathways in human brain. 
RegulomeDB [Boyle et al 2012] provides an initial assessment as to what role a given variant 
might play in gene regulation. Variants are evaluated as to: 1) whether they were enriched as 
quantitative trait loci (eQTLs, meQTLs) as determined using the scoring method of GeneVar 
[Yang et al 2010] and/or GTEx [Lonsdale et al 2013]; 2) whether the variant was located in open 
chromatin in the tissue of interest (e.g., brain, neuronal cell line, liver, immune cell, HepG2, heart 
or other); 3) whether the variant was hypomethylated; and 4) what specific histone marks were 
associated with the variant that defines its assignment as a promoter, enhancer or transcribed 
domain to impute chromatin state [Ernst et al 2015, Ernst et al 2012].  
 
We also determined the degree to which a variant altered the strength, number and type of binding 
sites for transcription factors, and which transcription factors were bound to the variant to 
understand the function of the corresponding genomic regulatory element. These were determined 
using several public resources including HaploReg 3.0 [Ward et al 2012] and manual inspection 
of the variant in the UCSC [Karolchik et al 2014] and epigenome roadmap [Zhou et al 2015] 
browsers. Multi-level mapping in chromatin interaction networks for variants located in human 
brain help provide evidence for probable functional pathways. In neuropsychiatric 
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pharmacogenomics, it is also critical to evaluate whether annotated regulatory elements and their 
target genes exhibit biochronicity, a general feature of pharmacogenomic variation [Zhang et al 
2014]. Results shown in 2-5. In the workflow analysis, variants are assessed as to 1) whether they 
are enriched as quantitative trait loci (eQTLs, meQTLs); 2) whether the variant is located in open 
chromatin; 3) whether the variant is hypomethylated; 4) what specific histone marks are associated 
with the variant;  5)  the degree to which a variant alters the strength, number and type of binding 
sites for transcription factors; (6) which transcription factors are bound to the variant; 7) what 
interactions and/or contacts the variant makes with other genomic regulatory elements, such as 
transcription start sties (TSS) in chromatin networks; 8) the location of the variant in brain regions 
or liver that are consistent with the function of the variant; and 9) whether the variant exhibits 
biochronicity, a general feature of pharmacoepigenomic variation. These assessments can be 
performed using a variety of public bioinformatics resources. Other attributes may also be 
important, including evolutionary conservation as determined using GERP++, or whether a variant 
is within a human accelerated region of the genome.  Biochronicity checking using published 
literature resources provides additional detail to the annotation model to check whether a given 
variant and its corresponding genomic regulatory element exhibit circadian, ultradian or seasonal 
rhythmicity. These signs are indicative of dysregulated core symptoms in the clinical context of 
psychiatric disorders such as bipolar disorder and major depressive disorder, and can be checked 
using the knowledge update engine. The impact, if any, of the glucocorticoid receptor (GR) on the 
variant is also checked, because it mediates the stress response and is the primary driver of circadian 
and ultradian rhythmicity. The input variant is also checked to determine whether it is a member of 
the CLOCK gene family or a closely related gene.  
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We further examined the output of assignments from our workflow and compared them to those 
made by the epigenome roadmap consortium. This involved examination of the SNPs using the 
roadmap epigenome browser [Zhou et al 2015], followed by definition of regulatory elements 
using the WUSTL genome browser [Zhou et al 2011]. We then compared these results with the 
results shown in Figure 2-3. 
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A                       
 
 
B 
 
 
 
KEY – CLASSES OF REGULATORY ELEMENTS 
Epigenome roadmap consortium   Workflow ENCODE 
Enhancer 
 
Genic Enhancer 
  Enhancer   
Enhancer     Enhancer  boundary, 
including  CTCF,  RAD21  and 
SMC3 
Promoter 
Active Transcriptional Start Site 
Flanking  Transcriptional  Start 
Site 
  Promoter 
Promoter    Promoter  boundary, 
including CTCF and RAD21 
Strong Transcription    Transcribed domain  Translational Elongation Weak Transcription   
Quiescent     Quiescent Quiescent 
 
 
Intron, 1161, 57%
Intergenic, 228, 11%
5'UTR, 324, 16%
3'UTR, 190, 10%
Coding variant, 121, 6%
Enhancer, 23Enhancer boundary, 1
Promoter boundary, 3
Promoter, 3
Transcribed, 3
Quiescent, 1 not assignable, 1
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C 
Type  SNP  Association [PMID]  Workflow  Roadmap   Consensus Assignment 
AD
DI
CT
IO
N
 
 
rs2470893  Caffeine  dependence[21876539] 
    Enhancer  Liver 
rs2472297  Coffee  consumption [21357676] 
    Enhancer  Liver 
rs8192725  Nicotine  dependence  [23049750] 
    Promoter boundary  Liver 
rs11878604  Nicotine  dependence  [23049750] 
    Transcription  Liver 
rs11083595  Nicotine  dependence  [20418890] 
    Enhancer  Liver
rs1329650  Nicotine  dependence  [20418890] 
    Enhancer  Brain
rs13280604  Nicotine  dependence  [22524403] 
    Enhancer  Brain
rs2072134  Alcohol  consumption [21270382] 
    Enhancer  / 
Transcription  Brain    
rs10849915  Alcohol  consumption[21270382] 
    Quiescent  Brain
rs2074356  Alcohol  consumption[21270382] 
        Transcription   Brain
rs3811647  Alcohol  dependence [21665994] 
    Enhancer  Brain
rs12053259  Opiate  addiction [23533358] 
  Enhancer  Brain
rs60349741  Opiate  addiction[24143882]* 
  Enhancer  Brain
rs2236855  Heroin  addiction [22500942]* 
  Enhancer  Brain 
rs2629540  Cocaine–induced euphoria [23958962] 
    Enhancer   Brain 
AN
AL
GE
SI
A 
rs2551941  Post‐surgical  opiate analgesia [23183491] 
  Promoter 
boundary   Brain 
rs2709394  Post‐surgical  opiate analgesia [23183491] 
  Promoter 
boundary    Brain 
rs2650805  Post‐surgical  NSAIDanalgesia [19207018]   
    Enhancer boundary  Brain 
DR
U
G R
ES
PO
N
SE
 
rs4354668  Lithium  response [23023733]* 
  Promoter   Brain 
rs7816924  Antidepressant response [23726668]   
  Enhancer      Brain 
rs4986894  Antidepressant response [24528284]* 
  Promoter  Liver 
rs1080989  Antidepressant response [24528284]* 
  not assignable 
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rs2486416  Antidepressant response [19207018] 
 
Enhancer  Brain 
AD
VE
RS
E E
VE
N
TS
 
rs6741819 
Antipsychotic  drug‐
induced  cardiac  risk 
[20195266] 
  Enhancer  Brain 
  Enhancer  Heart
rs79535779 
Antipsychotic  drug‐
triglycerides 
[20195266]  
  Enhancer  Brain
    Enhancer  Pancreas
rs4959235 
Antipsychotic drug‐QT 
prolongation 
[20921969] 
 
  Enhancer  Brain 
rs77484422 
Antipsychotic  drug‐
induced  dyskinesia 
[19875103] 
 
  Promoter  Brain 
RG
AN
 IN
JU
RY
 
         
rs2844796# 
Carbamazepine‐
induced  adverse 
events [21149285] 
 
  Enhancer  CD34 cells 
rs1633021# 
Carbamazepine‐
induced  adverse 
events [21149285] 
 
  Enhancer   CD34 cells 
rs1061235# 
Carbamazepine‐
induced  adverse 
events [21428769] 
 
  Enhancer   CD14 cells 
rs183266# 
Lamotrigine‐induced 
hypersensitivity 
[22379998] 
 
  Enhancer   CD34 cells 
 
Figure 2-3. Epigenome Context of Reported Variants 
[A] Pharmacogenomic SNPs from GWAS in neuropsychiatry map to noncoding regions of the 
genome. [B, C] Assignment of regulatory elements based on GWAS and selected gene association 
studies* to enhancer, promoter, transcribed and quiescent domains using chromatin state 
annotation based on agreement between epigenome roadmap browser scores [Zhou et al 2015] 
and our workflow assignments. In the key below, colors are based on the epigenome roadmap 
browser [Roadmap Epigenomics Consortium 2015, Zhou et al 2015, Ernst et al 2015], and 
those of the same shade indicate the same class of regulatory elements, and includes assignments 
from the ENCODE project [ENCODE Project Consortium 2012, Ernst et al 2012]. The 
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workflow further assigns a relationship to CTCF and cohesin subunits (RAD21, SMC3) for 
boundary definition. Epigenome roadmap scores are based on Histone H3 Lys (K) for the detected 
regulatory element [Zhou et al 2015].For brain, the region with the highest roadmap score for 
H3K27ac is usually indicated, but in some cases, the regulatory element may different between 
brain regions. # Tagging SNPs for HLA alleles. 
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Mapping of Effect Sizes and Allele Frequencies for Functional Variants 
 
We calculated the effect size and associated allele frequency for a number of functional 
pharmacogenomic SNPs (those from studies reporting odds ratios), as well as a background set of 
SNPs associated with neuropsychiatric diseases.  Minor allele frequencies were taken directly from 
published GWAS studies.  Effect sizes were calculated using SNP frequencies and odds ratios 
using a variant on Cohen’s D-test [Cohen 1992].  These were plotted on a two dimensional “Smile 
Plot” graph [Park et al 2010, Willer et al 2013, Lange et al 2015]; Figure 2-6.  The plot also 
includes statistical power curves for reference.  Power curves demarcating the lower bound on the 
effect size and frequency of SNPs detectable in a GWAS can be derived using the ‘pwr’ package 
in R.  [http://cran.r-project.org/web/packages/pwr/pwr.pdf]  For reference we include the 
power curves of two hypothetical GWAS surveys, which would be only barely able to detect the 
median background SNP, for one curve, and the most powerful such SNP, for the second curve.  
SNPs above a given power curve are more significant, in a statistical sense, than those below and 
those on the curve.  This plot provides a visual illustration of the comparative significance (in 
therapeutic terms) of a collection of SNPs based on their combined effect size and associated allele 
frequency. 
 
Spatial Cis- and Trans-Interactions Using Public Hi-C and ChIA-PET Data 
 
For prediction of cis-interactions of putative enhancer, we examined genes that fell within the 
purview of known enhancers identified by the ENCODE and Epigenome Roadmap consortia, and 
used knowledge-based prediction to identify those genes most likely to contribute to the drug 
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response phenotype under evaluation. These were then plotted as shown in Figure 2-7. A 
combination of known enhancer lengths are shown above each of this subset of examples, with 
potential TAD boundaries represented as shown based on correlation of the SNP to boundary 
factors such as CTCF and cohesin (i.e., RAD21 and SMC3). We used several databases of Hi-C 
and ChIA-PET in order to identify enhancer-target gene interactions in cis and trans. These 
included public Hi-C datasets and ChIA-PET data visualized in the UCSC genome browser [Dixon 
et al 2012, Rosenbloom et al 2010, Karolchik et al 2014]. In addition, we used the GWAS3D 
website [Li et al 2013] to confirm some of the spatial interactions found in the primary datasets. 
The 3DGD database of Hi-C interactions in certain human cell lines was downloaded and provided 
additional value for discrimination of spatial interactions [Li et al 2014]. For cis regulation of gene 
promoters by enhancers, we used the most probable targets based on a “guilt-by-association” 
method using known biochemical pathways and QTL relationships mined from published 
literature. In many cases of putative trans interactions, target regions of the genome contained no 
known genes or lincRNAs whose specific function had not yet been understood. The Ensembl 
genome bowser [Flicek et al 2013] was used to evaluate enhancer targets because they provide 
the most comprehensive documentation of lincRNAs, as well as extensive tracks for predicted 
genes. 
 
Results 
 
Functional SNPs Map to Predicted Pharmacoepigenomic Enhancers 
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In this the study, all of the predicted functional SNPs mapped to introns or intergenic regions, 
followed by 5’UTRs and 3’UTRs. Figure 2-3 A shows an overview of the distribution of SNPs 
by genome region. Many intronic SNPs were associated with enhancers that did not apparently 
regulate the gene in which they were located. Next we compared regulatory element annotation 
from the epigenome roadmap with the results of our workflow (Figure 2-3 B, C). The assignments 
between the 2 independent methods was high, with concordance in regulatory element class in 
different adult human tissues for 34 out of 35 assignments. Comparison with ENCODE cell line 
annotations also showed 97% agreement with our workflow (data not shown). Since we were 
including association with CTCF and cohesin (subunits RAD21 and SMC3) to define location 
within enhancers and promoters near presumptive borders between loop domains. As seen in 
Figure 2-3 B, tissue-specific assignments included 23 enhancers, 1 enhancer boundary, 3 
promoters, 3 promoter boundaries, 3 transcribed domains, 1 quiescent domain and 1 which was 
not assignable. 
 
Enrichment of Transcription Factors at Putative Enhancer, Promoters and Transcribed 
Domains 
 
Previous research has shown that TFs and DNA binding proteins bind in a sequence specific 
manner. Since the majority of our predicted functional SNPs are located in regulatory sequences 
in the relevant tissues (pharmacodynamics genes in brain and pharmacokinetic genes in liver), we 
determined whether selected DNA-binding proteins such EP300 were associated with enhancers, 
YY1 was associated with promoters, and the splicing factor TCERG1 was associated with 
transcribed domains. We selected those transcription factors associated with various regulatory 
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elements and tissue type. Figure 2-4 plots some of the known transcription factors and other DNA-
binding proteins whose binding was predicted to be altered by the SNPs, bound using ChIP-seq, 
or both, and were indicative of assignment to specific classes of regulatory elements. Statistical 
analysis showed that these specific transcription factors and DNA-binding proteins were 
associated with the consensus assignment to class of regulatory element (p<0.01; ANOVA). 
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Figure 2-4. Transcription Factor Context of Reported Variants 
Association of transcriptional factors and other DNA-binding proteins help define the domain 
occupied by different regulatory elements that could be unequivocally assigned and are active. 
CTCF and cohesion subunits (RAD21, SMC3) are significantly associated with enhancer and 
promoter boundary domains. CYMC, E2F1, ELF1, ETS1, GATA1, GATA2 and EP300 are 
associated with enhancers. EGR1 is associated with estrogen regulation, and NR3C1 association 
is suggestive of glucocorticoid regulation. TCEGR1 is a transcriptional elongation factor 
associated with differential splicing. YY1 is associated with promoters.  
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Tissue-Specific Localization of Regulatory Elements  
 
Tissue localization of regulatory elements were mapped based on data from the epigenome 
roadmap consortia [Zhou et al 2015].  Localization based on chromatin state annotation was in 
most cases consistent with organs involved in GWAS phenotypes, with HLA allele SNPs the major 
exception. The majority of regulatory elements were localized in liver and brain, consistent with a 
role in pharmacokinetic and pharmacodynamics pathways respectively. Also, in GWAS of adverse 
events from antipsychotic medications, the pattern of expression is consistent with affected organs. 
These include perphenazine-induced cardiac risk in which the enhancer is expressed in brain and 
heart, and clozapine-induced elevated triglycerides, wherein the impacted enhancer is expressed 
in brain and pancreas. In carbamazepine- and lamotrigine-induced adverse events, the predicted 
enhancer was localized in CD34 or CD14 cells. Although very specific liver and brain-specific 
transcription factor clusters have been described [Leung et al 2015], we only were able to 
characterize 3 examples in which tissue-specific transcription clusters could be assigned. 
 
Large Effect Sizes for SNPs Associated with Addiction, Analgesia and Drug-Induced Injury 
 
In contrast to the prevailing understanding that complex traits are predominantly influenced by 
many variants with small effects, we found that causal SNPs in neuropsychiatric 
pharmacogenomics GWAS typically exhibit large effect sizes (Figure 2-5). Figure 2-6 shows a 
“smile plot” comparing allele frequency from 0 to 1 versus effect size calculated using a revision 
of Cohen’s d-test based on odds ratio [Cohen 1992, Park et al 2010, Willer et al 2013, Lange et 
al 2015, Kato et al 2011]. As can be seen from the plot, functional pharmacoepigenomic SNPs 
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associated with caffeine, nicotine, alcohol and opiate addiction are common within human 
populations and exhibit large effect sizes. Similarly, HLA allele tagging SNPs for carbamazepine 
and lamotrigine, medications used to treat bipolar disorder, exhibit very large effect sizes but 
exhibit minor allele frequencies. SNPs associated with lithium response and antipsychotic drug-
induced cardiac risk are also common and have moderate effect sizes. Effect sizes for functional 
SNPs reported in psychotropic pharmacogenomic association studies were substantially larger 
than those reported in GWAS examining disease-risk variants for psychiatric and neurological 
disorders. 
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Effect size 
Allele 
frequency Phenotype SNP PMID 
0.371992921 0.4011 Caffeine dependence in EUR rs2470893 21876539 
0.48155789 0.23 Caffeine dependence in EUR rs2472297 21357676 
0.560900928 0.2472 Nicotine dependence in JPT rs11878604 23049750 
0.27667143 0.69 Nicotine dependence in AMR rs13280604 22524403 
0.405315116 0.2706 Nicotine dependence in AMR rs11083595 20418890 
0.722835812 0.35 Alcohol dependence in EUR rs3811647 21665994 
0.582689081 0.16 Alcohol dependence in ASN rs2074356 23183491 
0.452888527 0.0902 Opioid dependence in ASW rs12053259 23533358 
0.3671001 0.3371 Post-surgical opiate analgesia in female JPT rs2551941 23183491 
0.440686308 0.3371 Post-surgical opiate analgesia in female JPT rs2709394 23183491 
0.278641 0.75 Post-surgical NSAID analgesia in EUR rs2650805 19207018 
0.270373792 0.4 Lithium response in bipolar disorder I in AMR rs4354668 23023733 
0.07841444 0.75 Response to nortryptyline in EUR rs2486416 20360315 
0.1838899 0.2 Response to citalopram in EUR rs4986894 24528284 
0.15298036 0.88 Antipsychotic drug-QT prolongation in EUR  rs4959235 20921969 
0.27667143 0.28 Antipsychotic drug-induced cardiac risk in EUR rs6741819 20195266 
0.09283385 0.0059 Antipsychotic drug-triglycerides in EUR rs79535779 20195266 
0.8954187 0.101 Adverse response to carbamazepine in JPT rs2844796 21149285 
0.87222116 0.0962 Adverse response to carbamazepine in JPT rs1633021 21149285 
0.8993825 0.03 Adverse response to carbamazepine in EUR rs1061235 21428769 
Background neuropsychiatric disease risk SNPs for comparison 
0.132053536 0.2204 Bipolar disorder rs10994415 24618891 
0.0961068 0.1414 Bipolar disorder rs12290811 24618891 
0.072391305 0.1768 Bipolar disorder rs17826816 24618891 
0.062612533 0.5 Bipolar disorder rs12202969 24618891 
0.067523554 0.4394 Bipolar disorder rs6550435 24618891 
0.077216543 0.8333 Bipolar disorder rs2011503 24618891 
0.28332797 0.1667 Schizophrenia rs114002140 23974872 
0.057657467 0.3182 Schizophrenia rs7085104 23974872 
0.113328685 0.798 Schizophrenia rs1198588 23974872 
0.052657558 0.37 Schizophrenia rs1006737 23974872 
0.082000003 0.096 Schizophrenia rs17691888 23974872 
0.047611987 0.0505 Schizophrenia rs4129585 23974872 
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0.118846066 0.0404 Schizophrenia rs17504622 23974872 
0.082000003 0.2273 Schizophrenia rs6932590 19571808 
0.114372469 0.0758 Schizophrenia rs9960767 19571808 
0.0938122 0.101 Schizophrenia rs3131296 19571808 
0.118846066 0.96 Schizophrenia rs17693963 22688191 
0.017528719 0.0606 Schizophrenia rs11191580 22688191 
0.063614443 0.3081 Schizophrenia rs12666575 22688191 
0.0961068 0.3889 Autism rs4307059 19404256 
0.078554294 0.5202 Bipolar disorder & schizophrenia rs11789399 20889312 
0.0795 0.3118 Major mood disorders rs2251219 20081856 
0.181538157 0.4451 Major depressive disorder rs1545843 21521612 
0.116524317 0.3485 Epilepsy rs13026414 22949513 
0.145419923 0.26 Epilepsy rs72823592 22949513 
0.213227868 0.197 Epilepsy rs10496964 22949513 
0.050644856 0.36 Migraine rs2651899 23793025 
0.074809192 0.1364 Migraine rs12134493 23793025 
0.036463696 0.65 Migraine rs2274316 23793025 
0.078560092 0.28 Migraine rs6741751 23793025 
0.043031237 0.3897 Migraine rs9349379 23793025 
0.052667603 0.1869 Migraine rs11759769 23793025 
0.058652042 0.1 Migraine rs4379368 23793025 
0.037844981 0.75 Migraine rs827382 23793025 
0.10104635 0.65 Migraine rs3790455 22683712 
0.100407764 0.38 Migraine rs7640543 22683712 
0.045353072 0.37 Migraine rs9349379 22683712 
0.08252895 0.5909 Migraine rs6478241 22683712 
0.136396365 0.17 Migraine rs10166942 22683712 
0.085162964 0.3535 Migraine rs11172113 22683712 
0.100734286 0.16 Migraine rs11757063 22683712 
 
Figure 2-5. Effect Sizes of Reported Variants 
Effect sizes for graph for Figure 5 were calculated using a revised version of Cohen’s d-test 
[Cohen 1992], which was adapted to GWAS that report odds ratio. Using this method, effect sizes 
of 0.20 represent small effects, 0.50 represent large effects, and 0.8 represent very large effects. 
This method may differ from effect sizes calculated using different methods in GWAS. An effect 
size of unity (1.0) determines that if an individual harbors the variant, they will express the 
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pharmacogenomic phenotype. Since human genes (~25%) demonstrate significant allele-specific 
bias [Palacios et al 2009], it is important to recognize that incomplete penetrance may result from 
skewed gene expression. Allele frequencies were determined from either 1000 Genomes Project 
data [1000 Genomes Project Consortium 2012] or from HapMap [Gibbs et al 2013]. 
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Figure 2-6. The Smile Plot 
In contrast to neuropsychiatric disease risk SNPs which characteristically have low effect sizes, 
psychotropic drug SNPs (colors) exhibit moderate-to-large effect sizes and moderate-to-high allele 
frequencies.  Almost all exceed the statistical power threshold of the median disease SNP (grey 
dotted line) and 80% exceed the power of all disease SNPs (red dotted line).  Noncoding SNPs 
associated with addiction (dark blue) and analgesia (light blue) are notable for large effect and 
high frequency.  Tagging SNPs at HLA loci associated with drug-induced organ injury (magenta) 
exhibit very high effect sizes but rarer allele frequencies. The SNP rs4354668 associated with 
lithium response in bipolar I patients of European ancestry (green) exhibits a moderate effect size 
and a common allele frequency, as does SNP rs6741819 (violet) which is associated with 
antipsychotic drug-induced cardiac risk. Neuropsychiatric disease risk SNPs were mined from the 
NHGRI GWAS catalog for bipolar disorder, schizophrenia, major depressive disorder, migraine 
and epilepsy, and are indicated in gray. 
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Knowledge-Based Discovery of Putative Spatial Interactions in Cis and Trans 
  
Multiple public datasets were used to evaluate the spatial interactions of enhancers and promoters 
impacted by SNPs in gene association studies of psychotropic pharmacogenomic phenotypes, 
followed by knowledge-based discovery methods using published literature as described. Spatial 
interactions were plotted as shown in Figure 2-7. Several functionally-important relationships 
were inferred based on systematic evaluation of published literature, as well as other data sources 
such as www.clinicaltrials.gov. These relationships are concordant with RNA-Seq results [Zhou 
et al 2015]. In some cases, the association of enhancer RNAs (eRNAs) with this subset of known 
enhancers supported their role as active genome regulatory elements in the tissue of interest.  
 
Figure 2-7-1 shows examples of SNPs that disrupt enhancers associated with addiction and 
analgesia. The SNPs rs2470893 and rs2472297 are well-replicated, statistically significant 
associations with caffeine dependence in European populations [Sulem et al 2011, Amin et al 
2012]. In cis, not only does the cognate enhancer control CYP1A1 gene expression, but also the 
regulation of the CYP1A2 gene, whose product is the rate-limiting enzyme for the metabolism of 
caffeine [Zanger et al 2013]. In addition, the large enhancer appears to regulate the NKX2-5 gene, 
in which a SNP is significantly associated with correlated with increased caffeine metabolism in 
liver [Cornelis et al 2011].  For long distance (trans) interactions, the identified enhancer disrupted 
by these SNPs is in spatial contact with the CACNA1B gene as determined by Hi-C in immortalized 
liver cells (HepG2). Mutations in the CACNA1B gene have been linked to caffeine-induced anxiety 
in animal models [Domschke et al 2012]. In a study of nicotine dependence in a Japanese 
population [Kumasaka et al 2012], the statistically significant lead SNP rs11878604 disrupts an 
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enhancer that regulates expression of the CYP2A6 gene, which encodes a protein that metabolizes 
nicotine to cotine [Zanger et al 2013], as well as CYP2A13, whose product CP2AD metabolizes 
the major nitrosamine found in tobacco, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [Su et al 
2000]. An enhancer involved in nicotine dependence [Tobacco and Genetics Consortium 2010] 
is linked in trans to the promoter of the CHRNB2 gene, in which variants are correlated with the 
euphoric effects of nicotine [Hoft et al 2011] and the SNP rs11083593 located in the same locus, 
may activate differential splicing of the CYP2B6 gene through a long-distance interaction with the 
TCERG1 gene that generates a splice variant associated with increased incidence of lung cancer 
[Timofeeva et al 2011]. The SLC17A8 gene is a glutamate transporter in brain whose expression 
has been significantly associated with addictive behaviors [Enoch et al 2014]. The SNP rs2336855 
is located in an intron of the OPDR1 gene is associated with a population of individuals of European 
ancestry who were heroin addicts in a large case-control candidate study which has been replicated 
[Nelson et al 2014]. The same enhancer appears to control the splicing factor SRSF4 which is 
thought to be responsible for alternative splicing of the OPRD1 gene [Pandit et al 2013]. In trans, 
it contacts the GABRA3 gene, in which variants associated with reward deficiency and opiate 
addiction have been identified [Kertes et al 2011, Blum et al 2011]. In a GWAS of opioid 
dependence [Liu et al 2013], a significant SNP imputed from a population of African-American 
males shows that the enhancer regulates NCK2, which encodes a protein involved in 
synaptogenesis, and has been shown to be significantly associated with morphine tolerance in an 
animal model [Huroy 2012]. The SNP rs2074356 is significantly associated with alcohol 
dependence in a Korean population [Baik 2011] impacts an enhancer that modulates the ALDH2 
gene, in which variants are significantly associated with alcohol-related neuropathy and cancer 
[Cederbaum et al 2012, Duell et al 2012]. The enhancer also effects the CTSB gene, which has 
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been correlated with both addictive behavior in humans, alcoholism and alcohol-induced liver 
injury [Lind et al 2013, Razvodovsky et al 2013, Jagannathan et al 2012]. The enhancer is in 
spatial contact with the promoter of the ATNX2 gene on the same chromosome.  Variants in the 
ATXN2 gene are responsible for a disorder called spinocerebellar ataxia [Wang et al 2015], which 
is a characteristic adverse event associated with alcohol intoxication [Modig et al 2012]. 
 
Figure 2-7-2 shows further examples of the spatial interactions of enhancers and a promoter 
associated with psychotropic drug response and enhancers associated with antipsychotic drug-
induced adverse events. These spatial relationships suggest the nature of the interaction that 
provides insight into mechanism or potential pathway components. In a GWAS of sustained 
antidepressant response, the significant SNP rs7816924 located in an intron of the CSGALNACT1 
gene, contacts the CNTNAP3 gene in trans. CNTNAP3 encodes a contactin-associated protein 
located at central synapses in which variants have been significantly associated with autism, 
intellectual disability syndromes and depression [Zuko et al 2013, Verpelli et al 2014, Mitchell 
et al 2012, Berezin et al 2013]. This enhancer also appears to regulate the DLC1 gene, whose 
expression in human brain, methylation state and variants have been significantly associated with 
posttraumatic stress disorder, substance abuse, suicide attempts and suicidal ideation [Mehta et al 
2013, Mullins et al 2014, Gelernter et al 2014]. The SNP 4354668 located in the promoter of the 
SLC1A2 gene, which encodes a high-affinity glutamate transporter in human brain, is correlated 
with lithium response [Dallaspezia et al 2012], exhibits a large effect size in patients of European 
ancestry with bipolar disorder, and is connected in trans to the PLD5 gene. Variants in the PLD5 
gene have been significantly associated with bipolar disorder in bipolar patients of European 
ancestry [Djurovic et al 2010]. Mutations in the SLC1A2 gene have been significantly linked to 
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essential tremor in GWAS, and tremor is a significant side effect of lithium treatment [Their et al 
2012]. In a GWAS studying the adverse event of QT prolongation in patients that take second 
generation atypical antipsychotic medications [Aberg et al 2012], the imputed SNP rs4959235 is 
associated with quetiapine-induced QT prolongation, and the same enhancer impacts NQO2 gene 
in cis, which has been associated with clozapine-induced agranulocytosis [Ostrousky et al 2003], 
and is involved in acetaminophen hepatotoxicity [Miettinen et al 2014]. This enhancer is spatially 
connected with the NOS1AP gene, which has recently been shown to control QT prolongation in 
multiple, replicated studies [Chang et al 2013, Jamshidi et al 2012, Kapoor et al 2014, Tomas 
et al 2010]. In a GWAS examining cardiac risk as a consequence of antipsychotic medication use 
in a European population [Adkins et al 2011], the corresponding enhancer appears to regulate the 
RNF144A gene, in which variants have been significantly associated with cardiac dysfunction 
[Kolder et al 2012].  
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Figure 2-7: Spatial Context of Reported Variants 
Figure 2-7-1: Spatial interactions of enhancers associated with addiction and analgesia 
plotted onto circular genome-wide maps.  [A, B] SNPs significantly associated with caffeine 
dependence in individuals of European ancestry replicated in multiple GWAS; [B] A SNP 
significantly associated with nicotine dependence in a Japanese population; [C] A functional SNP 
associated with heroin addiction in Europeans; [D] A SNP associated with opioid addiction in 
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African-American males; [E] A SNP significantly associated with alcohol dependence in a Korean 
population. 
Figure 2-7-2: Spatial interactions of enhancers associated with psychotropic drug response 
and antipsychotic-induced adverse events plotted onto circular genome-wide maps. [A] A 
SNP associated with sustained antidepressant response; [B] A SNP located in the promoter of the 
SLC1A2 gene associated with lithium response in bipolar patients of European ancestry; [C] A 
functional SNP associated with quetiapine-induced prolonged QT syndrome in an American 
population; [D] A SNP associated with antipsychotic drug-induced cardiac risk in a European 
population.  
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Discussion 
 
Linear and combinatoric pharmacogenomic variant genotyping tests have already demonstrated 
considerable value in a number of systems.  The discovery of additional variants which predict 
clinically important phenotypes is of great potential value.  This study was undertaken to determine 
if candidate pharmacoepigenomic regulatory variants in humans could be identified using 
informatics and extant public data resources prior to further analysis in cell lines, animal models 
and clinical trials. Although these are bioinformatics-based predictions, they differ from genome-
wide applications such as ChromHMM [Ernst et al 2012], ChromImpute [Roadmap 
Epigenomics Consortium 2015], GBR [Libbrecht et al 2015] and Segway [Hoffman et al 
2012] because they make use of context-specific datasets collected in disease-relevant tissue types. 
For this reason, and because they are derived from gene association studies in human populations 
and many exhibit substantial effect sizes, our candidate variants and their predicted sites of action 
represent candidates for subsequent investigation and utility in biological experiments, biomedical 
and clinical validation research and, ultimately, in clinical practice. 
  
The informatics-based predictions of mechanisms found in this study, as illustrated in Figure 2-7, 
can be validated by subsequent experimental studies in cells and tissues to observe spatial 
interactions between promoter-enhancer pairs in cell lines and tissues.  These studies may use 
methods such as FISH microscopy, tissue-based Hi-C, and related methods for the study of 
dynamic genome architecture as was demonstrated in Rao et al [Rao et al 2014]. These variants 
and others found using these approaches may also be considered high priority variants for 
combinatoric effect size analysis.  Although combinatoric effect size analysis has proven 
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intractable in a genome-wide context, where the number of comparisons allows statistical noise to 
overcome faint signals, with a reasonable number of loci such as the outputs of an experiment of 
this sort, the number of comparisons in combinatoric analysis is such that reasonable experiments 
(e.g. GWAS and clinical trial cohorts) may provide enough statistical power for such analyses to 
yield meaningful results.  This analysis provides a straightforward and comprehensive approach 
to prioritizing psychotropic pharmacoepigenomic variants and corresponding regulatory pathways 
that will support a new generation of clinical pharmacogenomic tests and CNS drug discovery.   
  
In addition, these results and others point to an emerging understanding about potential new ways 
to interpret GWAS datasets. 
  
First, the importance of noncoding regulatory variation in the determination of pharmacogenomic 
response and adverse drug events is now being realized. Although non-synonymous mutations 
within exons contribute to disease risk and variable drug response, this biological phenomenon 
cannot begin to explain the human variome, with additional clarity provided by epistasis and 
epigenomics. Zanger et al [Zanger et al 2014] have discussed this phenomena concerning 
noncoding SNPs in CYP genes. Since significant evidence suggests that the majority of variation 
in human traits lies outside protein-coding regions of the genome [Kellis et al 2014], epigenome 
informatics provides a step towards a better understanding of the variation in pharmacogenomic 
traits that exist in noncoding regions of the human genome [Boyle et al 2012, Schaub et al 2012]. 
  
Second, the epigenome, in addition to serving as a mechanism for non-sequence inheritance and 
regulation of transcription patterns, is important in both clarifying which variants are important 
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and predicting their mechanism of action. The brain generates the highest transcriptional 
complexity of any tissue by more than an order of magnitude [Hawrylycz et al 2012, Kang et al 
2011], involving transcription of at least 40% of all human coding genes [Roadmap Epigenomics 
Consortium 2015], and the regulatory networks involved in neuropsychiatric diseases are likely 
to be similarly complex. Thus, it is probable that the spatial connections of the enhancers, 
promoters and transcriptional elements detected by these significant variants can provide 
explanatory value given the examples as shown in Figure 2-7.  New data types including pQTLs, 
metQTLs, and sequence based predictions of variant effects on the epigenome are likely to provide 
explanatory value as well.  Like any new approach in biomedical research that needs further 
experimental validation, epigenomic analysis of noncoding variants that explain gene regulation 
will demonstrate its utility through a more thorough understanding of the corresponding 
phenotype. We note that many of the new intragenic and intronic pharmacoepigenomic SNPs we 
have uncovered in this work are of the PD class, which is dramatically under-represented in 
pharmacogenetics today. 
  
Third, the 4D nuclear context (3D structure plus temporal dynamics) is quite important in 
interpreting neuropsychiatric GWAS.  In parallel with emerging results from studies of 3D nuclear 
architecture, phenomena such as circadian rhythmicity of gene expression [Zhang et al 2014] and 
the timing of interactions between specific CLOCK gene loci demonstrated by Hi-C [Aguilar-
Arnal et al 2014], emphasize the importance of temporal dynamics for understanding the 
functional impact of gene expression.  New evidence is challenging existing dogma including 
recognition of the pervasive nature of mono-allelic transcription in mammalian cells as determined 
using single cell RNA-seq and 3D FISH at the cellular level [Borel et al 2015, Deng et al 2014, 
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Osborne et al 2004, Palacios et al 2009] and allele-specific expression at the tissue and 
population level, distinct from known mechanisms of genomic imprinting [Schalkwyk et al 2010, 
McDaniell et al 2010].  Non-coding variants identified in genome-wide association studies 
(GWAS) can be annotated as genomic regulatory elements [Ward et al 2012, Schaub et al 2012], 
supporting the discovery of novel regulatory pathways that can be studied temporally.  
  
Fourth, GWAS have demonstrated variable utility in different systems.  GWAS research in 
complex human diseases has frequently shown a large number of small-effect, high frequency 
SNPs [Park et al 2010, Willer et al 2013, Figure 2-6], and seldom shown common high-effect 
SNPs [Park et al 2011]. Our results clearly demonstrate that neuropsychiatric pharmacogenomic 
phenotypes do not exhibit the same constraints. Several of the pharmacogenomic systems we 
investigated display SNPs that are sufficiently powerful and in high frequency such that, alone or 
in combination [Stringer et al 2011], they could potentially be used in clinical pharmacogenomic 
assays if validated in clinical research studies. 
  
The reasons why this appears to be common in pharmacogenomics but rare in disease prediction 
remain unclear. The literature in disease GWAS is converging on the notion of an evolutionary 
"ceiling" on the significance (prevalence and effect size) of individual variants imposed by the 
deleterious fitness effect of disease [Cohen 1992, Lange et al 2015]. Although it could be argued 
that pharmacogenomic phenotypes would not be subject to the same evolutionary constraints 
because some of these medications only appeared recently in evolutionary terms, this explanation 
makes less sense in light of the relatively large effect sizes observed for SNPs for naturally-
occurring addictive drugs such as alcohol and opiates which have been used by humans for at least 
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3500 years (opiates) to 9000 years (alcohol) [Brownstein et al 1993, Crocq et al 2007].  
Xenobiotic substances in general often act on, or are acted on by, biological systems which are 
key physiological processes subject to positive of balancing selection [Sadee et al 2014], and so 
these loci may emerge as hits in disease or other GWAS, while the particular variants responsible 
for response to xenobiotics may still not have been subject to direct selection. Further work will 
define the contours of this phenomenon, but it is clear that the utility of GWAS may vary 
substantially by phenotypic class, rendering global judgements in this area premature. 
  
Fifth, the relevance of the traditional significance threshold (and in the future, any hard threshold) 
is declining. While the Bonferroni or “X2“ threshold often limits the number of significant lead 
SNPs reported in pharmacogenomic studies, recent studies have used imputation methods to 
identify variants in high LD with sub-Bonferroni lead SNPs, often greatly increasing the 
significance of “functional” or “causal” variants that represent bona fide associations with the trait 
of interest as opposed to so-called “tagging” SNPs [Edwards et al 2013]. Other researchers have 
convincingly argued that more informed systems approaches indicative of pleiotropy, including 
false discovery rate, are more accurate measures of significance in GWAS compared to traditional 
metrics [Lee et al 2012, Benjamini et al 1995, Jia et al 2010]. The totality of these strategies and 
our findings demonstrate that there is a great deal of useful data to be mined from existing GWAS 
that may have previously been dismissed as inconsequential [Shi et al 2011].  There is every 
indication that a strategy of permissive thresholding, followed by screening with other forms of 
information, is to be preferred, at least in further pharmacogenomic studies. In the future, “co-
imputation” strategies may emerge which dispense with GWAS significance thresholds entirely 
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and screen variants with a combination of association and other methods from the very beginning 
of the workflow. 
  
The results presented here are promising targets for future research that validate neuropsychiatric 
pharmacogenomic regulatory variants as clinical biomarkers, and the methods used to discover 
them, as part of an emerging new understanding of GWAS methods and significance, can offer 
powerful utility for discovering, interpreting, and validating functional variants in a number of 
systems, eventually adding to the considerable value already obtained from pharmacogenomic 
testing.  Such variants may include not just SNPs but also indels, and these methods are extensible 
to probe variants called from NGS profiles of patient cohorts. Results from this study provide 
insight into potential regulatory mechanisms of gene expression underlying psychotropic drug 
response, and establish an in silico bioinformatics-based pipeline approach to discovering novel 
putative pharmacoepigenomic variants. This approach can serve to streamline the discovery of 
novel variants, which can then be further validated in cell lines, animal models and clinical trials 
using a diverse set of molecular and morphological data types. 
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The Lithium Glutamatergic Pathway 
 
Motivation 
 
Bipolar disorders are a spectrum of neuropsychiatric disorders characterized by abnormal shifts in 
energy, activity levels, and mood. Patients diagnosed with bipolar disorder also meet criteria for 
another lifetime disorder, more than half of whom had 3 or more other psychiatric disorders 
[Merikangas et al 2011].  There is a strong genetic component to susceptibility to bipolar disorder. 
Since bipolar spectrum disorders are heterogeneous and coincide with other comorbid disorders, 
estimates of heritability need to be carefully defined as to the subtype that is evaluated. 
Neuroimaging studies performed in family cohorts provide some of the most accurate data 
[Ladouceur et al 2008]. The lifetime risk for bipolar affective disorder is 15%–30% in individuals 
with 1 first-degree relative with bipolar disorder and up to 75% in those with 2 affected first-degree 
relatives [Grof et al 2002]. Recent studies have demonstrated strong overlap between gene 
associations and pathways shared between different psychiatric disorders [Sullivan et al 2012, 
Cross-Disorder Group 2013]. The genetic concordance rate for monozygotic twins is around 
70%. The concordance rate among monozygotic twins is higher for bipolar disorder than unipolar 
affective disorder, suggesting a relatively greater contribution from genetic factors in the etiology 
of bipolar disorder compared with schizophrenia and unipolar depression [Noga et al 2004]. 
However, monozygotic twins may differ by variance in epigenome alterations produced by gene 
by environment interactions, so divergence is not wholly attributable to genetic variation [Petronis 
et al 2003, Fraga et al 2005, Bel et al 2011].  
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Lithium is an alkali metal with no known role in human physiology, although many solute carrier 
proteins encoded by the SLC gene family can transport lithium across the cell membrane. Lithium 
salts were first used to treat mania in the 1950s and bipolar disorder in the 1960s.   There appears 
to be a subpopulation of bipolar patients that are excellent responders to lithium salts, and this trait 
demonstrates familial clustering [Grof et al 2002, Rybakowski et al 2010, Passmore et al 2003]. 
Bipolar disorder patients who respond well to lithium salts exhibit higher genetic liability, which 
has led to a variety of studies focusing on the families of these patients, and most of these studies 
have confirmed an increased frequency of bipolar disorder among relatives [Grof et al 2002, 
Rybakowski et al 2010]. Studies investigating family histories of patients who respond to other 
drugs such as lamotrigine [Passmore et al 2003, Turecki et al 2001] suggest that different 
treatments may be most effective in patients who are clinically and biologically distinct from those 
patients who respond well to lithium. However, many bipolar patients take multiple psychotropic 
medications and may have a poorly-defined history of medication use and/or drug abuse, so 
definitive pharmacogenomic results have been difficult to obtain. 
 
Two studies have examined lithium response in bipolar disorder with single nucleotide 
polymorphisms (SNPs) using genomewide association (GWA) in human cohorts. A genomewide 
association study (GWAS) examining lithium response in a Han Chinese population reported 
highly significant SNPs within introns of the GADL1 (glutamate decarboxylase-like 1) gene [Chen 
et al 2014]. The human GADL1 gene not only shares homology with GAD1 and GAD2, which 
function in the conversion of glutamate to the inhibitory neurotransmitter GABA (g-aminobutyric 
acid), but also displays homology with an archaeal glutamate decarboxylase homolog, which 
functions as an aspartate decarboxylase [Tomita et al 2014]. L-glutamate and L-aspartate are 
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excitatory neurotransmitters in human brain that act as agonists at members of the NMDA and 
AMPA receptor families.  
 
In another replicate GWAS examining time-to-recurrence of bipolar disorder in patients treated 
with lithium that was withdrawn from the National Institute of Human Genome Research Institute 
(NHGRI) GWAS catalogue, Perlis et al [Perlies et al 2009] found no associations that met the 
statistical threshold of GWAS.  They did, however, find a SNP in a noncoding domain of the 
GRIA2 (glutamate receptor ionotropic AMPA 2) gene that did not meet the rigorous “X2” GWAS 
statistical threshold, but whose gene expression is significantly down-regulated following chronic 
lithium treatment in a human neuronal cell line and human hippocampus [Seelan et al 2008, Du 
et al 2008]. Using functional magnetic resonance imaging (fMRI), concentrations of glutamate in 
cortex, amygdala, striatum and hippocampus have been consistently shown to be significantly 
increased in bipolar patients that respond to lithium compared to controls [Lim et al 2013].  
    
Candidate gene association studies have implicated a number of almost exclusively noncoding 
SNPs associated with lithium in bipolar disorder. Candidate SNPs, although limited by the small 
sample sizes and confounding problems that are characteristic of many published gene association 
studies, have been linked to dozens of genes. These include genes with properties suggestive of 
bipolar disorder and/or lithium.  Among these are genes which:  
1. Convey weak genetic effects to risk of bipolar disorder and other neuropsychiatric diseases 
2. Participate in inositol–based second messenger systems 
3. Are involved in synaptic vesicle recycling or are structural components of post-synaptic 
densities 
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4. Regulate cell proliferation, growth and apoptosis 
5. Are members of the CLOCK gene family that are dysregulated in bipolar disorder and 
major depressive disorder 
6. Are significantly associated with central glutamatergic neurotransmission 
7. Enhance neuronal cell adhesion 
8. Are solute carriers or ion channels or are transcription factors involved in brain patterning, 
development and hormonal regulation of gene expression 
 
Recent discoveries in human genetics, genomics and epigenomics has broadened the range of 
variants that can be used to classify patients by drug efficacy and drug-induced adverse events.  
Research over the past 5 years has upset orthodox views that emerged from the sequencing the 
draft human genome at the turn of the 20th century.  Results of the Encyclopedia of DNA Elements 
(ENCODE) project [ENCODE Project Consortium 2012] and the Epigenome Roadmap 
Consortium [Roadmap Epigenomice Consortium 2015, Leung et al 2015]  studies that have 
defined the three-dimensional (3D) organization of the human genome at resolution using methods 
such as chromatin conformation capture, including Hi-C [Rao et al 2014] and reinterpretation of 
GWAS data using pathway analysis [Jia et al 2010, Shi et al 2011, Tasan et al 2014, Califano 
et al 2012, McGeachie et al 2014], have demonstrated the following:  
 
1. Coding variants represent a fraction of the genetic differences between human cohorts for 
traits such as drug response [Zhou et al 2013, Kellis et al 2014, Meyer et al 2013, Maurano 
et al 2012, Roussos et al 2014, Onengut-Gumuscu et al 2015, Weinhold et al 2014]. The 
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majority of statistically-significant SNPs found by GWAS are noncoding and disrupt 
regulatory elements such as enhancers [Farh et al 2015]; 
2. GWAS SNPs that may not have met the traditional, stringent statistical threshold of p < 5 
x 10-08 are now being shown as integral to understanding the genetic foundation of 
phenotype, particularly if they provide explanatory mechanistic power using pathway 
analysis [Jia et al 2010, Shi et al 2011, Tasan et al 2014, Califano et al 2012, McGeachie 
et al 2014]. In addition, several psychiatric disorders share common genome regulatory 
pathways [Cross-Disorder Group 2013], as do complex disease traits [McGeachie et al 
2014], and epigenome pathways contain common risk variants for seemingly unrelated 
diseases [Farh et al 2015]; 
3. In diseases associated with psychological stress, epigenomic modifications of the human 
genome are the best indicators of disease risk and drug response, and these alterations can be 
transmitted from parent to child [Crews et al 2012, Dietz et al 2011].  These results reinforce 
decades of research in the social sciences, clinical psychology and psychiatry, showing that 
the offspring of abused children were most likely to abuse their own children [Peled et al 
2011, Kaufman et al 1987, Larrance et al 1983]; 
4. The bulk of recent studies suggest that “so-called” missing hereditability is not genetic, but 
rather epigenetic [Petronis 2010, Slatkin 2009, Labrie et al 2012, Cortijo et al 2014, 
Badyaev et al 2014], with inherited disease-related variation located in genomic regulatory 
elements [Kellis et al 2014, Maurano et al 2012, Farh et al 2015, Parker et al 2013, Kumar 
et al 2013]; 
5. The 3D chromatin environment in the nucleus provides the foundation for the regulation of 
gene expression, and gene transcription is organized into nuclear compartments, including 
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topologically-associating domains that involve both intra-chromosomal and inter-
chromosomal interactions that vary in space and time [Dekker et al 2013, Jin et al 2013, 
Lieberman-Aiden et al 2009, Deng et al 2012, Seitan et al 2013, Kleinjan et al 2005, 
Noordermeer et al 2011, Li et al 2012, Cremet et al 2001, Wendt et al 2014, Aguilar-
Arnal et al 2014]; 
6. The specific milieu of any given genomic element, as determined by accessibility to 
transcription factors in open chromatin, and driven by genome variants, such as SNPs and 
transcription factor binding, dictates its function [Ernst et al 2010, Ernst et al 2012, Hon et 
al 2009, He et al 2012, John et al 2012]; and 
7. Differences in chromatin state are a major determinant of what had previously been attributed 
to genetic differences between human phenotypes [Heyn et al 2013, Hellman et al 2010, 
Kasowski et al 2013], often resulting in allele-specific methylation and allele-specific 
expression [Shoemaker et al 2010, Schalkwyk et al 2010], largely driven by gene variants 
and correlative binding of transcription factors [Kilpinen et al 2013, McVicker et al 2013, 
Jones et al 2013]. 
 
When viewed in the context of these recent findings, it is no longer tenable to maintain that the 
majority of complex, polygenic inherited traits such as drug response are only, or even primarily, 
a consequence of missense or nonsynonymous changes in exons that alter protein structure and 
function. The paucity of coding variants predictive of psychotropic phenotypes, and the presence 
of a "missing inheritance" gap, as well as the presence of a profundity of transcriptional regulation 
in the brain, suggest that psychiatry is no exception.  Our hypothesis in the present study is that 
combining functional SNPs imputed from lead SNPs reported in association studies of lithium 
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drug response, together with those associated with bipolar disorder, will provide insight into 
genomic regulatory pathways that mediate psychotropic drug response [Jones et al 2013, Flister 
et al 2013, Edwards et al 2013, Schaub et al 2012]. We developed and applied a novel 
bioinformatics pipeline method for characterization of noncoding SNPs that includes chromatin 
state annotation, spatial mapping of enhancers and promoters in 3D space, neuroanatomical 
localization using both in situ hybridization of mRNA and enhancer in postmortem human brain 
tissue,  neuroimaging data from patients and controls, and pathway analysis. In this article, we 
present preliminary data on imputed SNPs that were screened using pathway analysis and RNA 
localization in the context of existing knowledge of human brain function and lithium response in 
bipolar disorder. 
 
  
  93   
 
 
Figure 2-8. Diagram of Lithium Analysis Methods 
For neuroanatomical characterization, we used a variety of resources, including (1) Human data 
from the Allen Brain Institute, which includes postmortem human brain tissue sections used for 
in situ hybridization, RNA-seq and microarray analysis [Sunkin et al 2013], and (2) Data on 
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enhancer RNA localization from the epigenome roadmap consortium [Roadmap Epigenome 
Consortium 2015].  A federation of publically-available resources, including those of the Allen 
Brain Institute, the NIH epigenome roadmap project and databases in bioinformatics provide a 
highly detailed, comprehensive map of connectivity in human brain, including transcriptomic 
signatures for many neuronal subtypes and other cell types. Similarly, there are sources of 
detailed data on the localization of functional enhancers in major regions of human brain that 
were used, including validated RNA-seq measures of enhancer RNA, methylome signatures and 
many other epigenomic characteristics.  
  95   
 
Methods 
 
Figure 2-8 shows an overview of the method that was used in the study that is further described 
in the text.   The major steps in the “pharmacoepigenomic trait workflow” included SNP 
imputation from GWAS and candidate gene association studies examining lithium response in 
bipolar disorder, genetic and epigenetic fine mapping, chromatin state annotation, pathway 
analysis and multiscale epigenome analysis. All are described in detail below. 
 
Study Selection and Fine Mapping 
 
A literature review was performed using Google Scholar [Pomerantz 2013] and PubMed [Lu 
2011] for studies published prior to March 15, 2015, using different search strings including 
“bipolar AND lithium AND gene AND association” and “lithium response AND variants AND 
bipolar disorder.” In addition, the National Human Genome Research Institute’s (NHGRI) GWAS 
catalogue was searched, and spreadsheets were downloaded for evaluation. In the NHGRI catalog, 
many single nucleotide polymorphisms (SNPs) related to bipolar disorder, other psychiatric 
disorders and sleep habits were shared. For example, several GWAS had identified the same or 
linked ‘lead’ SNPs in the ANK3 and CACNA1C genes.  
 
Sets of lead SNPs, reported in genetic association studies, were examined for linkage with 
noncoding SNPs that could identify genomic regulatory elements such as enhancers. Several sets 
of variants derived from single studies and combinations of studies were evaluated. Studies were 
selected in 3 phases: (1) 2 GWAS of lithium response in patients with bipolar disorder, (2) 
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Candidate gene association studies examining association between lithium response and bipolar 
disorder and (3) GWAS of bipolar disorder and other psychiatric disorders in which functional 
SNPs could be imputed that were the same as found in the first phase of study selection.   
 
Fine mapping to determine the causal nature of a given SNP has been described elsewhere [Farh 
et al 2015, Edwards et al 2013, Mi et al 2013], but uses methods based on assumptions that, in 
the majority of association studies, it is necessary to discriminate SNPs that represent the most 
likely functional or causal variants from those with strong but significantly less association to the 
drug response trait, so that the remainder of SNPs at a given locus can be excluded from further 
analysis. As a consequence of tight LD that exists within a haplotype or haplotypes associated with 
a trait, the ‘lead’ SNP(s) that attain the threshold of significance used in GWAS may not serve as 
the best candidates for functional or ‘causal’ SNPs. Unfortunately, it has been difficult to obtain 
large sample sizes in psychiatric pharmacogenomic studies, resulting in a major limitation of the 
power of such association studies.  
 
Accurate determination of a SNP’s significance of association with a pharmacogenomic trait and 
exclusion of non-functional SNPs at a given locus included steps based on Edwards et al [Edwards 
et al 2013]. Dense genotyping and imputation methods were used to define what SNPs are 
contained in a haplotype block identified in a GWAS or other study. For determination of LD 
between SNPs, r2 values were calculated in a pairwise manner using the genotype dataset of each 
SNP [Flister et al 2013, Wang et al 2012]. LD blocks were defined among the SNPs that exhibited 
strength, using multiple approaches. These included re-calculation of the upper and lower 95% 
confidence limits on r2 for a strong LD that were set at 0.8. LD patterns between the SNPs with 
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minor allele frequency ≥ 0.05 in the same genomic position were similarly analyzed using 
HaploReg, version 2 [Ward et al 2012]. These methods have been independently demonstrated 
[Higgins et al 2015].   
 
The first phase included 2 GWAS, the first one performed by Perlis and collaborators looking at 
response to lithium for prevention of recurrence in bipolar disorder [Perlis et al 2009]. The 
investigators did not find any SNP associations that met the “X2” statistical threshold, but found 
several that showed strong sub-"X2" threshold. Using pathway analysis, including Ingenuity 
Pathway Analysis™ [Kramer et al 2013] and open source tools including pathway commons and 
Panther [Cerami et al 2011, Mi et al 2013], we were able to identify a SNP in the GRIA2 gene 
that was part of a very significant pathway. The second included GWAS found noncoding SNPs 
in the GADL1 gene that were significantly associated with lithium response in a Han Chinese 
[Chen et al 2014] population.  
 
The second phase included the following studies: (1) SNPs reported from a Sardinian population 
that exhibited long term responsiveness to lithium [Squassina et al 2011]; (2) Rare variants 
obtained from sequencing families that might represent lithium-responsive pedigrees [Cruceanu 
et al 2013]; (3) A SNP in the SLC1A2 gene, which has been associated with lithium response in 
recurrent bipolar disorder in an Italian population [Dallaspezia et al 2012]; (4) SNPs in the 
SLC4A10 gene that were associated with lithium response in bipolar disorder [Rybakowski 2013, 
Schulze 2012, Rybakowski 2014]; (5) SNPs in the GSK3 gene that were associated with lithium 
mechanisms in brain [Benedetti et al 2005, Lin et al 2013]; (6) SNPs recommended for further 
investigation for their association with lithium response in bipolar disorder, with the exception of 
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brain-derived neurotrophic factor, in which data from human studies where not significant  
[McCarthy et al 2011, McCarthy et al 2010]; and (7) SNPs in CLOCK genes which had been 
significantly associated with lithium response in bipolar disorder [Rybakowski et al 2014]. 
 
The third phase included the following studies, which had lead or imputed functional SNPs shared 
with the phase 1 and phase 2 SNPs [Byrne et al 2013, Soronen et al 2010, Ferreira et al 2008, 
Psychiatric GWAS Consortium Bipolar Disorder Working Group 2011, Chen et al 2013, Liu 
et al 2011, Rietschel et al 2010, Green et al 2013, Schizophrenia Psychiatric GWAS 
Consortium 2011, Rueckert et al 2013, Schumacher et al 2013, Spellman et al 2011, Schulze 
et al 2009, Thier et al 2012]. This phase also included SNPs from 2 studies that might have SNPs 
related to the side effects of lithium response in bipolar disorder, or with symptomatology of the 
disorder.   These include a SNP in the SLC1A2 gene associated with essential tremor [Thier et al 
2012], Brugada syndrome [Crawford et al 2015, Wright et al 2010, Darbar et al 2005], and 
sleep disruption [Parsons et al 2013]. The third phase was important because many of the same 
variants associated with bipolar disorder have been associated with lithium response in the disease 
[Manchia et al 2013, Philips et al 2014, Strakowski et al 2012]. This phase also included SNPs 
from GWAS showing association with side effects observed with lithium response in bipolar 
patients, including tremor and sleep habits. 
 
Pathway Analysis 
 
Several different strategies were used to determine the relationship between genomic regulatory 
elements identified by the SNPs. Since the objective of this study was to discover novel regulatory 
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genes and pathways for the mediation of lithium response in bipolar disorder, our initial research 
used both commercial and open source pathway analysis applications, including IPA™ [Kramer 
et al 2013], pathway commons [Cerami et al 2011] and Panther [Mi et al 2013]. The fact that the 
majority of the SNPs identified elements that were located with introns and flanking regions of 
genes presented a challenge because function of many SNPs is still not well understood. However, 
we used pathway analysis of known biochemical interactions, and sought to further understand 
these pathways using disease and pharmacogenomic databases supplemented by extensive 
literature review. 
 
Multi-Scale Epigenome Neuroanatomical Circuit Mapping 
 
Our methodology also included manual examination of the imputed, functional SNPs and further 
classification of the functional SNPs in regulatory pathways based on neuroanatomical substrate 
and molecular interactions. Application of a neuroanatomical filter based on presumptive sites of 
lithium action in bipolar disorder was also included. Using a recent review about the 
neuroanatomical substrate summarizing the neuroimaging data, we filtered using this model–  
“Bipolar disorder can be conceptualized, in neural circuitry terms, as parallel 
dysfunction in prefrontal cortical (especially ventrolateral prefrontal cortical)-
hippocampal-amygdala emotion- processing and emotion-regulation circuits 
bilaterally, together with an “overactive” left-sided ventral striatal-ventrolateral 
and orbitofrontal cortical reward-processing circuitry… A potential structural 
basis for these functional abnormalities is gray matter volume decreases in the 
prefrontal and temporal cortices, the amygdala, and the hippocampus and 
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fractional anisotropy decreases in white matter tracts connecting prefrontal and 
subcortical regions.” [Philips et al 2014]. 
 
Our expectation was that brain regions sampled and represented in data from both the epigenome 
roadmap consortium and data on RNA localization from other sources, including examination of 
the neuroanatomical distribution of RNAs from candidate regulatory elements from postmortem 
human brain, would indicate those brain regions showing regulatory events associated with lithium 
response in bipolar disorder. The human brain atlas from the Allen Brain Science Institute [Sunkin 
et al 2013] provides in situ hybridization and RNA microarray data on the distribution of specific 
mRNAs, while enhancer RNA localization data are available from the epigenome roadmap 
consortium [Zhou et al 2015]. We classified epigenome regulatory elements as to sites of cis-
expression according to the following: (1) Mid-frontal cortex,  as well as dorsolateral prefrontal 
cortex when available; (2) Angular gyrus, although there is less direct evidence to support an 
association, it is involved in the face processing pathway like the fusiform gyrus [Dima et al 2013]; 
(3) Anterior caudate, which contains the ventral striatum and nucleus accumbens; (4) Cingulate 
cortex; (5) Hippocampal formation, and (6) Inferior temporal cortex, which contains circuitry 
between the amygdala and hippocampus and prefrontal cortex and orbitofrontal cortex. 
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SYMBOL HGNC NAME FUNCTION / SIGNIFICANCE 
ANK3 Ankyrin 3, node of Ranvier (ankyrin G) 
Cytoskeletal adaptor protein that regulates sodium 
channel activity and sodium ion homeostasis at CNS 
GRIA2 synapses. 
ARNTL 
Aryl hydrocarbon 
receptor nuclear 
translocator-like 
Transcription factor that forms dimer with CLOCK. 
Exhibits greatest circadian rhythmicity in human brain. 
The same SNPs have been significantly associated with 
lithium response in bipolar disorder. 
CACNG2 
Calcium channel, 
voltage-dependent, 
gamma subunit 2 
Used to be known as ‘Stargazin’ – a transcription 
factor. 
Function in voltage-gated calcium channel in human 
brain not defined. 
CACNA1C 
Calcium channel 
voltage-dependent L 
type alpha 1C 
Regulates heart contraction and fibrillation.  Same SNP-
detected enhancer responsible for Brugada syndrome:  
lithium-induced heart failure. 
CDKN1A Cyclin-dependent kinase inhibitor 1A 
Regulates SWI/SNF mediated chromatin remodeling. 
Found in central glutamatergic neurons. 
CREB1 
Cyclic AMP-
responsive element-
binding protein 1 
Ubiquitous distribution and function. SNP associated 
with SSRI antidepressant response and addiction, but 
data are not definitive. 
GRIA2 Glutamate receptor, ionotropic, AMPA 2 
GWAS showed association with lithium response in 
bipolar disorder and risk of schizophrenia.  
GSK3B Glycogen synthase kinase 3 beta 
A kinase in the ATK / WNT signaling pathway. The 
same SNPs have been significantly associated with 
lithium response in bipolar disorder in many studies. 
NR1D1 
Nuclear receptor 
subfamily 1, group D, 
member 1 
A transcription factor that regulates circadian 
rhythmicity. The same SNP has been significantly 
associated with bipolar disorder and lithium response in 
bipolar disorder.   
SLC1A2 
Solute carrier family 1 
(glial high affinity 
glutamate transporter), 
member 2 
Located in GRIA2 neurons in human CNS. The same 
SNP-detected enhancer associated with tremor, a side 
effect of lithium therapy. The same SNPs have been 
significantly associated with lithium response in bipolar 
disorder in many studies. 
 
Figure 2-9: Reported Genes from the Liuthium Analysis 
Ten Genes in Which Noncoding SNPs Were Found Within Introns and 5’UTRs. HGNC: HUGO 
Gene Nomenclature Committee. 
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Results 
 
Filtered Set of Functional Lithium-Associated SNPs 
 
Based on our hypothesis, and those of previous researchers [McCarthy et al 2011, McCarthy et 
al 2010, Philips et al 2014, Strakowski et al 2012], that psychotropic drug response and 
psychiatric disease may share the same or overlapping sets of variants, we imputed, analyzed and 
annotated SNPs reported in GWAS that had been associated with bipolar disorder, other 
psychiatric disorders or side effects of lithium from the NHGRI GWAS catalogue. This phase 3 
set included GWAS SNPs significantly associated with tremor, an adverse drug event associated 
with lithium response [Thier et al 2012], sleep habits [Parsons et al 2013] and Brugada syndrome, 
which can be a consequence of lithium “un-masking’ of ventricular arrhythmias related to sudden 
adult death syndrome [Crawford et al 2015, Wright et al 2010, Darbar et al 2005].  Following 
removal of spurious associations and epigenetic fine mapping according to the methods of 
Dunning et al [Farh et al 2015, Edwards et al 2013], we characterized a set of 78 SNPs as bipolar 
disorder epigenome regulatory variants using our workflow.   
 
Overlap Between Lithium-Response and GWAS Risk Variants 
 
All 3 phases of this study were examined for SNPs shared in common, including phases 1 and 2 
looking at lithium response candidates, as well as phase 3 GWAS studies that found SNPs in 
specific loci or genes carrying variants associated with bipolar disorder, a continuum of psychiatric 
disorders including bipolar disorder, risk variants for major depressive disorder and drug response, 
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and adverse events associated with lithium. We identified substantial overlap between SNPs from 
the published association studies on lithium response in bipolar disorder (phases 1 , 2) and the 
SNPs found in the bipolar, bipolar and major depressive disorder, bipolar and schizophrenia, 
bipolar as part of a continuum of psychiatric disease, and tremor genomewide association studies 
(phase 3). 27% of the phase 1 and phase 2 SNP sets, 217 SNPs, were also present in the phase 3 
set.  Of the 217 SNPs, 78 SNPs were annotated as active regulatory elements such as enhancers 
and promoters in a tissue-specific manner were located in 10 genes.  
 
Comparison of Results with Those from Epigenome Roadmap Consortium 
 
Through a process of LD pruning, we selected 19 functional SNPs that we characterized in more 
detail.  Using data from the epigenome roadmap consortium browser [Zhou et al 2015] for 
selection of brain regions or left ventricle (for Brugada syndrome), followed by definition using 
ChromHMM [Ernst et al 2012], ChromImpute [Ernst et al 2015] and the WUSTL epigenome 
browser [Zhou et al 2011], we found high concordance between the results of our workflow and 
that of the epigenome roadmap consortium.  The SNPs and the corresponding regulatory elements 
with tissue-specific localization for only mid-frontal cortex and hippocampus were provided by 
results from the epigenome roadmap consortium. Both mRNA and eRNA location is consistent, 
at least in human brain, with the tissue-specific assignment, as determined by corresponding data 
from the Human Brain Atlas from the Allen Brain Science Institute [Sunkin et al 2013] and from 
the epigenome roadmap consortium [Zhou et al 2015]. Not every SNP-detected regulatory 
element is reported for every brain region and peripheral tissue, just those considered important in 
the context of pathway analysis and RNA localization. The CACNA1C SNP associated with 
Brugada syndrome is expressed as a strong enhancer in the left ventricle.  
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RNA Localization  
 
Most human brain region projects show some relationship to degenerative changes observed in 
bipolar disorder, and depending on the neurotransmitter circuits involved, may play a more central 
role than had been previously thought. Since our molecular mapping analysis had shown that 
GRIA2 mRNA is regulated by enhancers, we compared the distribution of the expression of these 
genes with each other and with those regions compromised in bipolar disorder and thought to be 
sites of lithium response.  
 
Both GSK3B and CREB1 mRNAs show a pattern resembling either non-specific hybridization to 
neurons or expression like housekeeping genes. In contrast, although SLC1A2 shows more uniform 
neuronal expression, it does resemble known distribution of glia or non-neuronal cell-types in 
these regions, although it has commonly been described as the “glial glutamate drug transporter” 
in the literature [Thier et al 2012]. 
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Figure 2-10. The Lithium Glutamatergic Pathway  
Using the gene set shown in Figure 2-9, this shows an integrated glutamatergic pathway called 
by this software. This pathway is very significantly enriched for the “glutamate receptor” at 
p<10-27 (Fishers exact test). Colored objects in this regulatory network indicate the 10 genes that 
were found in this study, purple indicating ones that IPA™ called as bipolar risk genes (ANK3 
and CACNA1C), although SNPs in other genes in this pathway have been associated with risk of 
bipolar disorder.  
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Pathway Analysis and Gene Set Enrichment  
  
To understand the connections among our selected SNPs, we looked at the relationship between 
these genes using both open source and commercial pathway analysis software. Figure 2-9 shows 
the 10 genes in which 19 noncoding SNPs were found to be significantly associated with lithium 
response in bipolar patients of European ancestry.  Figure 2-10 shows data from Ingenuity 
Pathway Analysis (IPA™; Qiagen) showing the enrichment of this gene set within a canonical 
glutamate receptor pathway. The same pathway was also found using open source pathway 
analysis software, including Panther network visualization based on Gene Ontology [Mi et al 
2013].  
 
In addition, this pathway contains other genes of interest, such as DLG4, discs large homolog 4, a 
ionotropic glutamate receptor ligand, and nitric-oxide synthase regulator that acts in serotonin 
receptor signaling, in which mutations have been significantly associated with schizophrenia and 
bipolar disorder [Frank et al 2011, Cheng et al 2010]. In addition, the pathway also contains 
HTR1A, the 5-hydroxytryptamine (serotonin) receptor 1A, which is involved in behavioral 
reinforcement of reward [Zhao et al 2014] and, which mutations have been associated with 
schizophrenia. Another constituent of this pathway is the GRIA4 glutamate receptor, the glutamate 
receptor ionotropic AMPA 4, in which mutations have been correlated with antipsychotic drug 
response in schizophrenia and bipolar disorder [Makino et al 2003, Chiesa et al 2012].  It is 
important to note that the gene product of CACGN2, the calcium channel voltage-dependent 
gamma subunit 2, originally called stargazin, is a primary regulator of GRIA2 expression 
[Selvakumar et al 2009, Hafner et al 2015]. 
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A 
 
GO cellular component Number (#) # 
Expected 
Fold 
Enrichment 
+ / - P value 
Dendrite 381 4 0.16 + 0.0122 
Neuron part 981 5 0.40 + 0.0222 
Neuron projection 797 6 0.33 + 0.00809 
B 
 
ID Molecules in Network Score Focus Molecules 
1 
Abcb1b,AKR1B10,AKR1C3,ANK3,ARNTL,CACNA1C,CACNG2,CD
KN1A,CEBPA,Creb,CREB1DLG3,DLG4,EIF4EBP2,EMCN,ERK1/2,F
SCN1,Gpcr,GRIA2,GRIA4,GSK3B,HTR1A,L1CAM,miR-26a-5p, 
NR1D1,NSF,NTN1,PDE3A,RASGRF2,RGS2,SBSN,SLC1A2,SRR,TNI
K,VCAN 
27 10 
C 
 
Diseases or 
Functions 
Annotation 
p-Value Molecules # Molecules 
Neurodegeneration 
of brain cells 6.47E-11 ANK3,CREB1,GRIA2,GSK3B,SLC1A2 5 
Neurodegeneration 
of cerebral cortex 
cells 
3.92E-10 CREB1,GRIA2,GSK3B,SLC1A2 4 
Behavior 8.78E-09 ARNTL,CACNA1C,CACNG2,CDKN1A,CREB1,GRIA2,GSK3B,SLC1A2 8 
Neuronal cell death 2.04E-08 CDKN1A,CREB1,GRIA2,GSK3B,NR1D1,SLC1A2 6 
Movement 
Disorders 2.32E-08 
ANK3,ARNTL,CACNG2,CREB1,GRIA2,GSK3B,N
R1D1,SLC1A2 8 
Degeneration of 
neurons 3.33E-08 ANK3,CREB1,GRIA2,GSK3B,SLC1A2 5 
Neurodegeneration 
of hippocampal 
neurons 
6.04E-08 CREB1,GRIA2,GSK3B 3 
Mood Disorders 6.79E-08 ANK3,ARNTL,CACNA1C,CREB1,GRIA2,GSK3B 6 
Circadian rhythm 1.75E-07 ARNTL,CREB1,GSK3B,NR1D1 4 
Bipolar disorder 3.90E-07 ANK3,ARNTL,CACNA1C,GRIA2,GSK3B 5 
 
Figure 2-11. Gene Set Enrichment Analysis of Lithium Genes  
(A) Subcellular compartmentalization from pathway commons [Carbon et al 2009]; (B) 
Pathway analysis using IPA™.  All discovered genes (bold text) are contained within the same 
regulatory network. These genes are enriched in this pathway at p < 1 x 10-27 using Fisher’s 
right-tailed exact test. (C) Determination of top 10 diseases and phenotypes associated with this 
regulatory network using IPA™.  
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Evaluation of Pathway Components 
 
In this analysis, we identified multiple SNPs in some genes that had been proposed as candidates 
for mediation of lithium response and others that were identified by epigenomic mapping and 
pathway analysis. Within this set of SNPs that were filtered from a much larger dataset are 
contained CACNG2 (calcium channel voltage-dependent gamma subunit 2), also known as 
stargazin, which along with other AMPA transmembrane proteins, is a potent regulator of GRIA2 
expression [Selvakumar et al 2009, Hafner et al 2015]. Also in this network are the genes ANK3 
(ankyrin 3 node of Ranvier) which encodes ankyrin G, a protein which regulates central 
glutamatergic synaptic organization in the human CNS [Smith et al 2015], and CACNA1C 
(calcium channel voltage-dependent L type alpha 1C subunit), which is involved in the processing 
of episodic memory in human hippocampal neurons [Krug et al 2014]. Mutations in ANK3 and 
CACNA1C have been significantly associated in GWAS with a variety of psychiatric disorders, 
including bipolar disorder, psychiatric drug response, and disruption of sleep disorders. A 
CACNA1C risk variant has also been found to be one of several mutations in ion channel genes 
that give rise to Brugada syndrome, which is a shortening of the QT interval in humans that leads 
to sudden adult death syndrome (SADS), which can be unmasked in patients that are treated with 
lithium salts [Crawford et al 2015, Wright et al 2010, Darbar et al 2005].  
 
There have been several molecular mechanisms suggested as the basis of lithium response in 
human brain, ranging from non-specific effects based on its status as an elemental metal acting in 
a nebulous manner, such as membrane stabilization, to a very specific mechanism that impacts 
intracellular WNT signaling and other pathways working through GSK3B (glycogen synthase 
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kinase 3 beta). The first evidence for a role of lithium acting at GSK3B was the observation that 
this serine/threonine kinase is directly inhibited by lithium in cultured cells [Stambolic et al 1996]. 
This led to several studies in which a promoter SNP in GSK3B was found to be associated with 
lithium therapy in bipolar disorder and depression [Adli et al 2007, Benedetti et al 2005, Lin et 
al 2013], analysis of mechanisms of atrophy in bipolar disorders, and how lithium and GSK3B 
SNPs act in a similar manner to protect neural degeneration [Benedetti et al 2013]. These 
observational studies quickly led to the inclusion in lithium medication literature of GSK3B and 
related CREB pathways, which are widely distributed throughout all human cells that contain 
nuclei [Valvezan et al 2012, Brown et al 2013, Chiu et al 2010, Can et al 2014]. What is less 
widely recognized is that GSK3B is a potent regulator of ARNTL protein stability and circadian 
function through phosphorylation, as it does with other CLOCK genes [Sahar et al 2010].  
 
Since bipolar disorder is characterized by rapid cycling of mood, and by sleep disruption, it has 
always been an attractive hypothesis that members of the CLOCK gene family, whose proteins 
regulate circadian rhythmicity, must be key to dysregulation in this and other psychiatric disorders.   
In parallel, it has been of great interest to understand if lithium acts to establish normalization of 
circadian rhythmicity, which appears to be disrupted in major depressive disorder and other 
psychiatric disorders [Crisafulli et al 2012]. Extensive research has been dedicated to the role of 
CLOCK genes, bipolar disorder and lithium response [McCarthy et al 2010, McCarthy et al 
2011, Rybakowski et al 2014], although SNPs in these genes have not been found in any GWAS 
of bipolar disorder [Welter et al 2014]. However, in this study, SNPs in the ARNTL and NR1D1 
genes appear to contribute to enhance lithium drug efficacy in bipolar disorder. 
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This research clearly demonstrated that the SLC1A2 (solute carrier family 1 member 2) gene, a 
sodium-amino acid symporter that acts in L-glutamate transport and neuroprotection, formerly 
termed the high affinity “glial” glutamate transporter, is expressed in neurons in human brain. 
Starting with the premise that adverse events that emerge from lithium treatment, such as fine 
tremor, can be better understood with knowledge of which variants have been significantly 
associated with essential tremor as a disorder in its own right, we included them in this study. 
Again, the strategy of evaluating GWAS SNPs associated with a drug’s side effects in the context 
of examining pharmacogenomic response has been used previously by others [Schulze 2012]. 
 
Discussion 
 
This study implicates the involvement of a glutamatergic regulatory pathway in lithium response 
in bipolar disorder in individuals of European ancestry.  The research builds on a foundation of 
published literature of candidate gene association studies that have examined lithium response and 
remission, including the identification of a SNP in the GRIA2 (glutamate receptor ionotropic 
AMPA 2) gene found in a GWAS examining time to recurrence of lithium treatment in bipolar 
disorder [Perlis et al 2009]. The GRIA2 gene encodes a transmembrane receptor that is part of a 
family of glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole 
propionate (AMPA). It functions as a ligand-activated cation channel, and may form part of a 
channel that is assembled from 4 related subunits, GRIA1-4. The GRIA2 gene has been previously 
associated with diagnosis and response to antipsychotic treatment in patients with schizophrenia 
[Crisafulli et al 2012, Eastwood et al 1995], pharmacologic management of inflammatory 
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disorders involving chronic pain [Kuttikat et al 2011], and antidepressant response in major 
depressive disorder [Chiesa et al 2012].      
 
The results from the workflow we used in this analysis agreed with the results from annotation 
using data from the epigenome roadmap consortium.  Although we used a SNP from a GWAS that 
examined time-to-lithium recurrence that did not achieve the stringent Bonferroni-type correction 
that has traditionally served as a threshold in GWAS to rule out false positives, this approach is 
increasingly being used to “rescue” GWAS associations in the context of pathway analysis. Thus, 
not only have recent GWAS have used a similar approach as the one used here to select less 
significant variants using pathway analysis [Jia et al 2010, McGeachie et al 2014, Zhou et al 
2013], but recent GWAS studies and guidelines emphasize the less stringent methods of FDR and 
Fisher’s exact test as preferable to Bonferroni correction.  
 
While it is true that our lithium response network does share some loci with results on the genetic 
etiology of bipolar disorder, such as the genes ANK3 and CACNA1C, we feel strongly that it is not 
reducible to the genetic basis of the underlying disorder.  For one, on a basic level, the math does 
not check out: some 80% of the genes in the network we report are not involved in bipolar etiology.  
But for another, it should be no surprise that some of the same genes whose mutations and 
regulation influence a disease may also play host to mutations (not necessarily the same ones) 
which influence the effectiveness of treatment.  Examples of this phenomenon are forthcoming in 
disease, as for instance with BRCA1 and BRCA2, which play host to both mutations which predict 
the emergence of breast cancer, and also mutations that predict the effectiveness of breast cancer 
drugs.  Our approach of focusing on those brain regions where lithium protects against neural 
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atrophy has been used by other investigators [Philips et al 2014, Malhi et al 2013].   
 
Of course, while these results admit of both counterarguments and affirmative defense against 
these counterarguments, such questions will ultimately be resolved by additional experiments in 
biological systems to examine the molecular components of lithium-mediated signal transduction 
which we have identified.   While this analysis is based on tens of thousands of variants with 
demonstrated association with lithium response and adverse drug events in large human 
populations, this in silico analysis needs to be validated further in pharmacogenomic trials in 
human cohorts. 
 
The current generation of genotype-based tests in neuropsychiatric pharmacogenomics have 
demonstrated clinical utility [Mrazek 2010, Hall-Flavin 2013, Trinks et al 2014, Moaddeb et al 
2013]. Understanding the regulatory epigenome will provide the next generation of variants that 
will enable a new era of pharmacogenomic tests. These lithium variants and the methods that 
identified them are a promising method for finding candidate variants and loci of significance in 
epigenetic regulation of drug response.  
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Valproate: A Potent Initiator of Neurogenesis 
 
Motivation 
 
The mechanism of action of VPA as an anticonvulsant, mood stabilizer and analgesic in the human 
central nervous system (CNS) has not been adequately characterized.  VPA and its derivatives 
exhibit a variety of effects which are cell- and tissue-specific, differ based on disease state, age, 
gender and ethnicity, and may be effective or deleterious. VPA is a weak blocker of sodium and 
calcium ion channels, and may inhibit key enzymes in the catabolism of gamma-aminobutyric acid 
(GABA), including ABAT (4-aminobutyrate aminotransferase) at physiologically relevant 
concentrations [Ghodke-Puranik et al 2013]. There is also evidence that VPA exerts its 
antiepileptic action through differential regulation of the GRIN2B (Glutamate Ionotropic Receptor 
NMDA Type Subunit 2B) gene [Perucca 2002]. VPA is an effective inhibitor of histone 
deacetylases (HDACs), with an IC50 (0.4 mM) well within the therapeutic range of VPA (0.35–
0.7 mM in serum).  VPA causes robust chromatin decondensation, with a dspotent acetylation of 
core histones such as H3 and H4 that leads to activation of development gene expression 
[Gottlicher et al 2001, Gurvich et al 2004].  VPA has been shown to be neuroprotective in animal 
models of traumatic brain injury (TBI) [Halaweish et al 2015, Dash et al 2010], spinal cord injury 
[Lv et al 2011], and in neurodegenerative disease [Guo et al 2014]. In a swine model of TBI and 
hemorrhagic shock (HS) VPA decreases brain lesion size, improves neurologic recovery, and 
down-regulates genes associated with necrosis, apoptosis, and inflammation [Dekker et al 2014].  
The HDAC inhibitor, sodium butyrate, with a mechanism of action similar to that of VPA, has 
been shown to activate neurogenesis in rodent brain following ischemic injury [Kim et al 2009]. 
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These results suggest different ways in which VPA may act in parallel to provide benefit in 
epilepsy, mood disorders, migraine, as well as recovery following trauma. 
 
A recent study of the impact of VPA on the epigenome and gene expression in non-neuronal human 
cell lines demonstrated dose- and time-dependent up-regulation of TFs and cell type-specific 
histone modifications emblematic of poised, bivalent gene promoters active in cell fate 
specification and differentiation [Halsall et al 2015].  In the same study, the authors concluded 
that cells were actively buffering their homeostatic state in the presence of HDAC inhibitors to 
avoid hyper-acetylation that might lead to widespread and uncontrolled gene expression [Halsall 
et al 2015]. It appears that VPA-induced histone acetylation is not sufficient for chromatin 
decondensation, but rather a downstream effect of HDAC inhibition, suggesting that the drug 
suppresses the expression of proteins involved in maintenance of heterochromatin and/or uses 
chromatin remodeling proteins as intermediaries [Yi et al 2013, Marchion et al 2005]. VPA has 
been shown to direct the programming of fibroblasts into neurons [Chu et al 2015]. It is also 
routinely used to remove histone methylation in cellular domains such as the lamina-associating 
domain (LAD) located just interior of the nuclear membrane, a region containing heterochromatin, 
in which exposure to VPA abolishes H3K27 and H3K9 methylation [Kelkhoff et al 2016]. It is 
noteworthy that others have documented the presence of a “genomic storm” following TBI [Xiao 
et al 2011]. In addition, stem cell therapy has been heralded for treatment of trauma patients, 
including those with TBI [Ahmed et al 2016], suggesting that cell fate reprogramming with 
development TFs might also be a useful approach in such cases.  
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Recent studies of the epigenomic control of gene expression that has identified distinct 
mechanisms through which chromatin interactions mediate transcriptional programs involving 
topologically-associating domains (TADs), enhancer-promoter loops and actively transcribed 
regions of the human genome characterized by the histone mark H3K27ac [Kundaje et al 2015, 
Rao et al 2014, Gonzalez-Sandoval et al 2016]. It has been shown that SNPs which disrupt the 
boundaries of TADs cause serious health problems [Lupianez et al 2015]; and causal SNPs exhibit 
significant allele bias in open chromatin [Lee et al 2015]. In addition, the greater the number of 
spatial connections a given enhancer or promoter maintains genomewide indicates both the 
potency of the regulatory element and its validity [Ramani et al 2016], especially for CNS genes 
that are involved in coordinated transcriptional programs of neurogenesis and neuroplasticity 
[Thakurela et al 2015]. 
 
Our hypothesis is that VPA acts through transcriptional activation and repression of specific genes 
resulting in chromatin-mediated neurogenesis and neuroplasticity in the adult CNS and inhibition 
of glial scarring. To determine the validity of this premise, we analyzed experimental and public 
data. We then reconstructed a gene regulatory network that mediates VPA’s mechanism of action 
in human brain, and found that the drug exerts widespread effects in adult brain including a 
transcriptional program of neurogenesis and neuroplasticity, involving TFs that have been shown 
to program neuronal cell fate commitment and suppress oligodendrocyte cell fate. 
 
Methods 
 
Data 
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Figure 2-12 shows an overview of the experimental design, including public databases and sources 
used in this analysis. These included experimental results from a well-characterized swine model 
of TBI and hemorrhage [Halaweish et al 2015, Dekker et al 2014], that exhibits functional 
recovery following a single supra-therapeutic bolus of VPA evaluated for differential gene 
expression following VPA administration. Other primary data included microarray expression data 
from postmortem human brain tissue obtained from the Human Brain Atlas of the Allen Brain 
Science Institute [Sunkin et al 2013] and other sources [Higgins et al 2015].   
 
Experimental data from SK-N-SH cell lines 
 
Publicly available date from SK-N-SH cells were used for two applications: (1) For determination 
of DNase I hypersensivity and allele bias, as they are included as examples in the deltaSVM 
machine learning algorithm [Lee et al 2015], and (2) Evaluation of spatial interactions in the 
human genome using data from a high resolution Hi-C dataset [Rao et al 2014].  To discover how 
the VPA pharmacogenomic SNPs we selected produced robust pharmacogenomic stratification, 
evaluation of the chromatin interactions of regulatory elements they were located in was used to 
preliminarily map the putative VPA pharmacodynamic pathway in human brain.   
 
Published literature on pharmacogenomic associations and VPA targets and pathways 
 
Two hundred and fifty-four peer-reviewed published articles were retrieved between January 1 
and October 1 2016, including gene association studies, as well as basic and clinical pharmacology 
reports.  An automated Boolean search string was used consisting of “valproate OR valproic acid 
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OR sodium valproate OR divalproex sodium AND pharmacodynamics OR mechanism of action 
OR brain OR pathways AND pharmacogenomic AND bipolar disorder AND epilepsy AND 
migraine headache AND gene OR SNP AND association AND human.”  There are no published 
genomewide association studies (GWAS) that are focused on medication response or adverse 
events related to only valproic acid therapy in epilepsy, bipolar disorder or migraine.  There are 
however, several GWAS that have investigated SNPs associated with human populations that have 
treatment-resistant or refractory epilepsy. These studies are made up primarily of patients who do 
not respond to a combination of anticonvulsant drugs or worsen on therapeutic regimens.  Due to 
confounding related to polypharmacy these studies were excluded. For this study, we avoided 
anything but primary research studies in which we re-tested all of the parameters and statistical 
tests that were employed. This dramatically reduced the number of studies from 254 to 52 that 
could be included in this analysis. 
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Figure 2-12. Diagram of Valproate Analysis Methods  
(1) Shows steps to annotate putative VPA pharmacogenomics SNPS which were (2) 
mechanistically analyzed using integrative bioinformatics and regulatory network analysis 
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methods.  In (1) numbers refer to the different annotation steps of the bioiformatis pipeline. Details 
can be found in the text.  
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Analysis 
 
VPA Pharmacogenomic SNPs 
 
Pharmacodynamic variants that stratify drug response in human populations have provided insight 
into CNS targets and pathways for neuropsychiatric medications that have been in clinical use for 
decades but have ill-defined mechanism of action in human brain [Ghodke-Puranik et al 2013, 
Perucca 2002]. The published literature on the pharmacogenomics of valproic acid response in 
human populations has been sparse, constrained by small sample size, confounded by an over-
emphasis on exon variants, and a focus on pharmacokinetic genes.  To date, genome-wide 
association studies (GWAS) have examined epilepsy and anticonvulsant-induced adverse events 
but have not included VPA in their analysis except in combination with other anticonvulsant 
medications.     
 
To better understand human CNS pathways that are involved in the mechanism of action of 
valproic acid, we combined SNP imputation with bioinformatics analysis. SNPs that included in 
the analysis had to be located in genes expressed in human brain, were likely to be associated with 
known biological targets of VPA, could be functionally annotated, and were derived from primary 
research studies. For this analysis of potential pharmacodynamic pathways, we excluded 
pharmacokinetic genes and their variants such as the UGT and CYP super-families. To select VPA 
pharmacogenomic SNPs we combined SNP imputation from VPA pharmacogenomic association 
studies, and performed computational and bioinformatics analysis as described in detail in a 
previous publication [Higgins et al 2015]. DrugBank [Drugbank 2015] and the 
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pharmacogenomic mutation database (PGMD®; Qiagen) lists pharmacodynamic targets that have 
been associated with VPA [Kaplun et al 2016].  Studies were selected from the published 
literature as described in a previous study [Higgins et al 2015]. In addition, we interrogated the 
PGMD® (Qiagen GmbH) [Kaplun et al 2016] and DrugBank [Drugbank 2015] to gather 
additional information.   
 
In Figure 2-12.1, bioinformatics analysis was used to identify the most probable causal SNP from 
the association regardless of the lead SNP(s) that were reported, and included the following 
bioinformatics analysis to determine the functionality of the variant: (1) Location in open 
chromatin as indicated by peaks of DNase I hypersensitivity, (2) Low to moderate methylation of 
any cytosine residues, (3) The presence of histone marks that indicate regulatory function 
(H3K27ac + H3K4me1 = enhancer; H3K27ac + H3K4me3 = promoter), (3) The location of the 
variant within the context of the gene or in an intergenic domain, (4) Whether the regulatory 
element has yet to be annotated as a molecular quantitative trait locus (eQTL, hQTL, etcetera), (4) 
Proteins, including transcription factors, bound to the regulatory element as determined by ChIP-
Seq indicating its regulatory function, (5) Disruption by the pharmacogenomic SNP of 
transcription factor binding sites as indicated by alterations in the position weight matrix, (6) 
Association of the regulatory element with the requisite RNA species (e.g., bi-directional enhancer 
RNA=enhancer; mRNA= promoter), (7) Connectivity of the regulatory element with other 
elements in the genome as indicated by the Hi-C chromatin conformation capture method limited 
to SK-N-SH cells, which are the ENCODE Tier 2.5 neural surrogate cell line, (8) Transcriptional 
programming by factors which are responsible for determination of neuronal cell fate, (9) 
Determination of the allele bias of the allelic variant using the deltaSVM algorithm [Lee et al 
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2015], (10) examination of the neuroanatomical distribution of target gene expression data in 
postmortem human brain using both microarray and in situ hybridization data from the Human 
Brain Atlas of the Allen Brain Science Institute [Sunkin et al 2013].  This process revealed a total 
of 3 pharmacodynamic SNPs that warranted further investigation, including rs3764028_G located 
in the promoter of GRIN2B, rs2857654_A which detects an enhancer and is located in CCL2, and 
rs2269577_G, an enhancer located 5’ to XBP1. These were chosen because the objective was to 
provide a more detailed characterization of these SNPs and their corresponding regulatory 
elements to better understand VPA’s mechanism of action in the human CNS (Figure 2-12.2).   
 
For annotation, we focused on active enhancers, promoters and transcription start sites, so other 
chromatin states were not used in the present study, including flanking and poised regulatory 
elements, transcribed domains or repressed elements. Although potential regulatory variants may 
be repressed in one tissue or brain region but not another, we could directly assess function in any 
biological system in this study, so we relied on the data provided by the association studies. We 
harmonized our nomenclature with the results of the roadmap epigenome mapping consortium.  In 
all cases, gene and protein symbols and definitions were consistent with HGNC nomenclature (1), 
except as indicated by citation in the text.  Gene symbols are from GENCODE except where 
indicated, and genomic location coordinates are from build 38 of the Human Genome.  
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SNP GENE
1
 TYPE 
deltaSVM
SCORE
2
 
DISEASE EFFECT EFFECT SIZE 
rs2857654_A CCL2 Enhancer -2.275704 Epilepsy Response in children 1.45 (1.06-1.99) 
rs3764028_G GRIN2B Promoter -5.097029 Epilepsy Dose range 1.7553 (1.219-2.291) 
rs2269577_G XBP1 Promoter 4.710044 BPD Response
3
 
1.2754 (0.329-
2.221) 
 
Figure 2-13. Reported SNPs from the Valproate Analysis 
Selected Pharmacogenomic Variants Selected for Allelic Variation in VPA Dose, Response and 
Pharmacodynamics in Human Populations. Noncoding SNPs that identified regulatory elements, 
including enhancers and promoters.  SNPs included rs2857654 [He et al 2013], rs3764028 [Hung 
et al 2011], and rs2269577 [Kim et al 2009].  1RefSeq nomenclature; 2deltaSVM is a machine 
learning algorithm that determines the causal nature of gene variants, including DNase I 
hypersensitivity and allele bias [Lee et al 2015]; 3Total treatment response score, Kruskal–Wallis 
test for valproate prophylactic treatment response. BPD: Bipolar disorder, sample containing 
patients with BPD 1 and BPD 2.  
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Reconstruction of VPA Gene Regulatory Networks in the Human CNS 
 
Figure 2-12.2 shows the method by which we reconstructed the central VPA pathway in the human 
CNS. It involved: Identification of databases relevant to modeling the VPA regulatory circuit, Data 
aggregation from public databases and in-house data,  manual curation of the data in the context 
of a VPA central mechanism of action, preparation of curated data for model integration,  iterative 
gene set enrichment analysis (GSEA) using different public and commercial software, and 
pathway analysis using IPA® and the STRING database of protein-protein interactions 
[Szklarczyk et al 2014], as well as network analysis using weighted gene co-expression network 
analysis (WGCNA) in R [Langfelder et al 2008] and node-edge modeling systems modeling using 
Python [Kestler et al 2008]. In addition to applying redundant software analysis tools, we also 
used different open source and commercial databases, including IPA® [Kramer et al 2013], 
Pathway Commons [Cerami et al 2011] and Reactome [Croft et al 2014] databases as well as 
manual curation of the scientific literature, to determine network interactions.  
 
For reconstruction of VPA’s gene CNS regulatory pathway, we used a hybrid model development 
method that combines GSEA and pathway analysis/network modeling software used in 
bioinformatics with a technique for constructing core regulatory circuitry which includes super-
enhancers, TFs and auto-regulation, based on defined biological attributes of transcriptional 
regulation in the human CNS. During the course of the project, we discovered a number of other 
TFs that are regulated by VPA that directs cell fate, in addition to many genes whose was 
expression was regulated by ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1), 
NEUROD1 (Neuronal Differentiation 1), MEF2C (Myocyte Enhancer Factor 2C), MEF2D 
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(Myocyte Enhancer Factor 2D), MYT1L (Myelin Transcription Factor 1 Like), and TBR1 (T-Box, 
Brain 1). Many TFs were tightly coupled in terms of target promoters, many of which were also 
involved in neurogenesis and neuroplasticity. As such, this convoluted super-program was 
investigated in greater detailed.  Since many of these genes were also regulated by the same super-
enhancers or enhancers, we gained better insight into underlying coordinated mechanisms of 
transcription induced by VPA.  To do so, emphasis was placed on cellular reprogramming of 
neuronal cell fate and underlying mechanisms of coordination that supported VPA-mediated 
chromatin reorganization leading to functional recovery. 
 
 
Results 
 
Selection of VPA Pharmacogenomic SNPs for Further Examination 
 
Table 2 shows VPA pharmacogenomic SNPs that were selected for further analysis. The 3 SNPs 
stratify response to VPA in human populations, are located in regulatory domains (promoters or 
enhancers), and exhibit significant chromatin allele bias as measured by the deltaSVM algorithm 
(23). The latter is a feature of causal SNPs [Lee et al 2015]. They include: 
 
1. The intronic SNP rs2857654_A located within the CCL2 gene, which encodes the 
Chemokine C-C Motif Ligand 2, and is most significantly associated with cell movement 
and migration of cells and this enhancer interacts with VPA [Kramer et al 2013]; 
  126   
 
2. The 5’ SNP rs3764028_G located in the distal GRIN2B promoter is in a region associated 
with massive chromatin reorganization in brain in rodents and human cell lines. Spatial 
mapping in SK-N-SH cells shows that it forms an inter-chromosomal transcriptional hub 
(Figure 3A), contacting genes in cis- and trans- in SK-N-SH cells that are enriched for 
genes involved in neuronal differentiation and development of the CNS (Figure 2-14); 
3. The 5’ SNP rs2269577_G located in the promoter of the XBP1 (X-Box Binding Protein 1) 
gene, which functions as a transcription factor during endoplasmic reticulum (ER) stress 
by regulating the unfolded protein response. Required for cardiac myogenesis and 
hepatogenesis during embryonic development, and the development of secretory tissues 
such as exocrine pancreas and salivary gland. An enhancer co-regulates XBP1, EWSR1 
(EWS RNA Binding Protein 1), CCDCC117 (Coiled-Coil Domain Containing 117),  
KREMEN1 (Kringle Containing Transmembrane Protein 1) and ZNRF3 (Zinc And Ring 
Finger 3) genes, which are co-localized within a TAD located on chromosome 22 [Wang 
et al 2016]. The location of this SNP 5’ to the XBP1 gene is shown in Figure 2-14.  
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A            
     
B 
 
 
Figure 2-14. Spatial Contacts of Valproate SNPs 
(A) Whole genome plot of transcriptional hub based on cis- and trans-contacts of the SNP 
rs3764028_G in the promoter of the GRIN2B gene based on data from Hi-C mapping of this SNP 
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in the human neuronal cell line SK-N-SH. (B) Relative location of the VPA pharmacogenomic 
SNP rs2269577 (green line), with histone marks H3K27ac and H3K4me4 indicative of an active 
promoter, location in a DNase I hypersensitivity region indicative of open chromatin, and 
overlapping a HOT domain containing many TFs [Li et al 2016]. This SNP is located withinh a 
TAD located on chromosome 22 (26,600,000-28,000,000) [Wang et al 2016] containing the XBP1 
gene as well as other genes. Inset. Screenshots from the UCSC genome browser, build hg18, taken 
from the UCSC genome browser in (B) [Speir et al 2016].   
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VPA Modulates a Transcriptional Hub Consisting of 12 Genes in Spatial Contact with the 
GRIN2B Promoter  
 
The 5’ SNP rs3764028_G located in the distal GRIN2B promoter is in a region associated with 
massive chromatin reorganization in brain [Thakurela et al 2015, Bharadwaj et al 2014] in 
rodents and human cell lines. This SNP detects a promoter that maintains spatial contact, as 
determined by Hi-C maps of SK-N-SH cells, with 3 known enhancers including 2 super enhancers 
as well as a promoter with spatial contacts to genes associated with neuronal survival and plasticity. 
This replicates a result from a study in mouse brain in which researchers combined genome-wide 
analysis of data sets for chromatin accessibility (FAIRE-Seq) and the enhancer mark H3K27ac, in 
which they found a subset of genes associated with neuroprotection and plasticity that increased 
transcription in adult mouse brain following activation of the glutamate receptor [Bharadwaj et 
al 2014]. In our study, both gene set enrichment using Gene Ontology, as well as manual inspection 
of genes that maintain spatial contacts with the promoters and enhancers detected by our putative 
causal SNPs demonstrate selectivity for neuroplasticity and chromatin reorganization.  In 
agreement with their findings, genes whose abundance increased included NR4A1, which regulates 
dendritic spindle density and organization in human brain following neuronal excitation, BTG2, a 
transcription factor that inhibits neural precursor cell proliferation and stimulates neuron cell 
differentiation and acts in histone arginine methylation, ILRN, which is also in contact with an 
enhancer associated with SNP rs2857654_A, and NF1, which differentially controls neural stem 
cell proliferation. In addition, we identified contacts with GRASP, part of a receptor complex 
scaffold that regulates G protein-coupled glutamate receptor signaling, MEF2D, which is regulated 
by NEUROD1, and EPHB2 (EPH Receptor B2), a developmentally-regulated receptor tyrosine 
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kinase that functions in axonal guidance during development. This promoter also maintains long 
distance spatial contact with SETDB1, an H3-K9 histone methyltransferase that regulates 
epigenetic gene silencing to maintain stem cell pluripotency, a result that has been experimentally 
shown in rodent brain and cell lines by other researchers [Thakurela et al 2015, Bharadwaj et al 
2014].  
 
The distal GRIN2B promoter maintains spatial interactions with genes that program neuronal cell 
fate in humans, and are highly responsive to VPA. These are TBR1 (T-Box, Brain 1), which is up-
regulated by VPA following TBI in our animal model. TBR1 is a TF that acts as a potent 
programmer of neurogenesis [Mihalas et al 2016], controls the differentiation of pyramidal cells 
in neocortex, and controls expression of the GRIN2B gene in developing cerebral cortex [Notwell 
et al 2016]. The other is FGF9 (Fibroblast Growth Factor 9), which is produced by developing 
neurons to maintain homeostasis within the surrounding milieu. It plays an important role in the 
regulation of embryonic development, cell proliferation, cell differentiation and cell migration, 
regulation of gliosis during repair and regeneration of brain tissue after damage and the 
differentiation and survival of neuronal cells [Hadjab et al 2013]. Several of the genes that exhibit 
spatial proximity to the GRIN2B promoter in human SK-N-SH cells are also up-regulated by VPA 
in the swine model of TBI and hemorrhage. These include the following: 
 
1. FGF9 (Fibroblast Growth Factor 9): 1.74 fold (log2) (p-value = 0.005; t-statistic = 5.76); 
2. NR6A1: 1.75 fold (log2) (p-value = 0.0000546; t-statistic = 15.77); 
3. TBR1: 1.49-fold (log2) (p-value = 0.007; t-statistic = 4.73) 
4. MEF2D: 1.11-fold (log2) (p-value = 0.005; t-statistic = 5.42). 
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Synthesis 
 
With the successful completion of three variant discovery and analysis experiments in three 
separate drug-disease systems (and system agglomerations) in early 2015, it was clear within the 
Athey laboratory that such methods added significant value to the discovery of both variants and 
mechanisms for pharmacological phenotypes across the neuropsychiatric space.   
 
However, at this point, the epigenome variant discovery effort was handicapped by serious 
problems, including a lack of consistency in methods between and within our variant discovery 
efforts, and a resulting lack of reproducibility, which were of concern to journals, peer reviewers, 
and our partners at Assurex Health.  In addition to this, variant discovery experiments in this vein 
took a long time to conduct and to update in light of new information, and made extensive use of 
expert judgment in areas like neuroanatomy and tissue relevance, as well as thresholding, making 
them difficult to perform at scale.  Finally, research then breaking in the area of epigenome 
informatics and the spatial genome was then suggesting new information modalities for evaluating 
regulatory variants, which could not be undertaken in the semi-manual mode we had then adopted. 
 
The stage was then set for an automated pipeline which would synthesize the lessons of our manual 
variant discovery experiments into a broadly applicable featureset, to be run reproducibly on 
locally stored data, which would resolve these problems and lay a foundation for future 
development.  I embarked upon the creation of what would eventually become the 
Pharmacoepigenomics Informatics Pipeline. 
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Chapter 3: The Pharmacoepigenomics Informatics Pipeline 
 
This chapter described the Pharmacoepigenomics Informatics Pipeline, an integrative multiple 
omics variant discovery pipeline I created in order to make epigenome analyses in 
pharmacogenomics more powerful and easier to perform.  In its initial iteration, which replicates 
closely the methods of the lithium analysis [Higgins et al 2015], it has both replicated existing 
results and discovered previously unknown genetic and mechanistic basis for study phenotypes.  
In addition, the success of the PIP with warfarin, a system far outside of neuropsychiatry in a 
domain which has been the subject of a great deal of pharmacogenomics work which has borne 
little clinical fruit, is an indication that these epigenome methods and pipelines may add value in 
a variety of phenotype systems. 
 
Methodological Guidance from Pre-PIP Analyses 
 
The Pharmacoepigenomics Informatics Pipeline was conceived with the object of enabling 
epigenome analyses to discover variants for phenotypes, of the type demonstrated in the 
preliminary work, to be carried out with the benefit of three principal improvements: 
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Firstly, that they be easier to undertake and to maintain.  The epigenome analyses in the “variants,” 
[Higgins et al 2015] “lithium,” [Higgins et al 2015] and “valproate” [Higgins et al 2017] papers, 
described in chapter two, each took months of effort, and involved manually downloading and 
processing relevant datasets, as well as consulting online resources.  Any update to the analysis, 
e.g. including more variants or taking advantage of a new dataset, would require a similar scope 
of effort.  To scale to larger experiments, be available to collaborators, and be used more widely, 
this type of analysis needed to be more automated, so that input files could be assembled and run 
with less investigator effort. 
 
Secondly, that the methods be more standardized and the results more reproducible.  The three 
epigenome analyses described in chapter two each had a separate featureset containing different 
methods, and each contained many manual steps, including consulting external databases that 
change in an unversioned manner.  Thus, if such analyses continued to be carried out in such an 
ad-hoc manner, their results would not be directly comparable, not permitting all kinds of 
comparative measurements and judgments one might wish to make.  In addition, they would not 
necessarily be reproducible, either by other groups or by one’s own group over time. 
 
Thirdly, that future such analyses be able to benefit from advanced features not contemplated in 
current analyses.  As contemplated in chapter one, there was an awareness that the use of 
coimputation statistical approaches in scoring, as well as machine learning methods for variant 
effect and target gene identification, and advanced methods for processing spatial data, would 
enhance the discerning power of such analyses in the future, but many such methods are ill-suited 
for semi-manual processing and ad-hoc methods development. 
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With these three aims in mind, I undertook the formulation of a phased feature set for the 
Pharmacoepigenomics Informatics Pipeline, in three primary phases.  First, a minimal featureset 
designed to replicate the methods and reproduce the results of the lithium analysis.  Second, a 
tractable nearterm featureset within the context of my Ph.D. thesis; the version contained in this 
chapter.  And third, a longer term vision for the PIP as the foundation of third generation 
pharmacogenomics, containing advanced spatial genome and machine learning methods, with 
coimputation scoring, to occur subsequently. 
 
This construction was based on a number of important lessons from the prior analyses, including: 
 
Population specific Linkage: All three analyses benefited from the use of linkage analysis to 
expand the set of prospective SNPs beyond merely the lead SNPs of the source GWAS, and located 
potent regulatory SNPs, with important target genes, which were not reported lead SNPs.  The 
“variants” and lithium analyses benefited from the use of population-specific linkage analysis 
(using a similar genetic background to the original study populations) to uncover linked variants 
which did not exhibit linkage in a global population. 
 
Joint analysis of GWAS: The lithium and valproate analyses benefited from the analysis of GWAS 
for related phenotypes, which frequently show joint hits.  See the discourse on joint GWAS 
analysis in chapter 2. 
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Regulatory variants and chromatin state: All three analyses exhibited a predominance of regulatory 
variants over coding variants among the outputs of the analysis, including the observation that the 
outputs were predominantly located in areas of promoter and enhancer chromatin states with 
concordant chromatin marks, DNase accessibility, and TF binding. 
 
Tissue specific analysis: All three analyses benefited from the use of tissue specific omics 
information to clarify the chromatin states around candidate variants in the particular tissue 
involved.  Analyses based on less relevant tissues will inherently be less accurate. 
 
Importance of getting datasets: All three analyses involved the manual collection of relevant 
datasets, a laborious and imprecise process. 
 
Variant dependence: The “variants” analysis demonstrated conclusively both that regulatory 
variants identifiable as causal frequently exhibit allele-specific conformity with position weight 
matrices (PWMs) for transcription factors, and that they frequently exhibit concordant binding 
with the relevant transcription factors.  Allele-biased PWM conformity was a portion of the scoring 
function in the lithium analysis.  
 
Bimodal target genes with QTLs and spatial mapping: Although the lithium analysis only used 
sequence proximity as a means of identifying target genes, the “variants” and valproate analyses 
showed that the most potent effector variants had target genes throughout the genome, which could 
be identified by both molecular QTL mapping and spatial contacts. 
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Importance of pathway mapping: Both the lithium and valproate analyses benefited from using 
pathway connections to trim, rank, and organize putative candidate variants and their identified 
target genes. 
 
Thus, this set of important conserved principles was identified as critical to the success of the new 
pipeline, and each was included in the design of the PIP featureset. 
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Figure 3-1: The Five Box Model  
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The Five Box Model 
 
During the development of the PIP featureset in 2015, I began to conceptualize the function of 
such a multiple omics variant pipeline with what I refer to as the five box model (Figure 3-1), 
reflecting a conceptual scheme of five general properties a variant may exhibit which provide 
evidence, individually and collectively, that it may be a causal regulatory variant in a phenotype.  
They are permissive candidacy, regulatory function, variant dependence, target genes, and network 
analysis. 
 
By permissive candidacy, we mean that the variant has in some way come to the attention of a 
genome-wide screen: that it is located in a populations-specific linkage disequilibrium with a 
variant associated with a phenotype of interest, or that it regulates a gene whose mechanistic 
importance to the phenotype of interest has already been established. 
  
By regulatory function, we mean that the variant is resident in a portion of the genome which is a 
regulatory element, a promoter or enhancer, in one or more of the particular tissues which are 
relevant to the drug-disease system. 
 
By variant dependence, we mean that the function of this regulatory element must be dependent 
on the status of that variant, through the alteration of sequence features which help to determine 
the epigenome.  Such sequence features may be a specific binding site for a transcription factor, 
but may also be a more general propensity score for an epigenome feature, as determined by an 
appropriate bioinformatics algorithm such as a learning machine. 
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By target genes, we mean the variant have identifiable target genes with which it is spatially and/or 
functionally associated, putatively whose expression it regulates. 
 
And by pathway analysis, we mean that we may say of a collection of putative genes and variants 
for a phenotype or phenotype cluster, that taken as a totality they are associated with each other 
and with ontologic and/or network categories which are connected to the phenotype under 
investigation. 
 
These five concepts may be evaluated in different ways under different circumstances: with 
different datasets, with different algorithms, manually and under automation.  Nevertheless they 
are conceptually durable, and all the pre-PIP workflows, each extant version of the PIP, and our 
future plans for PIP-successor pipeline, fall within this overall orienting framework. 
 
Motivation and Plan of Action 
 
Pharmacogenomics is Poised for Transformation by the Epigenome 
 
Pharmacogenomics variant discovery has prioritized the search for protein coding variants with 
genetic association and biochemical methods [Black et al 2007].  With the sequencing of the 
human genome, the initial hope for immediate discovery of highly penetrant coding variants for 
many phenotypes [Collins et al 2001, Ganguly et al 2001] did not bear out, both in 
pharmacogenomics and in many other fields [Weinshilboum et al 2004].  And with the advent of 
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GWAS (genome wide association studies), pharmacogenomic phenotypes began to be investigated 
with this powerful new tool [Giacomini et al 2017].  While most available pharmacogenomics 
tests were and are based on highly penetrant coding variants, GWAS studies have revealed that 
the bulk of genetic variation in drug response, like many other phenotypes, comes from noncoding 
regulatory variants which are cooperative and combinatoric [Boyle et al 2012]. 
 
The development of the broader field of genomics and genomic regulation has been extremely 
fruitful in the last decade, but the deployment of GWAS in pharmacogenomics variant discovery 
has lagged deployment in other disciplines [Giacomini et al 2017], epigenomic interpretation of 
GWAS results has been underutilized [Nishizaki et al 2017], and the translation of GWAS results 
into clinical tests has been slower still in most areas [Florez et al 2017, Giudicessi et al 2017, 
Fabbri et al 2016].  Over the last decade, genome-wide methods have produced increasingly deep 
and broad atlases of both the genome and epigenome.  Genomic atlases have included HapMap 
[International Hapmap Consortium 2007] and 1000 Genomes [1000 Genomes Project 
Consortium 2015], while epigenome atlases have included ENCODE phases 1 [ENCODE 
Project Consortium 2007] and 2 [Kellis et al 2014], the Roadmap Epigenome Mapping 
Consortium [Roadmap Epigenomics Consortium 2015], the International Human Epigenome 
Consortium [Stunnenberg et al 2016], and the upcoming Human Cell Atlas [Regev et al 2017].  
Along with this, potent new techniques for probing the spatial and temporal genome have emerged, 
including time series omics analysis and spatial genome methods like Hi-C [Rao et al 2014]. 
 
Analysis of data from these atlases and targeted experiments has produced a new paradigm of 
regulation in which the spatial genome and epigenome take a prominent role [Roadmap 
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Epigenomics Consortium 2015, Rao et al 2014, Cremer et al 2015].  In this paradigm, gene 
transcription is the result of the convergence of a series of spatial and functional factors.  It takes 
place in chromatin loops at the spatial union of topologically associating domains (TADs) 
containing genic promoters with TADs containing controlling enhancers and co-regulated genes 
in a transcription factory [Rao et al 2014].  Such factories assemble prior to the initiation of 
transcription [Hub et al 2017, Krijger et al 2017], at the edges of chromosome territories [Rao 
et al 2014], in TADs localized to interior of the cell nucleus [Cremer et al 2015].  This process 
occurs with the aid of activating transcription factors and epigenomic marks [Roadmap 
Epigenomics Consortium 2015], in a dynamic [Chen et al 2015, Chen et al 2017], cell type 
specific [Rao et al 2014] manner, with different enhancers active in different cell types and tissue 
microenvironments, while some act in many or all cell types and tissues.   
 
This model, which has developed along with increasingly powerful epigenomic measurement 
techniques [Roadmap Epigenomics Consortium 2015], is yielding increasing predictive power 
and new insight in many areas.  Genome-wide, multi omics epigenomes (i.e. those which combine 
a number of complementary genome wide epigenomic measurements) are now available on a 
genome wide basis in many cell lines and tissues [Roadmap Epigenomics Consortium 2015], 
and even in multiple physiological conditions in many cases.  As a result of this, the epigenome is 
increasingly regarded like the reference genome: as a resource to be consulted for systems and loci 
of interest [Regev et al 2017], rather than an unknown quantity to be queried experimentally in 
specific contexts. 
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This transition is rapidly revolutionizing variant discovery with the emergence of integrated multi 
omics pipelines for variant discovery.  These pipelines, which include HaploReg [Ward et al 
2016] and RegulomeDB [Boyle et al 2012], screen association regions from the genome for 
variants bearing important marks of epigenomic regulatory variants.  These methods have allowed 
investigators to begin investigating at scale the over 90% of associated variants which are 
noncoding regulatory variants [Boyle et al 2012], and to get new and increasing value out of 
GWAS studies whose results were initially enigmatic [Fagny et al 2016, Tak et al 2015, Farh et 
al 2015]. 
 
The Pharmacoepigenomics Informatics Pipeline (PIP): Multi-Omics Variant Discovery for 
Pharmacogenomics 
 
However, in pharmacogenomics these insights have not as yet been broadly applied.  Despite 
recent work showing that an epigenome, 4D Nucleome based variant discovery and validation 
approach can yield value in excess of traditional methods [Higgins et al 2015, Higgins et al 2015, 
Higgins et al 2017], this new era of “pharmacoepigenomics” [Higgins et al 2015, Higgins et al 
2017] is still in its infancy.  Indeed, much pharmacogenomics variant discovery still proceeds 
along traditional lines involving the search for coding variants to be designated as star (*) alleles, 
with a particular emphasis on pharmacokinetic (PK) genes for absorption, distribution, 
metabolism, and excretion (ADME).  Such genes have formed the focus for test development for 
response, dosing, and adverse drug events (ADEs) and adverse drug reactions (ADRs). 
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To aid the wider dissemination of these advanced methods in pharmacogenomics, we have created 
the pharmacoepigenomics informatics pipeline (PIP), an integrative multi-omics variant discovery 
pipeline designed specifically for next generation pharmacogenomics and pharmacoepigenomics.  
It combines omics datasets (including epigenome compendia and phenotypically driven GWAS) 
with domain-specific knowledge (including key tissues and known significant genes).  The PIP’s 
variant discovery strategy is based on two separate workflows: a coding variant (CV) workflow 
based on traditional methods, and an expression regulatory (ERV) workflow that integrates 
bioinformatics algorithms and omics datasets to screen and organize regulatory variants.  These 
variants and their target genes are organized together at the end of the analysis to provide the input 
for downstream statistical analysis, gene-set enrichment, and pathway analysis to clarify the 
genotype-phenotype relationships.   
 
The ERV workflow is carried out with an overall model for combining multiple omics with 
preexisting knowledge about drugs and disease (i.e., relevant tissues and candidate variants) to 
discover variants and pathways that have a causal influence in chosen phenotypes.  It begins with 
lead SNPs from association studies and expands them in a population-specific manner with linkage 
mapping.  After this, tissue specific omics datasets are used to evaluate the regulatory function of 
the genomic regions around the variants, the dependence of that function on the status of the 
variants, and the identity of likely target genes.  Finally, variant-gene pairs passing all these tests 
are filtered and organized with pathway mapping and gene set enrichment. 
 
Nascent implementations of the ERV workflow have been used in several pharmacogenomics 
variant discovery experiments [Higgins et al 2015, Higgins et al 2015, Higgins et al 2017], in a 
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number of drug disease systems including lithium for bipolar disorder, valproic acid (VPA) for 
traumatic brain injury, and citalopram and ketamine for major depression (unpublished data).  The 
PIP is designed to introduce additional capabilities and further automation into such experiments. 
 
The Glutamatergic Lithium Pathway  
 
Since the publication of the lithium analysis, concordant work from other groups has shown that 
lithium response is controlled by a glutamatergic neuronal pathway operating in lithium-
responsive regions of the human brain. 
 
Variants in the GRIA2 gene have demonstrated evidence for association with lithium response in 
bipolar disorder in several studies [Perlis et al 2009, Hou et al 2016, Oedegaard et al 2016, Alda 
et al 2016]. In contrast to glutamate-induced neurotoxicity mediated by the NMDA receptor 
family, knockout of GRIA2 shows that this molecule is responsible for synaptic transmission that 
plays a role in long-term potentiation in the hippocampus, which mediates consolidation of long 
term memory [Jia et al 1996]. Knockout of the GRIA2 gene in a mouse model has also 
demonstrated the role of GRIA2 (GluR2) for stimulus-based reward conditioning [Mead et al 
2003]. This conditioned association between environmental stimuli and reward is important in the 
control of appropriate behavioral responses in bipolar disorder in humans [Murphy et al 2001]. It 
has also been implicated in addiction, suggesting a link between bipolar disorder and substance 
abuse, which is common in patients with mood disorders [Levin et al 2004].  
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There are numerous gene association studies and GWAS detailing SNPs in other genes in this 
pathway that are associated with lithium response and its adverse events in bipolar disorder. For 
example, mutations in the CACNA1C and CACNG2 (aka Stargazin) genes have been significantly 
associated with lithium response in bipolar disorder [Squassina et al 2011, Silberberg et al 2008], 
and these are presumed to be the voltage-dependent calcium channels associated with the GRIA2 
receptor.  Similarly, SNPs in the NR1D1 (aka Rev-erb-α) gene have been significantly associated 
with lithium response in bipolar disorder in a Sardinian population [Campos-de-Sousa et al 2010], 
and presumably are associated with disruption of circadian rhythmicity in these patients, a 
symptom of several mood disorders. In the context of adverse events associated with lithium, SNPs 
in HTR1A have been associated with weight gain [Can et al 2014, Murphy et al 2013, Myosinski 
et al 2014], SNPs in SLC1A2 have been associated with the type of tremor observed in bipolar 
patients who are on lithium therapy [Thier et al 2012, Brandler et al 2013], and SNPS in the 
CACNA1C gene have been associated with Brugada syndrome [Crawford et al 2015, Ou et al 
2015]. 
 
Several functional studies and a GWAS for lithium were published following the publication of 
the lithium analysis [Higgins et al 2015] in August of 2015. A genomewide association study 
(GWAS) for lithium-responsive bipolar disorder [Song et al 2015] found a significant association 
in European populations for SNP rs116323614, located within an intron of the SESTD1 (SEC14 
and spectrin domains 1) at p = 2.74 x 10-08. Following a search of the published literature and 
query of both Panther GO analysis and IPA®, SESTD1 was found to be significantly associated 
with a molecule in the pathway, DLG4, formerly known as PSD-95 [Jie et al 2015, Lee et al 2015, 
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Talpale et al 2014]. This image was taken from IPA® when DLG4 and SESTD1 were entered 
and the “connect” build function was used, following selection for expression in human brain:  
 
“Calcium channel genes associated with bipolar disorder modulate lithium’s amplification of 
circadian rhythms….In human fibroblasts, CACNA1C genotype predicted the amplitude response 
to lithium.” [McCarthy et al 2015] Again, SNPs within another gene in this pathway, CACNA1C, 
seems to be significantly correlated with functional disruption of calcium flux associated with 
lithium response. 
 
CACNA1C genotype alters the amplitude of the calcium current in human fibroblasts in response 
to lithium in bipolar patients [McCarthy et al 2015]. In addition, there are significant differences 
in the circadian expression of the CACNA1C gene in bipolar patients versus controls. It is of note 
that in the pathway described herein, both NR1D1 and ARNTL are transcription factors that are 
responsible for control of circadian rhythmicity. 
 
Accordingly, the replication of the lithium pathway by the PIP is a demonstration of its discerning 
power. 
 
The Need for Improved Warfarin Pharmacogenomics 
 
Warfarin is an anticoagulant used for the prevention and treatment of venous thromboembolism in 
cardiac disease, post-operative recovery, and other contexts involving the need for coagulation 
control [US FDA 2017].  An inhibitor of the vitamin K epoxide reductase enzyme complex 
  147   
 
(including VKORC1), it exhibits wide inter-individual response variation [US FDA 2017]. Dose 
requirements to achieve therapeutic international normalized ratios (INR) vary as much as 10-fold 
among patients [US FDA 2017].  Despite the recent availability of other oral anticoagulants, 
warfarin is still a commonly-prescribed anticoagulant, and until 2015 this venerable drug was the 
most popular prescribed oral anticoagulant with about 7 million office visit interactions resulting 
in a prescription [Barnes et al 2015].   
 
Warfarin has a complicated pharmacokinetics and pharmacodynamics, with its influences on the 
action of a number of clotting factors each exhibiting a different half-life [US FDA 2017].  It is 
widely acknowledged that warfarin dosing requirements and other phenotypes exhibit a strong 
patient-specific genetic element.  Factor-of-ten differences in typical dosing requirements based 
on alleles in CYP2C9, the primary metabolic enzyme of warfarin, are present on the package insert 
label [US FDA 2017], and data on association between warfarin requirements and other genetic 
loci have proliferated (see Figure 3-3, Figure 3-8).  There have been multiple attempts to provide 
clinicians with genotype-guided dosing algorithms based typically on genotypes of VKORC1 and 
CYP2C9 [Flockhart et al 2008].  Despite the strength of variation in these two key genes, there is 
a “missing heritability” problem: identified loci in these genes account for only 30% to 50% of the 
predictive power implied by heritability estimates [Flockhart et al 2008].  Current generation tests 
use only variants in these two genes, and almost all use the same three SNPs: rs1799853, 
rs1057910, and rs9923231 (a promoter SNP for VKORC1). 
 
Partially because of this, these tests have achieved only limited success despite intensive 
development and validation effort.  Despite hopes that two large trials (EU-PACT [Pirmohamed 
  148   
 
et al 2013] and COAG [Kimmel 2013]) would report good results, their appearance in the same 
issue of the NEJM did not bear out such hopes.  COAG reported no difference in time within the 
therapeutic range (TTR), and EU-PACT reported a difference, but only compared to fixed starting 
doses with subsequent adjustment, not to initial dosing methods based on clinical indications that 
represent the real-world alternative to genetic dosing.  Neither trial was powered to report a 
difference in bleeding and embolism events.  Subsequently, a published meta-analysis of nine 
randomized controlled trials (RCTs) of warfarin pharmacogenomics dosing algorithms vs manual 
dose determination showed that current-generation tests using VKORC1 and CYP2C9 offer no 
improvement in TTR, percentage of patients with high INR, or bleeding and coagulation events 
[Stergiopoulos et al 2014]. 
 
Since the conclusion of these trials, expert comment has indicated a consensus that such algorithms 
do not add clinical value relative to dosing on the basis of clinical indications, despite their 
predictive power [Kimmel 2015, Johnson et al 2016].  Although the recent GIFT RCT of genomic 
warfarin dosing found that genome-guided dosing provided a significant benefit in the composite 
endpoint of major bleeding, INR of 4 or greater, venous thromboembolism, or death [Gage et al 
2017], this generalizability of the study’s results is limited.  GIFT had narrow inclusion criteria: 
patients aged 65 years or older initiating warfarin for elective hip or knee arthroplasty. Those 
patients are at higher risk, and thus the generalizability of these results to larger patient populations 
and indications is debatable.  
 
Despite their predictive power, such tests have failed to deploy in mainstream clinical practice.  
This experience suggests that new lines of research should be opened, such as the application of 
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advanced genomic methods, to discover new variants, recover missing heritability, and develop a 
new generation of tests which can add value relative to dosing by clinical indications. 
 
Featureset 
 
The Pharmacoepigenomics Informatics Pipeline (PIP) 
 
The PIP uses lead variants from GWAS and candidate gene studies to find genetically linked 
permissive candidate variants (PCVs), using data from the 1000 Genomes Project for populations 
matched to the source studies.  These variants are evaluated by two separate workflows: the 
expression regulatory variant (ERV) workflow for regulatory variants, and the coding variant (CV) 
workflow for coding variants.  The ERV workflow evaluates the PCVs in disease-relevant tissues 
for DNA methylation, transcription factor binding, histone marks, DNase I hypersensitivity, 
chromatin state, quantitative trait loci (QTLs), and transcription factor binding site disruption using 
tissue-specific omics datasets.  The CV workflow finds common non-synonymous coding variants 
within the pool of PCVs.  Both sets of variants are mapped back to their host genes using RefSeq 
[O’Leary et al 2016], and screened for expression in relevant tissues.  The final output variants 
and their host genes are subjected to pathway analysis in Ingenuity Pathway Analysis® (Qiagen 
GMBH) [Kramer et al 2014], offering an additional level of screening along with mechanistic 
insight for subsequent pharmacogenomic test development.   
 
The methods of the PIP are shown in Figure 3-2.  The PIP is based on the methods of our previous 
paper on lithium pharmacogenomics [Higgins et al 2015].  We performed two experiments with 
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this pipeline.  First, a reproduction of the lithium experiment, with a restricted PIP feature set to 
replicate these methods, to validate the initial pipeline by reproducing our lithium pathway.  
Second, a new experiment in the pharmacogenomics of warfarin using the full feature set, to 
investigate whether the PIP may add value to a well-studied area of pharmacogenomics. 
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Figure 3-2: Schematic of the Pharmacoepigenomics Informatics Pipeline 
(A): The Permissive Candidacy portion of the PIP.  GWAS lead SNPs and known significant genes 
for the phenotype of interest are encoded by the user in a Master Variant File (MVF) and expanded 
by population-specific linkage and body SNP mapping (respectively) to generate a list of 
Permissive Candidate Variants (PCVs).  (B): The Expression Regulatory Variant (ERV) 
Workflow.  All of the PCVs are evaluated as putative regulatory SNPs using tissue-specific omics 
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data on phenotype-relevant tissues encoded by the user in a Master Tissue File (MTF).  They are 
evaluated according to the regulatory function of the chromatin state segment in which they reside, 
the dependence of that regulatory function on the variant allele, and the presence of identifiable 
target gene relationships.   (C): The Coding Variant (CV) Workflow.  In the CV workflow, all the 
PCVs are analyzed to investigate whether they are non-synonymous coding variants with a 
meaningful minor allele frequency.  (D): The Hierarchical Mapping portion of the PIP.  Variants 
passing either workflow (Intermediate Candidate Variants) are associated with target genes, and 
those expressed in relevant tissues (per the MTF) are subjected to pathway mapping and gene set 
enrichment in Ingenuity Pathway Analysis (IPA).  Gene sets associated with significant and related 
pathways are regarded as substantive, and the variants influencing them (regulatory and coding) 
are considered Candidate Variants. 
 
Construction of Input Files for Lithium and Warfarin PIP Experiments 
 
A PIP experiment begins with the input of associated lead variants in the form of a master variant 
file (MVF) which contains the refseq ID (rsID) of the variant, the populations in which the original 
association was derived using 1kG Phase 3 population codes, and the PubMed ID (PMID) of the 
study in which the association was derived.   
 
PIP experiments were undertaken for lithium/BPD and warfarin/anticoagulation, beginning with 
the construction of MVFs.  For the warfarin experiment, a literature review in September 2016 
identified 23 GWAS on warfarin response and other pharmacological phenotypes of warfarin, 
venous thromboembolism risk, and baseline anticoagulant protein levels in healthy patients.  Joint 
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analysis of studies on related phenotypes, and overlap between disease risk and pharmacogenomic 
variants, are known phenomena from previous work.  In addition, we added 23 variants annotated 
by PharmGKB®, yielding a total of 204 SNPs.  The input studies for the warfarin experiment are 
summarized in Figure 3-3. 
 
The warfarin experiment began with input data from populations all over the world, including 
European, East Asian, South Asian, African, and American cohorts.  Population specific 
associations from these groups were interpreted in the context of other population specific input 
data, from the worldwide genome catalog of 1000 Genomes.  Population descriptions are taken 
from the summary annotations in the original papers and the GWAS Catalog, but in the PIP input 
files they are represented in 1000 Genomes format to replicate the detailed descriptions in the 
original papers as precisely as possible. 
 
The various consortium data (ENCODE, REMC) and ChromHMM [Ernst et al 2012] chromatin 
states are imported for relevant tissues, with the relevant tissues being supplied in the format 
information for each consortium separately, for a unified set of tissues, in a Master Tissue File 
(MTF).  The MTF is designed for each experiment to contain the set of tissues which are relevant 
to the particular drug-disease system under investigation, so that tissue specific omics data may be 
used in the experiment.  Information on the relevant chromatin marks and transcription factors was 
imported in a series of TF and Chromatin mark whitelist files containing metadata codes in the 
formats of each of the consortia. 
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MTFs were constructed for both experiments.  The warfarin MTF included the human liver (site 
of warfarin metabolism), vasculature (site of action) and small intestine (site of absorption, a 
known variable in response, and metabolism).  These were represented by a mixture of cell line 
and tissue samples in the ENCODE, REMC, and GTEx datasets, but a complete epigenome with 
methylation, DNase accessibility, all core histone marks, and many TF binding tracks was 
available in all tissues.   
 
With the MVFs and MTFs generated for the lithium and warfarin experiments, the PIP was used 
to conduct its analysis. 
 
Permissive Candidate Generation and Variant Annotation 
 
Generation and annotation of Permissive Candidate Variants (PCVs) occurs in the following 
manner: 
 
 Linkage disequilibrium mapping is performed in the PLINK software package [Lu et al 
2017], version 1.9 [Chang et al 2014], with the May 2 2013 (latest) release of 1000 
Genomes consortium Phase 3 data.  For each of the SNPs in the MVF, PLINK computes 
LD coefficients and outputs a set of all cis and trans variants that achieve R2>=0.8 linkage 
with the input variant.  These variants constitute the set of permissive candidate variants 
(PCV). 
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 Chromatin state annotation is performed with the version of ChromHMM results available 
in the Washington University (WUSTL) epigenome browser [Zhou et al 2013] as of April 
2016.  Chromatin mark information on a number of indicative marks, along with DNA 
accessibility measurements, TF binding, and methylation (currently not used in scoring) 
are assayed using ENCODE and REMC data in the relevant marks and the relevant tissues 
as rendered in the Master Tissue File and whitelist files. 
 
 TFBS disruption data is assessed using TFM-Scan [Liefooghe et al 2006] on 23-bp-per-
side hg19 sequences on reference and alternate alleles from the source SNPs, using integer-
converted data from the PWM library used in HaploReg [Ward et al 2016], and requiring 
a threshold-crossing-or-10-point difference in score between reference and alternate alleles 
for a qualifying PWM, as a measure of significance. 
 
 QTL data were imported from eight sources: 1) The HaploReg QTL database [Ward et al 
2016], 2) SeeQTL [Xia et al 2012], 3) MuTHER [Grundberg et al 2012], 4) GTEx 
[Carithers et al 2015], 5) Shi et al meQTLs [Shi et al 2014], 6) McClay et al meQTLs 
[McClay et al 2015], 7) Banovich et al meQTLs [Banovich et al 2014], 8) GeneVar [Yang 
et al 2010].  Gene annotations were retrieved from the latest build of RefSeq in hg19. 
 
 Gene expression data was retrieved from the latest build of GTEx [Carithers et al 2015], 
and from the Allen Brain Atlas [Sunkin et al 2013]. 
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 The coding variant workflow located all non-synonymous coding variants among the PCVs 
using dbSNP data, then screened them for minor allele frequency with 1000 Genomes data 
on all human populations, using a MAF cutoff of .01. 
 
Variant Scoring, Expression Testing, and Pathway Analysis 
 
Scoring proceeded according to Figure 3-3 above, with SNPs being required to pass all of the 
separate thresholds in each of the individual portions of either one of the two workflows (ERV and 
CV) to proceed.  Then, their host genes must pass gene expression testing in relevant tissues in 
order to reach the final gene list.  All of these steps are undertaken on the Flux computing cluster 
at the University of Michigan.  Finally, the gene list is analyzed with IPA.   
 
 
Lithium PIP Experiment: (Mostly) Same Methods as Original Experiment 
 
The two experiments were conducted with slightly different feature sets.  The warfarin experiment 
used the full feature set, while the lithium experiment used a restricted feature set designed to 
match the semi-automated analysis from our 2015 paper, including no use of gene bodies as 
candidate region inputs, no CV workflow, expression analysis performed manually with Allen 
Brain Atlas in situ hybridization data on brain tissue, and the use of bio-chronicity analysis to 
screen genes.  
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The lithium MVF was constructed to contain precisely the set of input variants originally used in 
the lithium experiment previously published, a total of 108 SNPs.  The lithium MTF included the 
same tissues used in the original lithium experiment; BPD-relevant brain regions plus the human 
liver.  The lithium MTF does not feature GTEx data because the restricted featureset for this 
experiment used manual gene expression analysis with Allen Brain Atlas in-situ data in order to 
replicate the original lithium experiment.  The tissue files for both experiments are summarized in 
Figure 3-4. 
 
Despite this effort, the lithium experiment feature set of the PIP does not fully match the original 
experiment [Higgins et al 2015].  Several obstacles were encountered in which subtle differences 
in methods were necessitated by database deprecation, ambiguities in the documentation of 
available literature methods, and ambiguities in versioning of online resources.  These obstacles 
included: 
 
LD mapping methods.  In the original paper, LD mapping was performed in HaploReg v4.1 
[Ward et al 2016], which uses the Phase 1 cohort of the 1000 Genomes project [1000 Genomes 
Project Consortium 2015] as its LD mapping cohort.  However, this tool was developed after the 
Phase 3 analysis results became available for this cohort, and it is unclear if they used the Phase 1 
variant calls, or Phase 3 variant calls.  We elected to use the Phase 3 cohort and population 
stratifications with the Phase 3 variant calls, because they are the most accurate. 
 
Switch in QTL databases.  The GeneVar [Yang et al 2010] QTL database we used in the original 
analysis is no longer available in its full form.  We have contacted the original authors and they 
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have not responded.  Because of this, we have been forced to seek supplemental databases in 
addition to the partial GeneVar database still available, as described below. 
 
PWM integer approximation.  The PIP uses the same database of PWMs that was used by 
HaploReg [Ward et al 2016] during the initial Lithium analysis, and scores them against the 
flanking sequences using the same software, TFM-Scan [Liefooghe et al 2006].  However, the 
PWM matrices available for bulk download are in probability format, and TFM-Scan presents 
warnings about accuracy when using probability matrices.  It expects frequency matrices.  We do 
not know if HaploReg used the probability matrices and (possibly) suffered inaccuracies, or if they 
have copies of the matrices in natively-integer format which they have not made available, or if 
they converted the probability matrices to integer.  We have elected to convert the probability 
matrices to frequency matrices, but because of rounding this is imperfect and may introduce small 
errors.  
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PMID Phenotype Class Phenotype 
Sample 
Size Population Ancestry
* SNPs 
18535201 Response Warfarin maintenance dose 555 European 3 
19300499 Response Warfarin maintenance dose 1641 European 4 
20833655 Response Warfarin maintenance dose 1952 Japanese 5 
23755828 Response Warfarin maintenance dose 965 African American 1 
26265036 
Response 
Warfarin maintenance dose 2967 
Brazilian, European, 
Japanese, African 
American 
16 
22443383 ADEs 
Hemostatic factors and 
hematological phenotypes 951 European 9 
23381943 ADEs End-stage coagulation 2100 European 23 
24357727 ADEs 
Thrombin generation potential 
phenotypes 3224 European 4 
19278955 Disease/Background Venous thromboembolism 4884 European 1 
20212171 Disease/Background C4b binding protein levels 352 European 1 
20303064 Disease/Background 
Activated partial thromboplastin 
time 1431 European 3 
21980494 Disease/Background Venous thromboembolism 2652 European 4 
22216198 Disease/Background Anticoagulant levels 397 European 8 
22701019 Disease/Background Factor XI 997 European 0 
22703881 Disease/Background Prothrombin time 3569 European 2 
22703881 Disease/Background 
Activated partial thromboplastin 
time 11851 European 9 
22672568 Disease/Background Venous thromboembolism 5787 European and other 5 
23267103 Disease/Background Coagulation factor levels 3250 European 7 
23509962 Disease/Background 
Venous thromboembolism (SNP x 
SNP interaction) 4291 European 37 
23650146 Disease/Background Venous thromboembolism 51266 European 8 
25240745 Disease/Background Mitochondrial DNA levels 386 European 21 
25772935 Disease/Background Venous thromboembolism 65734 European 10 
22550155 Disease/Background Platelet thrombus formation 241 
European, African 
American 6 
Figure 3-3: GWAS Input Studies for the Warfarin Experiment 
23 associations from 22 GWAS [Cooper et al 2008, Takeuchi et al 2009, Cha et al 2010, Perera 
et al 2013, Parra et al 2015, Oudot-Mellakh et al 2012, Williams et al 2013, Rocanin-Arjo et 
al 2014, Tregouet et al 2009, Buil et al 2010, Houlihan et al 2010, Germain et al 2011, 
Athanasiades et al 2011, Sabater-Lleal et al 2012, Tang et al 2012, Heit et al 2012, Desch et 
al 2013, Greliche et al 2013, Tang et al 2013, Lopez et al 2014, Germain et al 2015, Edelstein 
et al 2012] met the criteria for inclusion in the warfarin experiment, and their significant 
associations were rendered into the MVF and organized into phenotypic classes, along with 23 
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additional variants annotated by the Pharmacogenomics Knowledge Base (PharmGKB®) [Whirl-
Carrillo et al 2012].  The 23 additional variants included all variants annotated by the PharmGKB 
as of September 2016, with a significant association with warfarin response, and were not already 
included in the list of variants identified from GWAS.  Population descriptions are taken from the 
summary annotations in the original papers and the GWAS Catalog, but in the PIP input files they 
are represented in 1000 Genomes format to replicate the detailed descriptions in the original papers 
as precisely as possible.  Although they represent a variety of ancestries, European ancestry 
predominated among 17 out of 22 (77%) of the study populations.  
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(A) Lithium 
Tissue ENCODE REMC 
Frontal lobe Brain_Mid_Frontal_Lobe H1-hESC:SK-N-SH 
Insula Brain_Cingulate_Gyrus H1-hESC:SK-N-SH 
Temporal cortex Brain_Inferior_Temporal_Lobe H1-hESC:SK-N-SH 
Cingulate cortex Brain_Cingulate_Gyrus H1-hESC:SK-N-SH 
Amygdala including_ 
Amygdalo-
hippocampal transition 
area 
Brain_Inferior_Temporal_Lobe H1-hESC:SK-N-SH 
Hippocampal formation 
including 
Parahippocampal gyrus 
Brain_Hippocampus_Middle H1-hESC:SK-N-SH 
Anterior caudate and 
Putamen Brain_Anterior_Caudate H1-hESC:SK-N-SH 
Thalamus, right Brain_Anterior_Caudate H1-hESC:SK-N-SH 
Fusiform cortex, 
Angular gyrus Brain_Angular_Gyrus H1-hESC:SK-N-SH 
Motor cortex, 
Substantia nigra, 
Cerebellum 
Brain_Substantia_Nigra H1-hESC:SK-N-SH 
Hypothalamus Fetal_Brain_Female: Fetal_Brain_Male H1-hESC:SK-N-SH 
(B) Warfarin 
Tissue ENCODE REMC GTEx 
Liver Adult_Liver:HepG2_Hepatocellular_Carcinoma 
HepG2:liver:hepatocyte:ri
ght lobe of liver Liver 
Vasculature 
Aorta: 
HUVEC_Umbilical_Vein_Endothelial
_Cells 
endothelial cell of 
umbilical vein:dermis 
blood vessel endothelial 
cell:pulmonary artery 
endothelial 
cell:endothelial cell of 
coronary artery: 
aorta:thoracic aorta 
endothelial cell:vein 
endothelial cell:lung 
microvascular endothelial 
cell 
Artery - Tibial: 
Artery - 
Coronary: 
Artery - Aorta 
Small Intestine Fetal_Intestine_Small:Small_Intestine small intestine:Caco-2:jejunum 
Small Intestine - 
Terminal Ileum 
Figure 3-4: Tissue Files used in the Lithium and Warfarin Experiments 
The tissue file coding used in the lithium (A) and warfarin (B) PIP experiments.  The first column 
contains natural language names for the tissues, while subsequent columns contain colon-delimited 
consortium ontology codes for related tissues and cell lines.  The lithium experiment does not have 
  162   
 
tissue codes for GTEx because annotation of gene expression mapping was done manually with 
Allen Brain Atlas in situ hybridization data [Sunkin et al 2013] in this experiment, as described 
herein.   
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The Lithium PIP Experiment 
 
More Significant Pathway, More Genes and Variants 
 
To demonstrate the ability of the PIP to replicate the results of previous integrative omics methods 
in pharmacoepigenomic variant discovery, we first undertook a PIP experiment to replicate the 
findings of our 2015 paper on lithium [Higgins et al 2015], as a positive control.  The featureset 
of the PIP used for this experiment was restricted to match that of the previous experiment, as 
described in the methods. 
 
The lithium experiment yielded a total of 1727 PCVs, of which a total of 78 passed the entire set 
of filters.  These results differ from and expand on the results of the original lithium analysis.  
Whereas the original experiment identified 19 SNPs in 10 genes, the new experiment identified 17 
out of 19 original SNPs, and all 10 original genes, plus more SNPs in these and two more genes 
for a total of 78 SNPs in 12 genes.  These are the 10 genes from the original lithium paper, with 
the addition of HTR1A and TNIK, both of which appeared in the glutamatergic lithium pathway 
called by IPA in the original lithium paper.   
 
Because of the factors mentioned in the methods, as well as imprecisions in the manual steps in 
the original lithium experiment, the lithium results differ subtly from those of the original 
experiment.  This underscores the importance of using versioned, locally stored versions of all 
databases in bioinformatics experiments to allow reproducibility.  In addition, however, the 
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automated analysis recovers additional genes from the same pathway in the lithium experiment, 
emphasizing the utility of automated workflows with advanced functionality. 
 
Thus we reproduce the glutamatergic pathway for lithium response with the PIP, as reflected in 
Figure 3-5 and Figure 3-6.  IPA calls the same pathway for both the 10 genes discovered in the 
original experiment, and the expanded 12-gene set.  The pathway also includes 22 additional genes 
not discovered in either experiment but used to connect them in the pathway mapping functionality 
of IPA.  The two pathways differ only in IPA’s inclusion of a group of miRNAs in the old pathway 
and not in the new, which is the result of an IPA database change.  The PIP recovers the same 
pathway as the original experiment.   
 
In addition to this, in the period of time between the execution of the 2015 lithium experiment and 
the publication of this manuscript, other groups have reported connections between lithium 
response and ADME and some of the genes we reported in this network [Crawford et al 2015, 
Mitjans et al 2015].   
 
Using substantially the same input data as the original lithium experiment [Higgins et al 2015], 
the PIP pipeline successfully identified the same glutamatergic pathway in the human brain, and 
identified additional genes which are part of the same pathway.  This constitutes a validation that 
the PIP replicates the discerning power of our previous semi-automated methods, and may function 
as a foundation for future development. 
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Figure 3-5: PIP Reproduction of the Glutamatergic Lithium Pathway  
The same lithium pathway discovered by both manual and PIP experiments.  The ten genes 
discovered by both experiments (ANK3, ARNTL, CACNG2, CACNA1C, CDKN1A, CREB1, 
GRIA2, GSK3B, NR1D1, SLC1A2) are in red; 2 genes (HTR1A, TNIK) discovered by the PIP 
experiment only are in purple.  The PIP discovers 78 candidate variants including 61 not 
discovered in the original lithium experiment.  Gene classes and relationship types are designated 
with line types and gene glyphs as shown in the legend and described in the IPA® documentation 
[Kramer et al 2014]. 
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A) 
 
B) 
 
 
Figure 3-5: Lithium Pharmacogenomic Gene GSEA Results 
(A): Top diseases and functions detected by IPA for the ten genes detected in the original lithium 
experiment.  (B): Top diseases and functions for the twelve genes detected in the PIP lithium 
experiment.  Although there is significant overlap in the top nine hits for the two gene sets (five 
categories) there are some significant differences, demonstrating that the extra discerning power 
of the automated methods may be adding value relative to the semi-manual experiments. 
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The Warfarin PIP Experiment 
 
Known and Novel Variants Form an Enhanced and Unified Pathway 
 
With the methods thus validated, we proceed to the results of the warfarin experiment in the PIP.  
The input variants from the warfarin study yielded a total of 4492 PCVs, which were analyzed for 
each of the criteria in the ERV and CV workflows.  Of these PCVs, there were significant 
associations between the sets of SNPs passing some related modules in the PIP, and some modules 
were, in this experiment, significantly stricter than others.  However, all the modules filtered out a 
meaningful number of SNPs as part of the overall process.  This process is summarized in Figure 
3-7. 
 
The ERV and CV workflows identifies a total of 223 SNPs, which were then mapped to their host 
and target genes, which were subjected to the expression test with GTEx data on tissues from the 
MTF.  Of these 223 SNPs, 87 were located in 41 genes passing the expression test.  Notable among 
them is the presence of classic and previously known warfarin response genes including CYP2C9, 
clotting factors and VKORC1.   
 
Next, we performed pathway analysis in IPA® on this set of 41 genes.  There are only four genes 
whose variants are used in current generation warfarin pharmacogenomics tests: VKORC1, 
CYP2C9, CYP4F2, and GGCX.  Despite the predictive power and clinical utility of these variants 
and the tests constructed with them, IPA does not connect them into a pathway, and previous 
warfarin literature has not conceptualized warfarin response in pathway terms.  Despite this, and 
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despite the typical pattern wherein IPA® discovers many pathways of questionable relevance, this 
analysis yielded only two pathways, one of them with 31 genes and a particularly striking p-value 
of 10E-65 (as calculated by IPA).  The gene list for this pathway is shown in Figure 3-8, while 
the pathway network diagram is shown in Figure 3-9.  It densely unites previously known warfarin 
response genes (including those not previously used in test design) with new genes.   
 
This pathway may be considered the “canonical” warfarin pathway based on the published 
literature base.  It consolidates the bulk of discovered genes, particularly all but one of those 
previously known for warfarin response, including VKORC1, warfarin-metabolizing CYP 
enzymes, and a collection of clotting factors.  This includes the FGA and FGG fibrinogen subunits.  
Despite the fact that they operate as a complex and cannot function separately, FGG had been 
previously identified for warfarin response but FGA had not, whereas the PIP identifies both genes, 
which are located in the same TAD and are co-regulated.   
 
Among previously known genes in this pathway, over 75% are highest-expressed in liver, while 
57% of newly discovered genes are highest-expressed in the intestines or vasculature.  Notably, a 
mixture of coding and regulatory SNPs are identified for both known and new genes. 
 
The second pathway contains only one previously known warfarin gene (and that one, BCKDK, of 
disputed significance), does not show coagulation-related GSEA results, and its central elements 
are not of relevance.  It may be considered an artifact. 
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Next, we processed the genes in the warfarin pathway with GSEA in IPA and GO.  The results of 
the GSEA are shown in Figure 3-10.  Warfarin and coagulation related terms are prominent among 
the results, and many of the genes contributing to these identifications were not previously 
identified as warfarin-related.   
 
The PIP has identified many known genes for warfarin phenotypes, and added both new coding 
and regulatory SNPs for known genes, as well as new genes. 
 
In addition to this, we investigated the warfarin input and output variants with DeltaSVM [Lee et 
al 2015, Ghandi et al 2014, Ghandi et al 2016], evaluating their propensity to differentially 
induce DNase accessibility in the HepG2 liver cell line.  Although the result SNPs contained a 
number of strong candidates by DeltaSVM, these candidates were not enriched relative to the 
candidates among the input set, nor were the mean and variance of the DeltaSVM scores 
significantly different between inputs and outputs.  This implies that our existing variant 
dependence algorithms (PWM alteration) are mostly independent of DeltaSVM’s predictive 
power, and that adding Delta SVM or similar methods to the variant dependence portion of the 
pipeline (with appropriate changes to the scoring system) would add value to the pipeline. 
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Figure 3-7: Disposition of PCV SNPs in the Warfarin PIP Experiment 
The disposition of SNPs within the workflows of the PIP during the warfarin experiment.  190 
input SNPs expand to 4492 PCVs.  After evaluating all of these PCVs, the ERV workflow outputs 
186 regulatory SNPs mapping to 57 genes, of which 30 (bearing 66 SNPs) were expressed in 
relevant tissues in GTEx datasets.  The CV workflow outputs 37 SNPs in 27 genes, of which 22 
in 17 genes pass the expression test.  These 87 genes in 41 SNPs were subjected to IPA analysis, 
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revealing a combined network of 31 genes bearing a total of 74 SNPs (53 regulatory and 21 
coding), as shown in Figure 3-8 and Figure 3-10.   
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Figure 3-8: Output Genes and SNPs of Warfarin PIP Experiment 
Genes passing all of the scoring thresholds in the warfarin PIP experiment, along with their known 
functions, highest observed expression levels in relevant GTEx tissues, and SNPs mapping to them 
detected in the warfarin experiment.  Known warfarin response genes [Malatkova et al 2016, 
Wadelius et al 2007, Chen et al 2014, Bare et al 2011, Marsh et al 2006, Bader et al 2016, 
Wang et al 2013, Eriksson et al 2016, Lind et al 2012, Lip et al 1995, Patillon et al 2012, 
Bargal et al 2016, Kimmel 2010, Undas et al 2005, McDonald et al 2009, Lee et al 2012, Scordo 
et al 2002, Kim et al 2012, Chang et al 2015, Limdi et al 2008, Kudzi et al 2009, John et al 
2017] are highlighted first, in black.  Below, shown in red, are detected genes not previously known 
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to be associated with warfarin response.  Among the SNPs, regulatory SNPs are identified in blue, 
while coding SNPs are shown in green.   
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Figure 3-9: The Warfarin Pharmacogenomic Pathway 
Pathway mapping results of warfarin response genes.  IPA connects a warfarin pathway discovered 
by the PIP, with thirty one genes and a p-value less than 1E-65.  Genes include: ABO, AKR1C3, 
CFHR5, CYP2C8, CYP2C9, CYP2C19, CYP4F2, F5, F7, F10, F11, F13A1, FGA, FGG, FMO5, 
HRG, KNG1, LYZ, ORM1, PCGF3, PROCR, PRSS8, PRSS53, SLC44A2, SPHK1, STX4, SURF4, 
TRPC4AP, USP7, VKORC1, VWF.  Previously reported warfarin response genes are in black, and 
new genes are in red.  Gene classes and relationship types are designated with line types and gene 
glyphs as shown in the legend and described in the IPA® documentation [Kramer et al 2014]. 
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Figure 3-10: Warfarin Pharmacogenomic GSEA Results 
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(A): Top IPA GSEA hits for the warfarin gene pathway.  (B): GO GSEA results for the warfarin 
pathway.  Warfarin-related and coagulation-related gene sets are prominent among the results for 
the pathway in both GSEA systems, including bleeding, coagulation, clotting, thrombosis, 
hemorrhage, and related gene sets.  Many of the genes contributing to the identification of these 
gene sets were not previously discovered. 
Runtime and Computational Performance 
 
The PIP is Scalable 
 
For the warfarin experiment, total runtime and its division into the various components of the 
workflow, are summarized in Figure 3-11.  The total experimental runtime on the University of 
Michigan Flux cluster was about 14,300 node hours (each node using two six-core Intel Xeon 
X5650 processors running at 2.67 Ghz, with 48GB of RAM).  Of this, the bulk was devoted to the 
initial LD calculations, QTL analysis, and the retrieval of epigenome data from REMC datasets. 
 
Although we anticipate substantial runtime improvements from code optimization in subsequent 
versions of the PIP, it is clear that this version is already computationally scalable for use in 
pharmacogenomics variant discovery in many systems.  When sufficient cluster resources are 
available, it can finish running after about six hours of computation.  Although REMC and QTLs 
are the largest contributors to total runtime, PLINK is a large contributor to parallel runtime 
because it is parallel on the level of input SNPs, not on the level of PCVs.  With a sufficient number 
of nodes PLINK accounts for a third of total runtime, though not total computation.     
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Figure 3-11: Warfarin Experiment Runtime Distribution 
The distribution of runtime among experimental modules in the PIP Warfarin experiment, in node-
hours.  Over 90% of total runtime was composed of just three pieces: Epigenome Roadmap data 
analysis, QTL analysis, and PLINK linkage calculations.  Of the remaining computational 
modules, shown in the smaller pie chart on the right, ENCODE data lookups and PWM analysis 
constitute the largest remaining steps.  The CV workflow was computationally minimal. 
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Discussion 
 
Warfarin Pharmacogenomics 
 
The discovery of a number of previously unknown candidate genes and SNPs for warfarin 
response, dosing, and ADEs, including a unifying pathway with known variants, is a potential 
direction for a significant improvement in warfarin pharmacogenomics.  This includes both 
additional variants controlling known warfarin response genes, and also putative new genes with 
associated variance.  Although the previously known variants in VKORC1 and CYP2C9 are 
almost certainly the most potent pharmacogenomic variants for warfarin phenotypes, accounting 
by themselves for 30% to 50% of the heritability of response, the additional predictive power of 
these new variants may make the difference in providing unambiguous clinical utility for such 
predictive models, which has so far evaded the field of warfarin pharmacogenomics.  And in the 
context of other anticoagulants, including warfarin analogues, these loci may play a larger role 
than for warfarin itself.  These variants should be included in the construction of next generation 
predictive models for warfarin and anticoagulation pharmacogenomics, and the mechanistic 
investigation of the newly discovered pathway may also be valuable.   
 
The genes discovered in this experiment cluster into a pathway.  Thirty one genes and 74 SNPs, 
including 17 previously known genes [Malatkova et al 2016, Wadelius et al 2007, Chen et al 
2014, Bare et al 2011, Marsh et al 2006, Bader et al 2016, Wang et al 2013, Eriksson et al 
2016, Lind et al 2012, Lip et al 1995, Patillon et al 2012, Bargal et al 2016, Kimmel 2010, 
Undas et al 2005, McDonald et al 2009, Lee et al 2012, Scordo et al 2002, Kim et al 2012, 
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Chang et al 2015, Limdi et al 2008, Kudzi et al 2009, John et al 2017], cluster into a coagulation 
pathway mainly made up of known genes, including clotting factors, CYP enzymes, and vitamin 
K epoxide reductase.  This may be considered the canonical warfarin pathway, although it appears 
not to have been explicitly described previously.  Thus, the PIP has systematized and extended the 
previous literature into a more integrated picture.  Because of the extensive pleiotropy observed 
with pharmacogenomics genes and variants, systematizing evidence is very important for 
integrative test design [Denny et al 2013]. 
 
It is noteworthy that in the warfarin experiment, the PIP was successful in rediscovering both key 
pharmacokinetic (PK) and pharmacodynamics (PD) genes.   
 
While pharmacogenomics has traditionally used more variants in PK genes, as discussed in the 
introduction, PD variants have proved to be extremely potent in the instances where they do find 
clinical use, including VKORC promoter variants used in current-generation warfarin genetic tests, 
which are the most potent variants used in such tests.  Thus it is heartening to see extensive 
discovery of PD genes in the PIP, including extensive discovery of regulatory variants for PD 
genes.  Discovery methods like the PIP may be able to aid the transition to make more use of PD 
genes in pharmacogenomics, as suggested previously [Higgins et al 2015, Higgins et al 2015, 
Higgins et al 2015]. 
 
PK genes discovered for warfarin include CYP2C9 and other key metabolic enzymes for warfarin.  
However, for PK genes, the PIP mostly discovered only coding variants, and not regulatory 
variants.  We suspect this may be the case for two reasons.  First, the CYP loci have a complicated 
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structure of homology with many similar genes in close proximity, which tends to confound both 
hybridization, linkage, and sequence alignment [Danielson 2002, Hoffman et al 2002, Zanger et 
al 2013, Nelson et al 2013], all of which are essential steps in the PIP and the omics assays which 
provide its source information.  Secondly, however, the current version of the PIP locates target 
genes by sequence proximity, rendering it unable to find distal regulatory elements like those 
which control many facultative metabolic enzymes.  It is anticipated, therefore, that subsequent 
PIP enhancements will enable better discovery of regulatory variants for PK genes. 
 
Warfarin is a major anticoagulant, but in recent years a host of other anticoagulants including other 
vitamin K analogue agonists as well as novel oral anticoagulants (NOACs) have been gaining in 
acceptance [Barnes et al 2015].  Many of these medications share known mechanistic elements 
with warfarin, and also have known differences in mechanisms [Sangkuhl et al 2011, Wanat et 
al 2013].  Various drugs that modulate the coagulation system are used for other purposes [Wanat 
et al 2013, Harter et al 2015], including clopidogrel, which is routinely prescribed on a chronic 
basis to reduce the risks of stroke and heart disease.  And some SNPs discovered in the PIP 
experiment for warfarin have also appeared in association experiments for other anticoagulants, 
especially vitamin K antagonists.  For example, rs2108622, a coding SNP in CYP4F2 which the 
PIP identifies as a warfarin response SNP, is also a response SNP for acenocoumarol [Teichert et 
al 2009].   A joint analysis of the pharmacoepigenomic properties of this broader collection of 
coagulation-system-modifying drugs, integrating and comparing pathways and mechanisms, could 
be of real benefit to extend the breadth of future anti-coagulation pharmacogenomics testing. 
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More broadly, these results indicate that the epigenome-and-3D-nucleome-informed paradigm of 
pharmacogenomics that we described in our 2015 papers [Higgins et al 2005, Higgins et al 2015, 
Higgins et al 2015] may generalize beyond neuropsychiatry into cardiovascular 
pharmacogenomics and other domains.  The genes and variants discovered with the PIP should be 
the subject of follow-up research in both pharmacogenomics test design and future anticoagulant 
drug development.  Automated pharmacoepigenomics-based variant discovery and investigation 
methods like the PIP should continue to be developed, with potential future application in 
pharmacogenomics over the coming years. 
  
Validation and Extension of the Pharmacoepigenomics Informatics Pipeline (PIP) 
 
Our successful reproduction of the results of the lithium experiment with the PIP demonstrates that 
reproducibility in bioinformatics experiments depends closely on adherence to important 
reproducibility principles.  Reproduction of previous lithium results was complicated by elements 
of the original experiment like the inclusion of manual steps, consulting resources from external 
databases without retaining them or documenting precisely which tracks were consulted, and the 
use of databases whose contents change in an un-versioned manner.  These lessons have been 
incorporated into the PIP with design features like the use of versioned, locally stored databases, 
the selection of resources and records in an algorithmic and reproducible manner, and the retention 
of intermediate results and code.  This ensures that PIP experiments are reproducible.  Remaining 
challenges, including the use of the un-versioned IPA database for pathway analysis, should be 
rectified in subsequent PIP refinements.  Conversely, however, it is clear from our results that the 
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automated pipeline offers better functionality than the semi-automated pipeline it was designed to 
reproduce. 
 
It is possible to make pervasive use of machine learning in gauging the variant dependence of 
enhancer function.  The current pipeline gauges variant dependence only with PWM 
measurements, but a number of machine learning algorithms have recently been published for 
gauging variant function, including DeltaSVM [Lee et al 2015, Ghandi et al 2014, Ghandi et al 
2016], methods of Nishizaki [Nishizaki et al 2017], and recently GKM-DNN [Zhang et al 2017].  
We have performed testing with DeltaSVM indicating that its predictive power is “orthogonal” to 
that of PWMs, and would add value, both by allowing rejection of variants that pass the current 
scoring system but do not show variant dependence with DeltaSVM, and rescue of variants that 
barely miss the current thresholds but exhibit strong variant dependence in DeltaSVM.  The 
integration of some of these published methods would strengthen the PIP.   
 
In addition, methods like the PIP may help alleviate a vexing issue in current pharmacogenomics 
and other genetic testing: inapplicability of some test results across populations.  Sometimes 
genetic associations discovered with association testing may hold in the population from which 
the study populations were drawn (predominantly European, although increasingly Asian 
populations are being used in research conducted in Asia), but not in other populations [Huizinga 
et al 2004, Cooper et al 2008, Visscher et al 2017].  In this case, only three of 23 studies included 
African populations.  This has been an issue of comment both in the literature [Condit et al 2003, 
Yasuda et al 2008, Urban et al 2010, Ortega et al 2014] and in the lay press [Stein 2011, Arthur 
2017].  Strategies for surmounting it have included including population-specific lead SNPs in test 
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design, designing separate tests for different populations, including population-linked SNPs in test 
design, and various combinations of these methods [Daneshjou et al 2016].  Warfarin response 
and coagulation phenotypes in particular are an area in which certain populations, including 
African Americans, have exhibited different response profiles and different GWAS lead SNPs 
from European populations [Heit et al 2012, Heit et al 2017].   
 
The PIP and similar methods may help to resolve this problem.  One mechanism by which such 
an effect may arise is when a GWAS lead SNP is only a tagging variant for an underlying effector 
SNP, and the LD relationship between these SNPs is population dependent.  In such cases, the PIP, 
by evaluating the population of population-specific LD partners of the lead SNP, and finding 
effector SNPs within this population, will sometimes enable tests to be designed on the basis of 
population specific GWAS which will function predictively in a population-agnostic manner.   
 
Methods like these may generalize in other drug disease systems.  PIP-style methods may identify 
trans-ethnic causal regulatory variants and recover missing heritability by interpreting association 
studies in the light of disease mechanisms and massive cohort omics.  These high quality novel 
variants may help to enable the development of new pharmacogenomics tests with greater 
predictive power and clinical benefit.  
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Chapter 4: The H-GREEN Hi-C Compiler 
 
Motivation: Distal Target Gene Finding for the PIP 
 
The initial version of the PIP had a notable weakness: it relied on sequence proximity to find the 
target genes of regulatory variants.  This decision resulted mainly from two things: a desire to 
replicate the featureset of the lithium analysis, and the lack of availability of automated methods 
for distal target gene identification.  Nevertheless, this is important both because of widespread 
evidence that important phenotypes are mediated by genome-wide spatial and functional networks 
uniting genes from multiple chromosomes in a transcriptional program with unifying regulatory 
elements, but also because of the demonstrated value of distal target gene analysis in the “variants” 
and valproate variant analyses. 
 
The construction of a multimodal target gene suite for a future version of the PIP rests on several 
pillars: spatial contact data, molecular QTLs, and machine learning.  The value of both spatial 
contacts and QTLs in identifying enhancer control relationships, and the explosive proliferation of 
both types of data, have made the deep and comprehensive use of these data modalities in a genome 
wide tool like the PIP plausible.  Moreover, new modes of analysis treating enhancer elements and 
genes as elements on a bipartite graph on a genome wide basis, along with high throughput 
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CRISPR screens for enhancer activity, have offered the possibility of using such high throughput 
contact data, along with the “ground truth” of CRISPR screens, in the context of network 
mathematics, to make target gene prediction amenable to matrix densification methods in machine 
learning. 
 
All the elements of this emerging vision of multimodal target gene discovery are in place, except 
for one.  Proximal target gene analysis with integrative analysis of Hi-C, epigenome, and QTL 
data is available in TargetFinder.  Hi-C, CRISPR, and QTL datasets are increasingly available.  
Bipartite graph analysis tools are increasingly robust.  Matrix densification is a well-studied area 
of active ongoing research in machine learning.  However, there are no currently available 
automated tools for distal (tens of MB to trans) target gene analysis with Hi-C data. 
 
For this reason, in 2015 I conceived and began the development of a new Hi-C compiler 
specifically designed for this challenge.  Unlike other extant compilers, it uses functional elements 
of DNA as its compiling bins, maximizing the discernment of functional element mediated 
connections in the sparse off-axis regions of squared genome space.  It was and remains my 
intention that these compiling methods be integrated into a PIP-style pipeline, and used with Hi-C 
data from relevant tissues to discover the long range spatial contacts of potent enhancer loci to 
identify their distal target genes. 
 
Introduction: 
 
The 3D Spatial Hierarchy of Chromosome Organization and Stratification of Drug Response 
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Noncoding regions of the human genome contain the infrastructure that regulates gene expression, 
and mutations within elements such as enhancers and promoters are critically associated with 
disease risk and drug response. Evidence that most SNPs (single nucleotide polymorphisms) in 
genomewide association studies (GWAS) and candidate gene studies that are significantly 
associated with disease risk, phenotypic traits and drug response have been mapped to enhancers 
emphasizes the importance of studying domains not found within the exome [Zhang et al 2014, 
Raj et al 2008, Fukaya et al 2016]. Regulation of gene expression depends upon the interaction 
between enhancers, transcription factors, chromatin remodeling proteins, histone modifications 
indicative of active chromatin, the ability of DNA-binding proteins to access a casual allele as 
indicated by DNase I hypersensitivity, TAD boundary proteins, and gene promoters within a TAD. 
The frequency of interactions of these elements within the spatial and temporal chromatin 
architecture of a TAD is much higher than are inter-TAD interactions [Bonev et al 2016, Higgins 
et al 2017, Cloney et al 2016].  The boundaries of TADs contain insulator proteins, including 
CTCF and cohesin [McCarthy et al 2012, Bunney et al 2015] and are timing transition regions 
[Yan 2015]. Mutations in TAD boundaries have been shown to cause disease in humans ranging 
from autosomal dominant Autosomal Dominant Adult-Onset Demyelinating Leukodystrophy 
(ADLD) [Kino et al 2010], to a variety of developmental limb malformations that disrupt 
enhancer-promoter interactions [Pope et al 2014].  
 
Differences in drug response and AEs among individuals represent an aggregate of 
pharmacodynamic and pharmacokinetic variation, but are most often attributable to altered 
regulatory and biotransformation pathways which are limited to a few tissues.  Since variation in 
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genomic DNA sequence, which should be roughly the same across all tissues, cannot account for 
the bulk of the genetic contribution in pharmacogenomics, it is likely that cell type-specific 
differences in chromatin organization and interactions may be responsible [Goel et al 2009, 
Chrousos 1995, Konturek et al 2011]. Previous studies using Hi-C demonstrate that the spatial 
organization of TADs appear to be invariant across tissues, but that TADs are either active or 
inactive based on developmental state, pathology and cell type [Bonev et al 2016, Goel et al 2009, 
Chrousos 1995, Konturek et al 2011, Chen et al 2015, Dai et al 2016]. During development, the 
binding of cell type-specific master transcription factors within subsets of TADs help determine 
cell fate [Tjong et al 2016]. Several drug classes, including HDAC inhibitors and 
chemotherapeutics, work by inducing genes that encode master transcription factors or other 
proteins that are important in determination of cell fate, leading to re-activation of developmental 
transcriptional programs [Tjong et al 2016, Bharadwaj et al 2014].     
 
Even in cases where an exon variant is linked to an AE, regulatory domains distant to the gene that 
harbors the mutation impact drug response. For example, 60% of patients with melanoma contain 
the V600E variant at amino acid position number 600 on the BRAF protein, in which the valine is 
replaced by glutamic acid. The chemotherapeutic drug vemurafenib interrupts the BRAF/MAPK 
(B-Raf Proto-Oncogene, Serine/Threonine Kinase-Mitogen-Activated Protein Kinase) pathway, 
and this drug is commonly used to treat patients with melanoma. However, drug resistance 
developed in almost all patients taking vemurafenib, as tumor cells switch to an alternate survival 
pathway. Using knock-out experiments in human cell lines and interruption of regulatory elements 
using CRISPR-Cas9, it was found that the CUL3 gene is a major contributor to drug resistance in 
these patients [Thakurela et al 2015, Hung et al 2011]. Bombardment with small guide RNA-
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mediated mutations in domains surrounding CUL3 found an enhancer located 22 kb from the TSS 
of the gene, which was found to be responsible for the regulation of the gene. This could be 
identified as the culprit regulatory domain responsible for drug resistance to vemurafenib [Hung 
et al 2011], leading to therapeutic strategies. For many genes, which encode ADME proteins, 
enhancer looping with promoters is not uncommon, as exemplified by the SLC2A13 (Solute 
Carrier Family 2 Member 13) gene [Chen et al 2015]. 
 
Although many regulatory interactions are constrained in cis, many long-distance interactions, 
including active inter-chromosomal spatial contacts, play a role in determination of 
pharmacogenomic response [Chen et al 2015, Hung et al 2011, Zhang et al 2014]. Inter-
chromosomal spatial contacts are common [Bush et al 2016, Denny et al 2010], and AEs 
associated with psychotropic drugs can be explained by these trans-interactions in some cases 
[Zhang et al 2014, Hebbring et al 2015].  Complementary methods such as Hi-C which 
employing deep sequencing for visualization of enhancer-promoter and promoter-promoter loops 
[Higgins et al 2015], or ChIA-PET [Hebbring et al 2015], in tandem with super-resolution 
microscopy [Bush et al 2016], may enable closer examination of these functional 
pharmacoepigenomic interactions.  It is probable that not all enhancer-promoter or promoter-
promoter interactions involve chromatin loops [Denny et al 2010].  
 
Hi-C sequencing and similar methods mapping contacts into squared genome space have emerged 
as the preeminent mode of gauging spatial organization of chromatin at a genome wide scale.  
Since the publication of the original Hi-C methods and results, experiments using these methods 
have proliferated in many biological systems at ever-increasing depths of sequencing, and resulted 
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in fundamental biological insights about the spatial structure of the genome, how it is regulated, 
its causative relationship with gene expression, and the ways that such connections operate in 
unusual tissue and disease contexts.  In addition to this, there has been a proliferation of 
methodological enhancements and related methods, including in-situ Hi-C [Rao et al 2014], 
capture Hi-C [Mifsud et al 2015], ChIA-PET [Li et al 2014] and Hi-ChIP [Mumbach et al 2016], 
Micro-C [Hsieh et al 2015], SPRITE [Quinodoz et al 2017], and Genome Architecture Mapping 
[Beagrie et al 2017]. 
 
Hi-C works by reconfiguring DNA sequences in the human genome to associate by spatial 
proximity rather than genomic contiguity, using fixation, cutting, religation, and then digestion.  
When the reconfigured DNA is sequenced with paired end sequencing, the paired reads correspond 
to spatially proximal elements which may be distal in linear sequence space, or on separate 
chromosomes.  The millions to billions of read pairs making up a Hi-C dataset are compiled into 
a contact frequency matrix in squared genome space, showing the contact frequencies for all pairs 
of loci in the genome. 
 
Chief among the discoveries flowing from Hi-C has been the discovery of Topologically 
Associating Domains (TADs) [Dixon et al 2012] in the human and other genomes.  These self-
associating regions have been identified as potent spatial and functional elements in the human 
genome.  The division of approximately 80% of the human genome into approximately 2500 TADs 
is remarkably robust, being largely conserved between cell types in the human body [Rao et al 
2014], between different humans [Ruiz-Velasco et al 2017], and under disease states [Rao et al 
2014].  In fact, syntenic regions of related genomes (e.g. mouse) often share the same TAD 
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structure as the related regions of the human genome [Krefting et al 2017, Nora et al 2013].  
TADs also function as replication domains [Pope et al 2014].  Moreover, TADs mediate long 
range spatial interactions [Rao et al 2014]: the contact frequency in any given portion of the 
squared genome will more closely correlate with a more sequence-distant portion which is in the 
same TAD pair than a sequence-proximal portion spanning TAD boundaries. (Figure 4-1) 
 
While the portion of a genome which composes a TAD is relatively invariant, TADs differ from 
one cell type and biological condition to another in their degree of transcriptional activity.  This 
differentiation between the “A” and “B” compartments is connected with the sign of the dominant 
eigenvector of a genome-wide Hi-C matrix [Dekker et al 2013], the degree of spatial openness as 
observed by both Hi-C, imaging, and biochemical experiments [Roadmap Epigenomics 
Consortium 2014], the degree of gene expression [Roadmap Epigenomics Consortium 2014], 
the presence of active histone marks [Roadmap Epigenomics Consortium 2014], the presence 
of activating transcription factors [Roadmap Epigenomics Consortium 2014], replication timing 
[Pope et al 2014], and the extent of long range and interchromosomal contacts [Rao et al 2014].  
Genes located in the same TAD tend to be co-regulated, and they are regulated partially by their 
TAD context. 
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Figure 4-1: Schematic Representation of Hi-C Compiling Concepts 
A schematic chromosome containing two TADs, designated TAD1 and TAD2, shown on top and 
at left.  Along the diagonal the intra-TAD TAD pairs (1,1) and (2,2) are shown in red, while the 
inter-TAD interaction area of TAD pair (1,2) is shown in pink at the top right and bottom left.  
Also shown are TAD bins for TAD1 and TAD2, designated by the horizontal and vertical black 
dotted lines.  Also shown are fixed bins 1-12, designated at top and by green dotted lines.  It may 
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be seen that TAD1 is contained within Bin2, which also contains sequence area outside of TAD1, 
while TAD2 is divided into Bin8, Bin9, and Bin10, two of which also contain sequence area 
outside of TAD2.  Accordingly, the TAD pairs (1,1), (1,2), and (2,2) are represented by one, three, 
and nine binpairs.  Also shown are four positions in TAD pair (1,2), designated in blue, with the 
two positions in (1,2) having more correlated signal intensities, even though two positions in 
adjacent TAD pairs are closer in sequence space to the top right position in (1,2). 
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Moreover, the sequence context governing these regulatory interactions is beginning to illuminate 
under sustained investigation.  High resolution Hi-C experiments have discovered a hierarchy of 
super- and sub-TADs running all the way down to the level of “loop domains” [Rao et al 2014] 
which spatially unite the proximal enhancers of genes with their intra-TAD proximal enhancers.  
These contacts, and those above them in the hierarchy, are largely governed by the presence of 
convergent pairs of CTCF sites [Nichols et al 2015, de Wit et al 2015] which form a CTCF-
cohesin anchor binding loci together by means of a loop extrusion mechanism [Sanborn et al 
2016] which has been verified by biochemical and imaging methods [Fudenberg et al 2016, 
Sanborn et al 2016].  Perturbations of these sequence elements by CRISPR in vitro, or by disease-
related mutations in vivo, as for example in enhancer hijacking in cancer [Northcott et al 2014, 
Weischenfeldt et al 2017], have the predictable effects on Hi-C maps, the epigenome, and gene 
expression [Wutz et al 2016, Sanborn et al 2016].  
 
Genes are often regulated by enhancer elements which are very distant from them in sequence 
space, referred to as distal-cis, or on different chromosomes, referred to as trans.  Some recent 
opinion has argued that these interaction categories should be considered together, as sufficiently 
distal cis interactions are no longer mediated by sequence proximity and may be considered 
effectively trans interactions [Wong et al 2017].  In any event, long distance enhancer interactions, 
including those of “super enhancers” which regulate many genes on many chromosomes, are 
validated, and such validated interactions often appear in Hi-C contact matrices [Rao et al 2014].  
There is increasing interest in using Hi-C maps to screen for such interactions. 
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However, current methods are not well tuned for this task.  Functional elements from TADs to 
chromatin state segments have become central to the interpretation and use of Hi-C maps in 
biological science, and Hi-C read pairs are mapped into squared genome space at the resolution of 
cut-sites (in the case of traditional Hi-C, 4-cutter or 6-cutter restriction enzymes) or at base pair 
resolution (in the case of Micro-C [Hsieh et al 2015]).  Despite this, the compiling of Hi-C read 
pairs into interaction matrices has largely proceeded by chopping the genome into evenly-sized 
pieces contiguous to each other, i.e. fixed binning [Lieberman-Aiden et al 2009, Dixon et al 
2012, Rao et al 2014].  This method has the advantage of being easy to implement and producing 
matrices which are relatively easy to normalize, as well as sparing the researcher the task of 
justifying a choice of bins.  It suffices for many purposes, particularly those analyzing on-axis 
measurements corresponding to proximal cis interactions. 
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Figure 4-2: Normalization Curves in Hi-C Compiling 
Shown are three distance normalization curves, representing the contact density (Y axis) as a 
function of sequence distance (X axis), on log10 based scales.  The Y axis is denoted in arbitrary 
units representing multiples of the contact density in the trans (inter-chromosomal) domain.  
Shown in gray is a power law spline density function used for normalization in some Hi-C 
compiling methods, while empirical density curves derived from two real datasets (fibroblasts and 
SK-N-SH neural cells) are shown in blue and orange.  The two empirical curves both show humps 
corresponding to the mononucleosome fragment, followed by monotonic curves with different 
slopes in different distance regimes, and a hump corresponding to the end joining of Chromosome 
1.  However, they differ substantially from each other and the synthetic curve, sometimes up to 
threefold, in a manner which differs by distance regime.  
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However, the method of fixed binning is poorly suited for the detection of long distance 
interactions between enhancers and their target genes.  Trans and distal cis interactions suffer from 
severe data sparsity, as read pairs in a linear genome are mapped into a squared genome whose 
area is over nine million squared megabases.  Moreover, read densities vary by five orders of 
magnitude with genomic distance and the majority of measured interactions are concentrated along 
the axis.  Thus with fixed bins, fine resolutions will result in a genome-wide matrix over 99.9% of 
whose entries are empty, while coarse resolutions will abuse the functional elements which 
mediate long range contacts, chopping them into pieces and combining them with adjacent 
sequence regions. (Figure 4-1) 
 
Accordingly, there is a need for Hi-C compiling methods designed to detect long range cis and 
trans interactions mediated by functional elements.  To answer this need we present H-GREEN 
(Hi-C compiling with Genomic and Regulatory Elements and Empirical Normalization), a Hi-C 
compiler designed for distal contact detection.  It compiles aligned reads into functional-element 
bins, normalizes them against an empirical density function, and detects contacts with statistical 
testing and comparison control. 
 
Because the distal contacts sit in a regime wherein there is substantial variability in the distance 
contact density of different Hi-C maps, and a functional-element-based compiler will be forced to 
normalize bins of variable size and shape, it is essential that the normalization package of such a 
compiler make use of dataset-specific empirical distance normalization curve.  (Figure 4-2) 
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Figure 4-3: H-GREEN Methods Diagram 
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The steps in the H-GREEN Hi-C compiling algorithm, beginning with alignment and quality 
control of reads, followed by the separate compiling of real and expected read count matrices, 
followed by statistical normalization and the availability of significant enriched and depleted 
interactions for end uses.  
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Hi-C Compiling with Genomic and Regulatory Elements and Empirical Normalization 
 
System and Methods, Algorithm, and Implementation: 
 
The H-GREEN algorithm is summarized in Figure 4-3.  It proceeds by way of alignment, quality 
control, compiling, integration, statistical testing, and result output. 
 
Raw paired end reads imported in FASTQ files [Cock et al 2010] are split into their single-ended 
components and then aligned with Bowtie [Langmead et al 2012] using standard settings, with 
multiprocessing and reordering. 
 
Then, the pairs are selected wherein both reads aligned singly with a quality score exceeding a 
threshold which would present only a .05 probability of misalignment in either read, and the unique 
read pairs satisfying this criterion are used in the subsequent analysis and recorded in a CSV file. 
 
Aligned, quality-controlled reads from published experiments are sometimes published in the form 
of text spreadsheets with a “.nodup” [Lieberman-Aiden et al 2009] file extension instead of raw 
reads, and in addition, sometimes they are published together but the needs of an experiment with 
H-GREEN may dictate the use of the same reads and alignments as in another analysis.  For this 
purpose, there is a script that converts “nodup” files directly into quality controlled read files. 
 
Then, alignment proceeds.  The bins are imported from a BED file of user designation, either a 
single set of bins for both axes, or two separate sets of bins, one for each axis.  The quality 
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controlled read pairs are mapped into their host bins with a binary search tree, [Booth et al 1960] 
wherein the ordering relation for the node indices is an ordering on genomic positions, as opposed 
to integer indices.  The read pairs wherein both reads are located in a bin for the relevant axis are 
mapped into the matrix. 
 
Separately, an empirical background density function is generated for each single base pair 
distance in cis squared genome space, by dividing the number of read pairs at each distance by the 
amount of squared genome space at that distance.  The same is done for trans interactions.  Then, 
the background density function is integrated over the rectangular region in squared genome space 
corresponding to each bin pair, to produce an expected read count for this read pair based on its 
size, shape, and position. 
 
Then, the expected and observed read counts for each bin pair are used to generate a p-value with 
a two tailed Poisson distribution.  The collection of p-values are then subjected to multiple 
comparison control with the false discovery rate methods of Benjamini and Hochberg [Benjamini 
et al 1995], and significant interactions (enriched and depleted) with a fold change of at least 
twofold are reported as significant interactions in a CSV spreadsheet. 
 
The H-GREEN algorithm is implemented in Python, with external calls to Bowtie for alignment, 
with the exception of the binary search tree for compiling itself, which is implemented in C++.  
With TAD bins, the use of a BST in C++ offered a fifteenfold performance improvement over a 
ranked list search, and a hundredfold improvement over a naïve list search. 
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On a 6th generation Intel Xeon processor, for one lane of Illumina Hi-Seq 2500 worth of data, the 
computational time involved in executing H-GREEN with TAD bins on both axes is approximately 
84 core hours for alignment, one core hour for quality control, two core hours for compiling, 120 
core hours for integration, and one core hour for statistical control and data output.  Notably, all 
phases of the process are data parallel so that a suitable implementation could run H-GREEN 
quickly.  Where n is the number of read pairs and k the number of bins in a square matrix, the 
complexity of each step is approximately O(n) for alignment and quality control, O(n*log(k)) for 
compiling, O(k) for integration, and O(k^2) for statistical control and data output. 
 
Superior Detection of Long Range Contacts 
 
For a first evaluation of H-GREEN’s discernment of distal contacts, we compared it directly with 
HOMER [Benner et al 2018], a widely used Hi-C compiler, on a published dataset of human 
fibroblasts [Chen et al 2015].  With H-GREEN, we aligned the raw reads and compiled them into 
a matrix with TAD bins [Dixon 2012] on both axes.  A set of enriched long range interactions was 
defined as those cis interactions at a range of greater than 10 megabases which were enriched 
twofold or more and passed comparison control, squared genome wide.  We then compared these 
interactions with the detected interactions by HOMER in published matrices of normalized 
interaction frequencies for cis interactions in all human chromosomes, at one megabase resolution.   
In defining TAD-TAD interactions in the HOMER-compiled published data on the same 
experiment, we were presented with the complexity introduced by the fact that unlike H-GREEN, 
HOMER uses fixed bins, and many such bins may intersect with the same TAD boundary.  To 
give HOMER maximal opportunity to detect such contacts, we defined a TAD pair as interacting 
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if any pair of bins containing parts of both TADs was enriched twofold in the HOMER-produced 
normalized matrix. 
 
We chose a 1MB compile not because this method would be optimal for the purpose of TAD 
contact detection with traditional methods; it’s well understood that higher resolution compiles 
with subsequent bin grouping are more optimal for detecting distal contacts [Rao et al 2014].  It 
is likely that the use of these post-compile methods with a higher resolution compile in HOMER 
would be capable of detecting many or most of the additional contacts H-GREEN detects, and 
rejecting those H-GREEN does not detect.  However, this compile resolution is most comparable 
to the TAD compile in terms of the overall number of bins in the genome and average size of bins, 
among widely used compiling resolutions in fixed-binning Hi-C compiling.  It therefore represents 
the closest direct comparison between fixed binning and H-GREEN’s TAD binning methods. 
 
At these settings, HOMER detects 18,220 contacts, and H-GREEN detects 17,720. (Figure 4-4)  
Of these, only 5,648 are common to the two methods.  Contacts detected by H-GREEN and not 
by HOMER, of which there are 10,193, may be attributed to the superior discerning power of H-
GREEN, which gauges all the signal from the TAD pair under inspection and does not dilute with 
signal from boundary regions and adjacent TADs.  Contacts detected by HOMER but not by H-
GREEN, of which there are 12,572, may be attributed to bins passing the thresholds which overlap 
one TAD pair due to a signal from an adjacent TAD pair.  Among such pairs, 82% fail the fold-
change cutoff in H-GREEN, 90% fail the FDR cutoff, and 72% fail both cutoffs.  Among such 
pairs, 92% have a neighbor TAD pair which did have an H-GREEN detected contact.  The non-
neighbor discordant HOMER contacts number 1,054. 
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If indeed long range contacts detected in low resolution compiles with HOMER and similar 
methods are susceptible to false positives in this vein, then other methods without this problem 
should be preferred.  Fortunately, however, the wide recognition that traditional methods are 
poorly suited for detecting distal contacts in sparse data has made such analyses uncommon, so 
the presence of such erroneous results in the literature is likely quite limited.  H-GREEN and 
similar methods are more suited to such analyses. 
 
 
  206   
 
 
Figure 4-4: Contact Discernment: H-GREEN vs. HOMER 
Direct comparison of contact discernment by H-GREEN and HOMER in human fibroblasts.  
Pictured are TAD-TAD contacts detected by H-GREEN and HOMER, divided into four 
categories: those concordant between the two compilers, those discordant and detected by H-
GREEN only, and those discordant and detected by HOMER only, divided into those attributable 
to bleedover of neighboring signal, in red, and those not so attributable, in green. 
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rsID Drug Chr Begin End 
TAD 
Num Contacts Gene 
Candidate 
Contacts 
rs3822158 Ketamine chr4 157080000159360000 693 5 GLRB 0 
rs17161937 Ketamine chr7 98880000 100320000 1063 388 CYP3A43 4 
rs34547970 Ketamine chr9 136840000137800000 1343 172 GRIN1 4 
rs12248560, 
rs77957608, 
rs61886222 Ketamine chr10 94240000 95440000 1418 206 
CYP2C9, 
CYP2C19 5 
rs71311904 Ketamine chr11 27480000 29360000 1472 73 BDNF 2 
rs3764028 Both chr12 13320000 14720000 1567 3 GRIN2B 0 
rs7980427 Ketamine chr12 108800000109360000 1636 46 DAO 2 
rs1543927 Ketamine chr15 74040000 75000000 1832 218 PPCDC 3 
rs7184748 Ketamine chr16 9160000 10920000 1862 48 GRIN2A 0 
rs2857654 Valproate chr17 33720000 35360000 1977 47 CCL2 1 
rs11083595 Ketamine chr19 38400000 40920000 2112 682 CYP2B6 9 
rs2269577 Valproate chr22 28040000 29080000 2245 134 XBP1 2 
rs28439297 Ketamine chr22 41920000 43480000 2258 609 CYP2D6 8 
Figure 4-5: Table of Neurogenesis-Gene-Containing TADs for Ketamine and Valproate 
Response 
The TADs involved in neurogenesis in the ketamine and valproate SNP analyses, including the 
rsID of the enhancer SNPs, the drug for which these SNPs is an association hit, the genomic 
coordinates of the TAD, its number in the Dixon et al TAD numbering scheme [Dixon et al 2012], 
the number of genome-wide TAD-TAD contacts in the SK-N-SH cell line, notable genes in the 
TAD, and the number of TAD-TAD contacts within the set of neurogenesis-related TADs.  
Pharmacokinetic TADs are shown in yellow; pharmacodynamics TADs in blue. 
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Automated Construction of Functional Interaction Networks 
 
After verifying that H-GREEN is capable of detecting long range contacts not detected by 
traditional methods in the same datasets at comparable resolution, we proceeded with an 
exploratory experiment in a different biological system, to directly gauge the usefulness of TAD-
TAD contact data in mapping regulatory circuits. 
 
We assembled a list of thirteen TADs which play host to genes and variants involved in the 
pharmacokinetics and pharmacodynamics of two drugs, ketamine [Soumier et al 2016, Huang et 
al 2016, Clarke et al 2017] and valproic acid [Higgins et al 2017], for which there is evidence of 
xenobiotic induction of neurogenesis in the adult human brain (Figure 4-5).  In a TAD-TAD 
compile of a published dataset of Hi-C on SK-N-SH neural cells [Guo et al 2015], we looked for 
contacts involving these TADs. 
 
Of the thirteen, all exhibited some distal contacts detected by H-GREEN (Figure 4-5), from three 
contacts up to several hundred throughout the genome.  Notably, TADs containing 
pharmacokinetic loci, e.g. the CYP genes which metabolize these drugs, appear to harbor the 
largest number of contacts.  In addition, of the thirteen TADs, ten have connections to other TADs 
within the same set of thirteen, forming a densely interacting spatial network of functionally related 
TADs (Figure 4-6).  The P-value for such a density of contacts, an enrichment of over tenfold 
relative to the background, is less than 1e-14. 
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H-GREEN is capable of finding distal contacts that are suggestive of functional connections, and 
may function as a means of finding target genes of regulatory variants. 
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Figure 4-6: Interaction Network of Neurogenesis TADs in SK-N-SH Cells 
The significant enriched interactions between neurogenesis-related valproate and ketamine 
response TADs, as called by H-GREEN in SK-N-SH cells.  Ten out of thirteen neurogenesis TADs 
join into a network, at p<10^-14.  The two TADs in the center of the network (2112 and 2258) 
contain metabolizing enzymes for ketamine and valproate which are expressed in the human brain.  
Pharmacokinetic TADs are shown in yellow; pharmacodynamics TADs in blue. 
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Discussion 
 
H-GREEN is capable of finding spatial contacts suggestive of functional regulatory interactions, 
and of finding connections that cannot be found with traditional methods in the same datasets at 
comparable resolutions.  Accordingly, these methods should be broadly used to find long range 
spatial contacts in Hi-C datasets, particularly for target gene detection for regulatory variants. 
 
This can be done either by compiling a dataset with one set of loci of interest along an axis, e.g. 
the chromatin state segments containing association hits, and a genome wide TAD collection on 
the other, or by selecting the loci of interest out of a squared-genome-wide compile, as we have 
done in the present work. 
 
In particular, the PIP will benefit substantially from the use of H-GREEN to find distal target 
genes.  As noted in Chapter 3, the current PIP only detects proximal target genes and has no module 
to detect distal target genes, which is one of the most notable weaknesses of the current PIP 
featureset.  Suggestive but inconclusive results show that this deficiency may be more critical in 
the detection of regulatory variants for pharmacokinetic SNPs relative to pharmacodynamics 
SNPs, as PIP experiments to date have consistently detected almost exclusively coding variants 
for pharmacokinetic genes, despite the existence of regulatory networks for PK genes.  The 
discovery of a spatial contact network uniting regulatory variants for PK and PD genes together 
using H-GREEN thus provides a hopeful note that the incorporation of H-GREEN and other distal 
target gene methods into the PIP will address this critical need, as contemplated in Chapter 5.  The 
finding of long range contacts for regulatory SNPs and the construction of spatiotemporal 
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regulatory contact networks has the potential to become a significant element of the standard 
methods for investigating the mechanism of regulatory variants, both across pharmacogenomics 
and in the broader field of human genetics as a whole. 
 
It will serve to discuss another noteworthy Hi-C analysis package which attempts, like H-GREEN, 
to dispense with fixed binning in Hi-C analysis and thereby to analyze long range contacts, but 
which takes a radically different approach.  The SHAMAN package [Cohen et al 2017] uses a 
sparse matrix at base pair resolution, and then generates a randomized matrix satisfying distance 
frequency and marginal coverage criteria sampled from the real matrix.  It uses this randomized 
matrix to compare to the real one, generating p-values which are compared with FDR statistics to 
address random error in Hi-C matrices, similar to H-GREEN.  However, the p-values are generated 
from the Kolmogorov-Smirnov D statistics for the density of the K-nearest-neighbor cluster 
around each of the individual read pairs in the database.  Pairs with a significantly dense K nearest 
neighbors may be considered enriched.  The selection of the K value for a particular experiment 
thus represents a significant tradeoff between resolution and statistical power, much like the 
selection of bin sizes in H-GREEN or in traditional Hi-C compiling. 
 
This approach shares many advantages with the H-GREEN approach: independence of fixed-
binning artifacts, sensitivity to low density, and natural scaling of statistical power with read 
density.  It is therefore certainly superior to coarse fixed binning for genome wide analysis, and 
probably more useful than H-GREEN for intra-TAD and other proximal work.  However, for distal 
cis contacts, it has one important disadvantage relative to H-GREEN, because it does not account 
for the mediation of contacts by large sequence elements.  The K nearest neighbors of a particular 
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read pair may not be significantly enriched, while the entire TAD pair in which the read pair sits 
may be enriched.  For a suitable value of K, these will be approximately concordant, but SHAMAN 
provides no way to choose such a K, which will in any event vary genome wide.  In addition, a 
read pair adjacent to a TAD pair with strong clustering may “stow away” on the sequence-close 
dense read pairs, generating neighbor-spillover contact detections, just in the manner of fixed 
binning.   
 
The developers of SHAMAN acknowledge these problems.  They attempted to detect long range 
contacts and noted that they were mediated by larger domains:  “Using the D scoring scheme, it is 
possible to screen   for   contact   enrichment   hotspots   throughout   the   entire   Hi-C   matrix   
without   prior assumptions.  We  applied  this  approach  to  the  high  depth  lymphoblasts  and  
ertirhroid  maps, deriving  462  and  1304  non-overlapping  contact  enrichment  hotspots,  
respectively  ranging  in distance  from  4Mb  to  100Mb  (Methods).  We  observe  that  many  of  
the  identified  hotspots  were characterized by a broad pattern of enrichment, associating together 
genomic elements at a much larger scale than observed above for CTCFs or TSSs…This confirmed 
the broad nature of nearly all long-range  contact  hotspots  we  identified,  showing  contact  
enrichment  at  distance  range  of  100kb around  the  center,  and  in  many  of  the  cases  larger  
distances  are  observed.  Highly  localized contacts  between  elements  genomically  separated  
by  more  than  4MB  are  very  rare.” 
 
It may be possible, in the fullness of time, to attain a synthesis of the methods of SHAMAN and 
H-GREEN by adapting the SHAMAN algorithm to use a distance metric function which is not 
sequence-agnostic, and accounts the distances between neighboring pairs according to their 
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insulating score in local Hi-C mapping.  This would tend to ensure that the nearest neighbors of 
any position fell into their local genomic elements, so that the algorithm would be more capable 
of detecting contacts mediated by these elements, as opposed to detecting nearby contacts of 
unrelated elements, or missing such contacts. 
 
It is possible to envision many applications of H-GREEN and similar methods which would 
necessitate some enhancements to the current H-GREEN package.  While the TAD bins used in 
the present experiments do not vary significantly by cutsite density or GC content, the use of 
smaller bins, e.g. gene binning or chromatin state segment binning, which do vary significantly, 
would require these elements to be accounted for in the normalization package in order to avoid 
major errors.  This would be a straightforward extension using methods already used to adjust for 
these factors in traditional normalization.  Coverage normalization is probably inadvisable as it 
would adjust away significant variation in the overall extent of genomic spatial contact which is 
observed to exist. 
 
In addition, with the multiple sampling distribution of the Poisson distribution, it is possible for 
the H-GREEN statistical framework to be used to detect differential contacts between two Hi-C 
datasets in different biocellular systems or biological conditions.  This could include, e.g., a survey 
of a large number of cell types based on published Hi-C maps.  This type of bodywide atlas of 
spatial connections will be particularly important in light of upcoming compendia of tissue Hi-C 
data such as the upcoming Human Cell Atlas [Regev et al 2017]. 
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H-GREEN was designed to overcome data sparsity and make maximal use of sparse signal for 
contact detection.  It may be that a version of these methods with a distance correction method 
optimized for this use may be useful in analyzing single-cell Hi-C data. 
 
Hi-C data is used for a large and growing number of purposes, and with the added discerning 
power of H-GREEN and similar methods, surveys of long range contacts, both for specific loci 
and on a squared-genome-wide basis, may be added to this collection, to the potential benefit of 
many areas of bioscience research. 
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Chapter 5: The Pharmacophenomic Atlas 
 
Pharmacogenomics in the Age of Omics Atlases, Biobanked EMRs, and Artificial 
Intelligence 
 
The Pharmacoepigenomics Informatics Pipeline and associated tools and methods have added 
value in the identification of causative enhancer variants for phenotypes of interest, and the 
identification of their target genes for future mechanistic work.  The variants, genes, and networks 
discovered for warfarin, lithium, valproic acid, and other drug-disease systems could be used 
directly in traditional test design, and other phenotypes can be investigated with these tools.   
 
However, this featureset is not the last word.  Advances in a number of areas, including the 
underlying biology of enhancer function, artificial intelligence, omics atlases, biomedical 
ontologies, and genotyped medical records from biobanks and clinical trials have opened the 
doorway to much more powerful PIP-style pipelines, which are more sensitive to interactions 
which cannot be detected by the current PIP, and more thorough in pruning out interactions which 
are not as promising.  More, they have opened the door to a future wherein such pipelines are used 
pervasively in parallel against thousands of biomedical phenotypes, with results that can be used 
in routine medical practice. 
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This chapter describes an evolved PIP featureset which is based on current cutting edge methods 
in all the subdomains of biomedical inference from which the PIP draws, and some notions of how 
to score variants and genes and pathways in an evolved PIP with machine learning.  It describes 
an orienting framework for how to use the output of PIP-style pipelines in biomedical genetic test 
design.  And finally, it concludes with a vision for the use of such a pipeline with biobank datasets 
and biomedical ontologies to create a genome-wide, phenome-wide pharmacophenomic atlas of 
predictive models for thousands of phenotypes, which could be then be implemented directly in a 
clinical decision support system.   
 
The availability of genetic prediction on a routine basis for medically important phenotypes, 
shortening the translation cycle on genetic discovery, can improve patient care. 
 
An Evolved PIP Featureset 
 
The underlying scientific domains of epigenome regulation, spatial genomics, and population 
genetics on which the PIP is based have not stood still since the PIP featureset was laid down in 
2016.  They have continued to advance.  And while a future evolved PIP featureset will still be 
based on the overall Five Box Model of regulatory variant discovery, every portion will be affected 
by these significant discoveries.  In addition to this, the universe of data from which a future PIP-
style pipeline can draw has expanded vastly.   
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This will begin with data input: unlike the current PIP, which treats all variant inputs and all tissues 
uniformly, an evolved PIP would separately take tissue inputs for a collection of related 
phenotypes, and separate inputs of the relevant variants and populations for each phenotype, as 
well as information about the degree of relatedness of phenotypes to each other.  In addition, the 
directionality of the variant effect is important: an evolved PIP would track which of the alleles of 
the SNP had which effect on the phenotype, and in the context of the variant dependence portion 
of the ERV workflow, the directionality of effects on TF binding and enhancer function will be 
gauged as well.  The concordance of this information within the scores for each SNP, and between 
the common regulatory SNPs for a gene, will function as important information in the context of 
scoring. 
 
Such a PIP would have the opportunity to draw on a wealth of data sources on which the current 
PIP does not draw.  In addition to the resources of the current PIP, new and not-previously-
available datasets which would add significant value would include: 
 Primary GWAS and genotyped cohorts for relevant phenotypes 
 Expanded collections of genomes for linkage analysis under the auspices of various 
biobanks and genomics initiatives 
 Expanded omics atlases with deeper omics on more tissues and cell types, under the 
auspices of the International Human Epigenome Consortium (IHEC) [Stunnenberg et al 
2016] and the upcoming Human Cell Atlas [Regev et al 2017] 
 Expanded atlases of TFBS motifs and binding data, under the auspices of MotifDB 
[Shannon et al 2018] and the omics atlases 
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 Collections of Hi-C data from the Hi-C laboratories (currently highly decentralized), and 
soon in the form of a bodywide atlas from the Human Cell Atlas 
 Expanded collections of molecular QTLs (currently highly decentralized) under the 
auspices of various biobanks, clinical trials, consortia, and individual analyses 
 Libraries of validated enhancers 
 The updated pathway mapping libraries of IPA [Kramer et al 2013] and other pathway 
mapping methods 
 
A conceptual featureset for such a pipeline is shown in Figure 5-1, and described in more detail 
below. 
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Figure 5-1: Conceptual Featureset for a Next-Generation PIP 
Schematic visualization of the envisioned featureset of a next-generation PIP, organized 
according to the five major elements of the five box model of regulatory variant discovery. 
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Permissive Candidacy 
 
Currently, all PCV identification in the PIP proceeds in a “forward” mode, proceeding from the 
phenotype toward a locus by association.  This is currently done with GWAS lead SNPs by 
population-specific linkage analysis. 
 
This forward mode of PCV discovery can be expanded.  For one, linkage analysis with 1000 
Genomes [1000 Genomes Project Consortium 2015] populations can be enhanced with the use 
of more relevant population groups as the number of analyzable genomes continues to expand, and 
the granularity of population genetics mapping continues to refine.  For another, while linkage 
analysis has been the best approach for secondary analysis of GWAS for which only topline results 
are available, primary analysis of GWAS and CGAS can offer a more granular approach, when 
such data are available.  Rather than using linkage, the collection of associated variants can be 
used together, in sum. 
 
Moreover, however, a second mode of PCV identification, the “backward” mode, can take on a 
more prominent role.  In the current PIP, we identify body SNPs of known genes of mechanistic 
importance in a phenotype as PCVs.  In fact, however, what is desired is not body SNPs, but those 
SNPs which alter the sequence or expression of these genes, i.e. both coding SNPs and regulatory 
SNPs for this gene, regardless of their position in the genome.  Thus, the evolved featureset can 
take gene inputs, just like the current one, and look for not only coding variants, but also tissue-
specific regulatory variants for these genes, no matter where they may be in the genome, using the 
same target gene tools as the ERV workflow to find PCVs. 
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Moreover, although the current PIP treats all PCVs equally, PCV status need not be a binary.  The 
strength of a PCV relationship may be modulated by a number of factors.  For example, currently 
all affiliated phenotypes are weighted equally; in the Warfarin analysis, this included not just 
response and adverse events, but also disease risk and background phenotypes.  In an evolved 
featureset, we would wish to give more weight to variants for more directly related phenotypes. 
 
But for another, the strength and directionality of identification matters.  For example, a variant 
exhibiting a lower p-value in a source GWAS, or stronger linkage to a lead SNP, is probably a 
stronger candidate.  So, too, is a “backward mode” variant with a stronger target gene relationship, 
or a relationship with a more validated target gene.  In addition, a variant identified through both 
“forward” and “backward” methods may be considered a particularly strong candidate. 
 
Regulatory Function 
 
In the current PIP, variants are evaluated for regulatory function in a rigid way: they must have 
one a promoter or enhancer chromatin state in a relevant tissue, and each of a collection of relevant 
histone marks in a relevant tissue, and be located in accessible chromatin in a relevant tissue.  
However, this status is awarded in a simple binary manner, and with no requirement that these 
tissues be concordant with each other or with other tissue-specific information. 
 
In an evolved featureset, in addition to using larger datasets with higher quality and more relevant 
data (e.g. on tissues of more granularity), the criterion could enforce concordance between the 
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tissues for each omics modality.  It would also serve to look for membership in databases of 
validated enhancers, and particularly potent categories of FIREs and super enhancers.  It would 
place more emphasis on the features whose relevance has been emphasized in recent work, 
particularly chromatin accessibility, Hi-C contacts, TF binding, and chromatin state, over 
individual histone marks and DNA methylation, which have been downplayed. 
 
In addition, of course, this status need not be binary (as in the current PIP), but could scale with 
the strength of the appearance of regulatory status, the level of inter-tissue concordance, and the 
degree of relevance of the tissues to the phenotypes for which the PCV attained PCV status. 
 
Variant Dependence 
 
The current PIP uses only one modality for variant dependence analysis, and this modality is both 
limited, and poorly evaluated.  This is PWM analysis, using the Kellis et al library of PWMs 
[Ward et al 2016] along with the software TFM-Scan [Liefooghe et al 2006] to look for 
alterations.  The rationale for this type of analysis is strong: variants altering TFBS are frequently 
potent enhancer variants [Higgins et al 2015], and PWMs are a potent means of gauging TF 
binding affinity [Stormo et al 1982].  In addition, the “variants” analysis [Higgins et al 2015] 
showed that concordant changes in TFBS affinity for enhancers located at ChIP-seq-validated 
binding sites were a good mark of regulatory variant function. 
 
However, the current methods in the PIP are weakened by an obsolete database of PWMs, as well 
as a crude and unmaintained algorithm for evaluating conformity.  In addition, there is a format 
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conversion from probability to frequency matrices which introduces some imprecision (Chapter 
3).  In addition to this, although the current PIP tests for conformity and tests for TF binding, it 
does not value concordance between these measures. 
 
An evolved PIP featureset would use a comprehensive versioned and updated PWM library in its 
native format, along with compatible and maintained code for PWM conformity.  MotifDB 
[Shannon et al 2018] is one possibility.  However, it may also be advisable to consider abandoning 
PWMs entirely in favor of a machine learning based method for gauging TFBS occupancy as a 
function of sequence, such as the Nishizaki algorithm [Nishizaki et al 2017], which can gauge 
both sequence effects and cell type effects (by using epigenome data). 
 
A more significant advance would be the use of machine learning methods to gauge variant effect 
on both epigenome tracks, chromatin state, and enhancer function.  Several machine learning 
applications have been developed for predicting the impact of non-coding SNPs in GWAS on 
phenotypes; however fewer than 40% of GWAS publications from 2015 utilized these tools 
[Nishizaki et al 2017]. Figure 5-2 lists some examples of deep learning software that score 
features, such as DHS for prioritization of regulatory function and protein annotation of chromatin 
loops, to predict functional enhancer-promoter interactions and drug-target inference. 
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SOFTWARE 
[REF] SOURCE CODE DESCRIPTION 
DeepSEA 
[Zhou et al 
2015] 
http://deepsea.princeto
n.edu  
Predicts the non-coding variant effects de novo from 
sequence by directly learning a regulatory sequence 
code from large-scale chromatin profile data, 
enabling prediction of chromatin effects of sequence 
alterations with single-nucleotide sensitivity. 
DeepBind 
[Alipanahi et 
al 2015] 
http://tools.genes.toro
nto.edu/deepbind/ 
Predicts potential transcription factor binding sites 
(TFBS) and RNA binding protein (RBP) binding 
sites; both in vitro and in vivo, outperforming 26 
previously tested algorithms. 
deepnet-rbp 
[Xu et al 
2015] 
https://github.com/thu
combio/deepnet-rbp 
Predicts RBP binding sites taking (predicted) RNA 
tertiary structural information into account.  
Basset 
[Kelley et al 
2016] 
http://www.github.co
m/davek44/Basset  
Predicts DNA accessibility, simultaneously learning 
the relevant sequence motifs and the regulatory logic 
with which they are combined to determine cell-
specific DNA accessibility. Predictions for the 
change in accessibility between variant alleles are 
greater for Genome-wide Association Studies 
(GWAS) in SNPs that are likely to be causal relative 
to nearby SNPs in linkage disequilibrium with them. 
DanQ 
[Quang et al 
2016] 
https://github.com/uci-
cbcl/DanQ 
Uses the same features and data as the DeepSEA 
framework, outperforming DeepSEA for 97.6% of 
the targets. 
DeepChrome 
[Singh et al 
2016] 
https://github.com/QD
ata/DeepChrome 
Predicts gene expression from histone modification 
signals and enables the visualization of the 
combinatorial interactions among histone 
modifications via a novel optimization-based 
technique that generates feature pattern maps from 
the learned deep model. 
TFImpute 
[Qin et al 
2017] 
https://bitbucket.org/fe
eldead/tfimpute 
Predicts cell-specific TF binding for TF-cell line 
combinations using a multi-task learning (MTL) 
setting to use information across TFs and cell lines. 
Rambutan 
[Schreiber et 
al 2017] 
https://github.com/jms
chrei/rambutan 
Predicts Hi-C contacts at 1 kb resolution using 
nucleotide sequence and DNase I assay signal as 
inputs. Predicted contacts exhibit expected trends 
relative to histone modification Chromatin Immuno-
Precipitation-Sequencing (ChIP-seq) data, 
replication timing measurements, and annotations of 
functional elements such as enhancers and promoters.
CpGenie 
[Zeng et al 
2017] 
https://github.com/giff
ord-lab/CpGenie/ 
Produces allele-specific DNA methylation prediction 
with single-nucleotide sensitivity that enables 
accurate prediction of methylation quantitative trait 
loci (meQTL). Contributes to the prediction of 
functional non-coding variants, including Expression 
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Quantitative Trait Loci (eQTL) and disease-
associated mutations. 
DeepCpG 
[Angermuelle
r et al 2017] 
https://github.com/can
germueller/deepcpg 
Identifies known and de novo sequence motifs that 
are predictive for DNA methylation levels or 
methylation variability, and to estimate the effect of 
single-nucleotide mutations. 
iDeep [Pan et 
al 2017] and 
iDeepS [Pan 
et al 2017] 
http://www.csbio.sjtu.
edu.cn/bioinf/iDeep/ 
https://github.com/xyp
an1232/iDeepS 
Predicts RBP binding sites by multimodal learning 
from multi-resource data, e.g. sequence, structure, 
domain specific features, and formats. Allows one to 
automatically capture the interpretable binding 
motifs for RBPs. 
FactorNet 
[Quang et al 
2017] 
https://github.com/uci-
cbcl/FactorNet 
Predicts TFBS by leveraging a variety of features, 
including genomic sequences, genome annotations, 
gene expression, and single-nucleotide resolution 
sequential signals, such as DNase I cleavage data. 
Basenji 
[Kelley et al 
2017] 
https://github.com/cali
co/basenji 
Predicts cell type-specific epigenetic and 
transcriptional profiles in large mammalian genomes 
from DNA sequence alone. Identifies promoters and 
distal regulatory elements and synthesizes their 
content to make effective gene expression 
predictions. Model predictions for the influence of 
genomic variants on gene expression that align well 
to causal variants underlying eQTLs in human 
populations; and can be useful for generating 
mechanistic hypotheses to enable GWAS loci fine 
mapping. 
Concise 
[Avsec et al 
2017] 
https://github.com/gag
neurlab/concise 
Predicts RBP binding sites using a spline 
transformation-based neural network module to 
model distances from regulatory sequences to 
genomic landmarks. 
DeepATAC 
[Hiranuma et 
al 2017] 
https://github.com/hira
numn/deepatac 
Predicts binding locations from both DNA sequence 
and chromatin accessibility as measured by ATAC-
seq, outperforming current approaches including 
DeepSEA.  
 
Figure 5-2. Machine Learning Algorithms for Gauging Variant Effects 
Examples of open-source deep learning software applications for the discovery of epigenomic 
regulatory interactions and variant annotation   
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Deep learning applications for detection of regulatory elements within the non-coding genome are 
beginning to emerge [Angermueller et al 2016, Ching et al 2018, Park et al 2015]. Most of 
existing applications are based on CNN architecture is trained either from k-mers [Min et al 2017, 
Cao et al 2017], or directly on genomic sequence data. For example, DeepSEA [Zhou et al 2015] 
is one of the first deep learning-based algorithmic frameworks for predicting the chromatin effects 
of sequence alterations with single nucleotide sensitivity. In addition, it is trained on diverse sets 
of chromatin profiles from ENCODE and Roadmap Epigenomics Consortium projects [Roadmap 
Epigenomics Consortium 2015, ENCODE Project Consortium 2012]. DeepSEA can 
accurately predict the epigenetic state of a sequence, including transcription factors binding, 
DNase I sensitivities, and histone marks in multiple cell types. In addition, it can further utilize its 
capabilities to predict the chromatin effects of sequence variants and prioritize regulatory variants. 
In another example, the DeepBind algorithm was implemented based on a deep convolutional 
neural network to calculate the ability of nucleotide sequences to bind transcription factors and 
RNA-binding proteins in order to characterize the effects of single point mutations on binding 
properties in various diseases [Alipanahi et al 2015]. More recently, the Basset CNN model was 
used to predict DNA accessibility within non-coding regions [Kelley et al 2016]; and is intended 
to predict allele-bias in DNA accessibility, which is indicative of causal variants. DNase-Seq data 
from 164 cell types that had been mapped by ENCODE and the Roadmap Epigenomics 
Consortium was used to create Basset. The Basset CNN learned both protein-DNA binding motif 
information, as well as the underlying regulatory knowledge that determines cell-specific DNA 
accessibility. In the analysis of GWAS SNPs that were determined to be casual autoimmune 
variants, Basset demonstrated that it could discriminate causal from non-casual SNPs in high 
Linkage Disequilibrium (LD). In contrast to inference of regulatory elements using annotation 
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based on pre-defined feature sets, models such as DeepSEA and Basset do not take handcrafted, 
preprocessed features. Instead, they adaptively learn them from raw sequence data during the 
training phase. This, combined with high expressive power, allows deep learning to outperform 
traditional machine learning models. More accurate prediction of non-coding variants and their 
functional annotations with deep learning methods promises to enable better understanding of 
pharmacoepigenomic variation and more accurate prediction of drug response and adverse events 
(AEs). 
 
Other recent applications of deep learning models to prediction of regulatory elements and their 
interactions with the state-of-the-art performance include enhancer prediction [Kim et al 2016, 
Xu et al 2016, Liu et al 2016]; classification of gene expression using histone modification data 
as input [Singh et al 2016]; prediction of DNA methylation states from DNA sequence and 
incomplete methylation profiles in single cells [Angermueller et al 2017]; prediction of enhancer-
promoter interactions from genomic sequence [Singh et al 2016]; prediction of DNA-binding 
residues in proteins [Jiyun et al 2016]; global transcription start prediction [Eser et al 2016]; and 
improved prediction of the impact of non-coding variants on DNA methylation [Zeng et al 2017, 
Eser et al 2016]. In 2016, Google and Verily Life Sciences published a pre-print describing 
“DeepVariant” – a deep learning-based universal SNP and small indel variant caller that won the 
"highest performance" award for the SNPs Administration-sponsored variant calling “Truth 
Challenge” in May 2016 [Poplin et al 2018]. Recently, an updated, open-source version of 
DeepVariant has been further evaluated on a diverse set of additional tests by DNAnexus [Carroll 
et al 2017]. These tests showed that application of a general deep learning framework exceeded 
the accuracy of traditional methods for SNP and indel calling that has been developed over the last 
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decade. Deep neural networks also demonstrated the ability to outperform conventional machine 
learning techniques in SNP–SNP interaction prediction [Uppu et al 2016, Uppu et al 2016]. 
 
Since the publication of GKM-SVM [Ghandi et al 2016] and its variant DeltaSVM [Ghandi et 
al 2014] in 2014, such applications have proliferated.  The use of DeltaSVM to gauge variant effect 
on chromatin accessibility and therefore enhancer function was used successfully in the walproate 
variant analysis, and exploration of the PCVs from the warfarin PIP experiment showed that the 
predictive power of this metric was orthogonal to the PIP.  While such applications have 
proliferated and address a variety of different factors, the type which are most likely to be useful 
in the context of a PIP-style pipeline would be those directly relating to enhancer function or 
chromatin state, and which are trained on tissue specific data.  This would probably be Basset 
[Kelley et al 2016] or DeepSEA [Zhou et al 2015], or similar methods. 
 
Variants that modified TFBS for TFs with binding activity at those loci, and with predicted allele 
bias, would have very robust evidence of allele dependence in the regulatory function of the host 
loci.  In addition, evidence of concordant directionality between TF binding and enhancer function 
predictions will be an important form of evidence. 
 
Target Genes 
 
The target gene module in the current PIP, which evaluates target genes only by sequence 
proximity, is inadequate.  Both the “variants” and valproate analyses showed the value of finding 
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target genes with Hi-C data, and recent work on target gene analysis with molecular QTLs and Hi-
C data, along with machine learning, has been extremely fruitful. 
 
An evolved PIP would locate target genes of regulatory variants with four methods: 
 
1) Databases of CRISPR-validated [Lopes et al 2016, Gasperini et al 2017, Klein et al 2018] 
enhancer targets. 
 
2) A comprehensive genome-wide and tissue-specific collection of molecular QTLs, 
comprising expression QTLs, DNA methylation QTLs, DNase accessibility QTLs, histone 
acetylation QTLs, and other modalities of molecular QTLs.  Such a library should address 
major eQTL mapping experiments from GTEx and the national biobanks.  A QTL 
relationship between a SNP and the expression of a gene or the epigenomic status of the 
gene body is indicative of an enhancer relationship. 
 
3) Hi-C based methods for proximal target identification, such as TargetFinder [Whalen et 
al 2016] and the target finding capabilities of Juicer [Durand et al 2016]. 
 
4) H-GREEN or similar methods for distal target identification. 
 
The number, type, and strength of target identifications with these methods will be an important 
gauge of the strength of a regulatory interaction. 
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In addition, it may be advisable to consider using the squared genome wide collection of tissue 
specific enhancer target interactions with matrix densification machine learning methods to 
densify sparse measures of target genes.  Of the methods above, both mQTL mapping and distal 
Hi-C mapping suffer from significant data sparsity, and densification methods may add value. 
 
Pathway Mapping 
 
The pathway mapping functionality in the current PIP relies on the human all-tissue grow and 
connect functions of Ingenuity Pathway Analysis [Kramer et al 2013], consulted manually on the 
basis of the output genes.  It should be possible to improve on this functionality in several ways: 
 
Firstly, it is important that an evolved PIP’s pathway mapping function run locally, run in an 
automated manner, and use versioned data.  IPA licenses are available which offer API access to 
IPA commands, along with local storage of the database and/or versioned online access to 
historical quarterly updates.  If the evolved PIP is to use IPA or another commercial or open-source 
pathway mapping tool, such features are essential. 
 
More fundamentally, however, IPA, in evaluating genes only without attention to their origin or 
their PIP-determined relationships, is in some sense operating in a reductive manner.  It can detect 
whether the collection of genes identified in a PIP experiment have known relationships with the 
phenotype under investigation or with each other, but it cannot assess the internal relationships 
among the set of genes and variants as identified by the PIP.  In addition to the external, literature 
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and experiment based relationships, it should strike us as important to pathway relationships if, for 
example: 
 
The same TFBS is altered and/or the same TF is present at multiple loci for a phenotype 
The same gene is regulated by multiple variants for a phenotype 
The same variant for a phenotype regulated multiple related genes 
The same genes and variants are concordantly identified for a cluster of related phenotypes 
 
While a full exposition of the types of relationships we should seek and evaluate would be 
essentially a reinvention of the entire field of pathway mapping, and thus outside the scope of this 
discussion, it will suffice to note that different pathway mapping options may exist, that new 
functionality recently added to IPA around regulatory variants may be helpful, and that particular 
needed functionality can be added. 
 
Scoring 
 
The scoring algorithm of the current PIP is minimal in nature, comprising an explicit scoring 
algorithm resulting a binary determination of status for each PCV for each of the components of 
the five box model, and a simple intersection at the end of scoring to determine a set of intermediate 
candidates.  This method was adopted not because it is optimal but because it is simple. 
 
In the evolved PIP, each component will generate a vector of numeric and qualitative scores of 
various types, which we wish to integrate into a holistic picture, not necessarily of which variants 
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“pass” a final binary, but of which variants from the set of PCVs are most likely to be predictive, 
which among them are likely to be mechanistically related, and which genes are likely to play in 
the mechanism. 
 
Among possible scoring systems, systems in which “points” are awarded for various categoric and 
numeric elements and summed up to determine a “score” are appealing for their conceptual 
simplicity, but unlikely to be suited for this complex task, because of the interrelated and 
cooperative nature of the types of evidence which make up a regulatory variant determination.  For 
example, a variant with no evidence of variant dependence is probably null, regardless of the 
potency of an enhancer element in which it is located or the target genes of that enhancer.  Despite 
our experiments with “points” based scoring systems, they are unlikely to be fruitful. 
 
The universe of possible explicit scoring algorithms, incorporating “points” and thresholds and 
sliding scales, is vast.  And complex explicit algorithms have achieved great success in many 
applications in biology, bioinformatics, and medicine.  It is possible to envision an ensemble of 
explicit methods capturing a great deal of complexity and yielding “good” scoring.  Nevertheless, 
it will be useful to consider another possibility: the use of machine learning methods to address 
this question. 
 
Machine Learning for PIP Scoring: Depth vs Context 
 
Recent applications of deep learning in biomedicine have already demonstrated their superior 
performance compared to other machine learning approaches in a number of biomedical problems 
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[Ching et al 2018], including those in image analysis [Litjent et al 2017, Iglovikov et al 2017, 
Rakhlin et al 2018, Shvets et al 2018], genomics [Angermueller et al 2016, Mamoshina et al 
2016]; as well as drug discovery and repurposing [Goh et al 2017, Ramsundar et al 2017]. This 
great success of deep learning models in many tasks is thought to be enabled by the explosive 
growth of volume of raw data along with significant progress in computing, including the use of 
powerful graphical processing units (GPUs) that are specifically well-suited for the optimization 
of deep learning models.  
 
Conventional machine learning algorithms are typically limited in their ability to process raw data 
[Lecun et al 2015]. Their performance heavily depends on the extraction of relevant 
representations or features that requires careful engineering and considerable domain expertise. In 
the past, biomedical datasets have typically been limited by sample size, and since often many 
more features could be measured, the performance of conventional machine learning algorithms 
degraded when useful information was buried in an excess of extracted features. This posed a 
challenge for the determination and extraction of the optimal feature set for the problem under 
examination. Two related and widely-used solutions are used to overcome this limitation: 1) 
dimensionality reduction methods that shrink the feature space to the set of most informative 
components [Li R et al 2017]; and 2) feature selection methods that identify a relatively small 
number of features that can accurately predict an outcome [Vidyasagar et al 2015]. While many 
of these general-purpose methods already exist, they are not necessarily optimized for 
pharmacogenomic biomarker discovery. This and other related pharmacological research 
applications require careful experimental design and choice of validation techniques. Overall, 
limitations of conventional machine learning methods include the need for extensive human 
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guidance, painstaking feature handcrafting, careful data pre-processing, and the above-mentioned 
dimensionality reduction to achieve top performance. 
 
In contrast, deep learning methods model data by learning high-level representations with multi-
layer computational models such as artificial neural networks (ANNs) [Lecun et al 2015]. While 
classic feed-forward ANNs might serve as drop-in replacement for other machine learning models 
and require input pre-processing and feature extraction; deep learning architectures, such as 
convolutional neural networks (CNNs), allow the algorithm to automatically learn features from 
raw and noisy data. Deep neural networks rely on algorithms that optimize feature engineering 
processes to provide the classifier with relevant information that maximizes its performance with 
respect to the final task. Such deep learning models can be thought of as automated “feature 
learning” or “feature detection,” which facilitates learning of hierarchical, increasingly abstract 
representations of high-dimensional heterogeneous data [Lecun et al 2015], also known as 
“representation learning.” Some common deep learning methods include deep feed-forward 
artificial neural networks (ANNs), convolutional neural networks (CNNs), recurrent neural 
networks (RNNs), stacked auto-encoders (SAEs), deep belief networks (DBNs), and deep 
reinforcement learning techniques [Lecun et al 2017, Leung et al 2016, Angermueller et al 
2016]. In biomedicine, these models are capable of unguided extraction of highly complex, 
nonlinear dependencies from raw data such as raw sequence data [Ching et al 2018].  
 
For this reason, since the data a PIP style pipeline accumulates about each SNP and gene is highly 
structured, it is likely that a conventional machine learning approach would be suited for this task 
without the need for a deep learning architecture.   
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Machine Learning for PIP scoring: Supervised Classification, Overfitting, and Data 
Availability 
 
While most successful deep learning applications relied on large labeled data, many biological and 
clinical datasets until recently were limited by amount of available labeled samples compared with 
the big data analytics applications such as natural image processing and NLP. Over time, as the 
number of samples increases and the number of relevant high-quality labeled datasets expands, the 
wealth of pertinent pharmacogenomics data that can be used for analytics will begin to resemble a 
big data challenge on par with contemporary applications in other domains. The rich variety of 
heterogeneous data types in pharmacogenomics can improve the utilization of highly flexible deep 
networks that can deal with sparse, high-dimensional, multi-modal data. The real power of deep 
learning in a domain such as pharmacogenomics will be realized when it is combined with a prior 
domain knowledge [Ching et al 2018], such as gene networks or pathways; a relevant example 
being used for the prediction of the pharmacological properties of drugs using transcriptomic data 
combined with pathway information [Aliper et al 2016]. Multimodal, multi-task, and transfer 
learning are often used to alleviate data limitations to some extent. Transfer learning approaches 
include training a deep network on a large existing dataset, and then using this pre-initialized model 
to learn from a smaller dataset, which typically leads to improved performance [Ching et al 2018]. 
When training data is not (fully) labeled, various semi-supervised techniques can be employed 
[Ching et al 2018, Iglovikov et al 2017, Beaulieu-Jones et al 2016]. Data quality is another 
important concern in deep learning applications. Although deep learning models can be trained 
directly on raw data, low quality datasets may require additional pre-processing and cleaning. 
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Publicly sharing the pre-processing code (e.g., Basset [Kelley et al 2016]) and cleaned data (e.g., 
MoleculeNet [Wu et al 2018]) is important to expedite further research and practical applications.  
 
A trained machine learning model may represent some attributes of the dataset that do not 
accurately reflect their underlying relationships. This problem may be magnified as the size of the 
feature or parameter set is increased relative to the size of the input sample set. Such models exhibit 
poor predictive performance, as they over-represent minor variations in the training data. 
Overfitting is an issue of trade-off between generalization and approximation of the training data 
in a model. A model can underfit high-dimensional, heterogeneous dataset with complex hidden 
patterns if the model’s representational power is low, which is often the case, for example, for 
linear models. Although overfitting is a common issue in machine learning, it is more likely to 
affect complex models, especially when there are not enough samples in the training set, learning 
is performed for too long, or where training examples are rare, causing the learner to follow the 
patterns in training data too closely. In the case of deep learning, overfitting is often a threat due 
to the high representational power of a model, which leads to the ability to “memorize” the whole 
training set very efficiently. Thus, deep learning methods require careful choice of model 
architecture and hyper-parameters. Although there are specific methods to prevent overfitting 
[Lecun et al 2015, Angermueller et al 2017], in general, the trained model should exhibit robust 
performance on test data using relevant properties of the trained data. For more detailed description 
of overfitting and model selection, see [Lever et al 2016]. 
 
Preventing overfitting also requires a very careful design of the model evaluation scheme, 
including usage of cross-validation techniques, normalization by subjects, etc. Validation metrics 
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may include mean absolute error or root-mean-square error (sample standard deviation of the 
differences between predicted and observed outcomes) for regression; accuracy; precision (also 
known as positive predictive value (PPV) – the fraction of retrieved instances that are relevant); 
recall (sensitivity - the fraction of relevant instances that are retrieved); precision-recall curve 
(PRC) and area under the PRC (AUPR); receiver operating characteristic (ROC) and area under 
the ROC curve (AUC); and mean average precision (MAP), for ranking [Lever et al 2016, Saito 
et al 2015]. Although some of these may seem intuitive, correct determination requires great care, 
and is often fraught with sources of error that are not easily understood, except in the context of 
the problem under study. For example, while the AUC plot is a common visual method for 
classification performance evaluation, it is not the most informative when classes are represented 
largely by a different number of samples in the dataset [Saito et al 2015], which is a common 
situation in pharmacogenomics. One test of the quality of the trained machine learning model is 
its ability to faithfully generalize into varying test sets that constitute different manifestations of 
the same problem. 
 
In the context of the PIP, the consequences of this are clear.  There does not currently exist a set 
of adequately characterized positive controls for pharmacogenomics regulatory variants, of a type, 
scale, or breadth, to allow the construction of a monolithic supervised machine learning algorithm 
for scoring PIP variants.  Indeed it is not entirely clear from where, with any plausible level of 
effort, such a training set would come.  This complicates matters considerably. 
 
However, subcomponents of the overall model exist wherein training sets for machine learning are 
available, including the portions described above where machine learning algorithms are used to 
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generate scores in individual modules of the PIP featureset.  These include the use of hidden 
Markov models to generate chromatin states, the use of neural networks to predict variant effects 
on DNase accessibility and chromatin state, motif discovery by clustering, matrix densification for 
regulatory variant target discovery, etc.  Artificial intelligence algorithms also have been 
demonstrated for variant imputation. 
 
It may be that databases of validated tissue specific enhancer variants may function as a training 
set along with omics atlas data, so that the entire ERV workflow (regulatory function, variant 
dependence, and target genes) may be carried out with a supervised-training machine learning 
algorithm to predict the presence or absence of a “validated-appearing” enhancer variant. 
 
In addition to this, the relationship between metrics of PCV status, like target gene status, 
association p-values, etc, and status as a plausible causative variant for the phenotype, among 
variants which are called as potent regulatory variants, may be addressable with Bayesian 
statistical approaches constructed synthetically from statistical models in population genetics.  
Similar approaches may be applied to network membership in the pathway mapping portion of an 
evolved workflow. 
 
Thus, although it appears intractable to attempt to replace PIP scoring with a monolithic machine 
learning algorithm using any current tools, it will be possible to gain more insight from more data 
by the replacement of progressively larger portions of the intermediate scoring (the more defined 
portions) with machine learning algorithms, even as the overall scoring system remains an 
ensemble constructed explicitly. 
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Using the Output of PIP-Style Pipelines to Develop Genetic Tests 
 
The output of the PIP is a set of variants, genes, and pathways with a putative causal role in a 
phenotype of interest.  Although such results may be useful for purposes of mechanistic research 
in the biology of a phenotype, or the search for druggable targets and repurposing opportunities.  
However, in the context of pharmacogenomics the object of most PIP analyses will be to develop 
genetic tests (and more broadly, clinical predictive models) for eventual clinical deployment.  
While an authoritative discussion of this subject is beyond the scope of this thesis, it will serve to 
discuss this topic briefly in light of the above. 
 
Typically, first generation pharmacogenomics tests were designed by a simple linear combination 
of variant effect sizes, or with a linear regression model.  Later first-generation tests such as the 
Genesight [Health Quality Ontario 2017] psychotropic panel were constructed manually as an 
explicit combinatorial decision tree algorithm on the basis of effect sizes, paired variant effects, 
and manual expertise and adjustment.  Then, these explicitly constructed tests could be validated 
against genotyped cohorts with response data before being tested in randomized controlled trials. 
 
The PIP and PIP-style pipelines can be used to design tests in this mode.  But doing so would 
deprive the designer of much of the benefit of the PIP and of modern data sources.  With significant 
pleiotropy between pharmacogenomic loci, the reduction of features to a tractable number, and the 
availability of genotyped cohorts and machine learning methods, it is anticipated that the ideal 
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method for designing a pharmacogenomics test on the basis of PIP results would incorporate these 
advances. 
 
In this case, a genotyped cohort with genomic information on all the output loci of a PIP 
experiment, along with clinical variables deemed important in test design, and outcome 
information, would be gathered, preferably retrospectively from a GWAS or biobank.  Then, a 
machine learning predictor would be trained to predict the outcome variable with this cohort, with 
cross validation.  Since this is a relatively low dimensional space with supervisory information, 
and because the intention would be to clinically deploy the finished predictor, a relatively simple 
machine learning method like an SVM or Random Forest would probably suffice.  Then, features 
could be reduced using an iterative marginal information analysis approach to arrive at a set of 
informative loci and clinical features to be used.  A predictive model trained on these features 
would function as a finished genetic test and could be validated and deployed. 
 
This approach is described schematically in Figure 5-3. 
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Figure 5-3: Using PIP-Style Pipelines to Design Genetic Tests 
Schematic of an overall method for using PIP-style pipelines to design genetic-clinical tests.  
After loci are generated by a PIP experiment, they are used along with tractable and predictive 
clinical features in a cohort dataset to generate a predictive machine learning model, which is 
tuned with ablation analysis to find features with high marginal information.  The minimal set of 
such features is used to generate a final predictive model which functions as a test, and can be 
validated in prospective and retrospective clinical trials. 
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Although historic regulatory approaches have demanded prospective clinical trials before clinical 
deployment of genetic tests and genetic prediction modules for clinical decision support, 
scientifically there is little conceptual distinction between a retrospective trial on a cohort which 
was not used in the construction of the test, and a prospective trial.  As the scientific consensus 
around these issues congeals and makes its way into the culture of regulatory thinking, it is likely 
that the greater speed and lower expense of this approach, along with the clinical utility of making 
genetic testing more widespread, will carry the day in favor of this kind of development. 
 
But in any event, even if prospective clinical trials were required in order to validate such 
predictive models, the fact that they were initiated on the basis of PIP-discovered variants with 
mechanistic validity should advantage such classifiers in the regulatory environment, compared 
with agnostic machine learning approaches based on whole genomes. 
 
Much has been made of regulatory barriers and cultural hesitance to use genetic information in 
some medical specialties as explanatory elements for the slow progress of pharmacogenomics 
testing deployment in many clinical specialties.  Historically, however, the single biggest factor 
preventing pharmacogenomics testing from reaching the clinic in any given case has not been 
regulatory or cultural barriers but the clinical utility of the underlying prediction.  In instances in 
oncology and neuropsychiatry where such tests have added value, they have typically met with at 
least enough regulatory permission and cultural tolerance to be applied.  It may be anticipated that 
if, in the fullness of time, tests for new phenotypes do add such utility, neither governments nor 
conservative clinicians will stand in their way indefinitely.  And as the number of domains where 
such tests add value grows, they may become the object of much enthusiasm. 
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Using PIP-style Pipelines to Construct a Phenome-wide Pharmacoepigenomic Atlas 
 
A PIP-style pipeline analysis, intended to discover variants with a causative role in a particular 
phenotype, takes place using a large amount of omics data which comes from the same database 
for each experiment, and is selected on the basis of preexisting knowledge about the phenotype 
under investigation.  In the current version of the PIP, this principally comprises the MVF and 
MTF, containing information about the key mechanistic genes and associated variants, and the 
relevant tissues.  In the case of the evolved featureset discussed in this chapter, other key 
information will come to the fore, including the most relevant Hi-C datasets, the degree of 
relatedness of clustered phenotypes, and the tissues for each phenotype.  But regardless, a five box 
model pipeline requires a certain set of specific information about a phenotype system in order to 
run. 
 
Many of the underlying elements of such a pipeline have begun to parallelize across all domains.  
For example, GWAS have now been conducted on thousands of phenotypes [MacArthur et al 
2017], and genotypes biobanks have enabled PheWAS [Denny et al 2010] methods to conduct 
parallel GWAS on thousands of phenotypes with one large cohort.  Epigenome atlases now address 
an increasingly large cross section of the human body, with increasing granularity.  Biomedical 
ontology databases now attempt to contain the knowledge on relatedness of phenotype categories 
and the contributions of tissues to phenotypes within a structured, computable vocabulary.  And 
research in the design of EHR parsers is now proceeding [Denny et al 2013, Beaulieu-Jones et al 
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2016], gesturing to a future world wherein individual health records can be grouped into 
phenotypic classes on a reliable and automated basis for an ever larger span of phenotypes. 
 
The maturity of these trends will culminate in a world wherein, instead of performing a targeted 
PIP-style analysis on a particular phenotype of interest and using it to design a test, the converged 
datasets and methods described here will be used to perform parallel analyses and parallel test 
design for thousands of phenotypes.  The predictors for these phenotypes could, for genotyped 
patients, then be contributed directly to an EHR system and used for clinical decision support.  
Furthermore, the genotypes, clinical records, and outcomes of patients within an EHR system 
could be used to refine the predictors for such a system on an ongoing basis. 
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Figure 5-4: Conceptual Process for Constructing a Pharmacophenomic Atlas 
Schematic representation of a conceptual process for parallelizing a PIP-style pipeline across 
thousands of phenotypes to create a genome-wide, phenome-wide pharmacophenome atlas.  
With either automation of parallelized manual work, MVFs and MTFs are created for thousands 
of phenotypes on the basis of PheWAS, biobanks, and/or the GWAS catalog, and thousands of 
PIP experiments run.  Then, automated test generation as described in Figure 5-3 is undertaken 
in parallel for all the phenotypes based on separate cohorts from a biobank and/or PheWAS.  
Finally, this set of thousands of predictive models for a comprehensive collection of 
pharmacological phenotypes may be used in every CDSS and research context wherein it may 
add value.  
  247   
 
The concluding section of this thesis will describe a future vision for the means by which this 
process could take place, which is also pictured schematically in Figure 5-4. 
 
The first step in such an analysis would be the construction of a phenotype set for investigation.  
Each PheWAS analysis already constructs such a set, typically manually. 
 
The construction of tissue files on an automated basis requires a degree of natural language 
processing.  Ontologic mapping of phenotypes to relevant diseases, along with crawling of 
structured literature databases like the EBI GWAS catalog [Macarthur et al 2017], and natural 
language processing, could be used to create variant input files on an automated basis, by locating 
the relevant phenotypes in natural language and extracting the locus and population information.  
In addition to this, the output of a PheWAS on the same set of phenotypes could be used to 
construct the variant files. 
 
Similarly, ontologies mapping drugs and diseases to their sites of action (e.g. SNOMED [Millar 
2016]), cell lines to their cytologic properties and tissues of origin (e.g. Cell Line Ontology 
[Sarntivijai et al 2014]), organs and tissues in a hierarchical tree (e.g. NeuroFMA [Turner et al 
2010], HOMER [Zhang et al 2011], BRENDA [Gremse et al 2011]), and synonymous tissue 
names to each other, may allow the creation of tissue files on an automated basis.  This would 
create a description of all the relevant tissues for each phenotype. 
 
With this done, it would be possible to run a PIP-style pipeline in parallel on many drug-disease 
systems to create a genome wide, phenome wide atlas of significant pharmacogenomic loci and 
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gene networks.  In particular, such experiments could be conducted in parallel on the basis of 
association data from EHR records for large populations [Denny et al 2013].  This atlas could 
include all the drug disease systems, disease risks, and other pharmacological phenotypes for 
which the underlying genetic associations and tissue specific omics are available. 
 
Theoretically, if such automated methods as are described above proved impractical, and if 
sufficient resources were available, the manual curation of a library of tissue and variant files could 
be undertaken for a large library of phenotypes.  The creation of input files for the current version 
of the PIP has already been reduced to a matter of days for two investigators, and with a suitable 
graphical interface for curation, could be reduced further, perhaps to the point where manual 
curation by a small dedicated staff with access to a variety of medical specialists became a tractable 
alternative.  Certainly this has been the predominant approach in PheWAS design. 
 
With a separate linked biobank not used in the original analysis, such a “PIP-WAS” atlas could be 
used to design predictive models for every phenotype under investigation.  This would require the 
phenotypic extraction, key clinical variables, and clinical variable extraction for each phenotype 
from the second biobank to be automated as well.  In addition, it would require the test generation 
and marginal information ablation analysis to be automated, a requirement which would require a 
lot of hyperparameter tuning.  Nevertheless I am confident it is possible with current methods. 
 
This comprehensive pharmacogenomics atlas would represent the industrialization of 
pharmacogenomics.  It would enable, among other things, the scalable parallel design of tests for 
many diseases and drugs on the basis of genotype-linked EHR data, and the development of 
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microarrays or sequencing panels containing the genetic information for many tests, or all, in one 
package.  Such information could then be available in the EHR for a variety of purposes, and could 
even be present on, e.g., a military “dog tag” in the form of a QR code or other linked identifier 
for use in emergency and traumatic care settings. 
 
Nor, indeed, would the construction of such an atlas need to be a discrete versioned event.  If 
genotyped EHR data were added to the system, predictive models could refresh on an ongoing 
basis with new information, and new phenotypes could be added to the catalogue as their relevance 
was established. 
 
Coda: Pharmacogenomics in 2030 
 
What would medicine look like, in a world wherein such an atlas had been constructed, and 
wherein it had been incorporated into the EHR systems in use in the clinic, and in which patient 
genotypes were routinely available?  Every time a patient required general health guidance, 
clinicians would have access to predictive information suggesting the diseases and syndromes 
which might present the greatest risk.  For every prescription decision, the pharmacogenomics of 
the various drugs available such such an indication could be displayed, along with the particular 
adverse events most concerning for each one, for the individual patient.  And for public health 
concerns with rare indications, the application of an optimized classifier to the covered population 
of a health system could prospectively identify a cohort who would benefit from prophylactic 
guidance or treatment. 
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Only twelve years ago, before the advent of GWAS, genetic tests were designed manually for each 
phenotype on the basis of painstaking, locus-specific mechanistic work, almost exclusively using 
coding variants, and then loci were assayed individually before being reported, often with a delay 
of weeks.  While the clinical side of this picture has seen only muted change in the time since, 
rapid and fundamental advances on the research side, including the PIP and H-GREEN, have made 
it possible to see forward to a future, twelve years from now, when the parallel design of genetic 
tests for thousands of phenotypes, incorporating tissue-specific regulatory variants, machine 
learning, and large cohort datasets, has made the display of genetic predictive information on 
relevant phenotypes a routine and automatic part of life in the health care clinic. 
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